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Objectives – Cognitive ageing is an inevitable part of human life. Research from 
disciplines such as epidemiology, medicine and neuroscience implicate a wide range 
of determinants in the pathophysiological processes that lead to clinical symptoms of 
neurodegeneration. Markers of systemic inflammation are postulated to play an 
important role in mechanisms underlying a neuro-pathological cascade, either 
directly, through neuro-inflammatory processes, or through the mediating effect of 
diseases that are associated with cognitive deficits, such as cardiovascular disease 
and variation and disruption to cerebral blood flow. This may be particularly 
important in people with type 2 diabetes, where the increased prevalence of vascular 
events and glycaemic upset along with elevated levels of various circulating 
biomarkers, have been implicated in accelerated cognitive decline. Increasingly, 
evidence suggests a contribution of vascular disease state in the development of 
Alzheimer’s disease in which inflammation could be a significant factor. 
Determining the direction of association between individual markers of inflammation 
and altered cognitive performance is important in order to understand the possible 
role of inflammation in the development of cognitive decline and to inform the 
development of preventive clinical interventions. Therefore investigating these risk 
factors in relation to the trajectory of age related cognitive decline is crucial; in this 
respect, longitudinal evidence, detecting change in cognitive performance over a 
defined period of time, is most appropriate. To date, the majority of evidence is 
inconclusive, predominantly due to methodological obstacles embedded in the 
prospective design of cognitive ageing studies and in the investigation of a complex 
 
 
disease state, such as insufficient follow up period and restricted cognitive 
assessment.   
Since associations reported from modelling late life cognitive change in 
epidemiological studies may be the result of confounding variables, such as gender, 
vascular risk factors/disease, education attainment and social status, investigating the 
causal nature of inflammatory mediators in cognitive decline, has proved more 
problematic.  Additionally, even a casual association may be due to ‘reverse 
causation’. One method of unravelling such associations is through the use of genetic 
association, where the exposure variable of interest (such as genetic variants 
affecting plasma biomarker levels) is modelled against the outcome, thereby 
overcoming some of the problems of confounding and reverse causation inherent in 
non-genetic epidemiological studies. 
Aim – The primary aim of this thesis was to test for associations of baseline 
measures of acute-phase proteins (fibrinogen and C-reactive protein) and central pro-
inflammatory cytokines (interleukin – 6 and tumour necrosis –) with four-year 
change and estimated life-time change in cognitive ability in older people with type 2 
diabetes. The second aim was to explore the association between fibrinogen-related 
SNPs (SNPs shown previously to be associated with altered plasma fibrinogen 
levels) and cognitive ability in the general population. 
Methods –Data from the Edinburgh Type 2 Diabetes Study (the ET2DS), a 
prospective epidemiological study of older people with type 2 diabetes were 
available, including that collected at a baseline clinic (2006-07) on 1066 participants, 
 
 
mean age 67.9 years (SD 4.2). For the present study, follow up cognitive assessment 
was carried out after four-years (2010-11) at which cognitive data was collected on 
828 survivors. Cognitive ability at both time points was assessed using the same, 
comprehensive, seven neuropsychological tests battery, including measures of fluid 
as well as crystallised intelligence (vocabulary test). Principal component analysis 
was conducted to derive a general cognitive factor ‘g’ and a general inflammatory 
factor, derived from individual cognitive scores and from baseline measures of four 
inflammatory markers (fibrinogen and C-reactive protein, interleukin – 6 and tumour 
necrosis –), respectively.   
Genotype and cognitive data were collected from seven, well-established population-
based cohorts with clearly defined sampling frames and data collection procedures. 
Five cohorts comprised of community-dwelling elderly people, living in central 
Scotland (AAA Trial, n = 2061, EAS, n = 534; ET2DS, n = 1045; LBC 21, n = 517; 
LBC 36, n=1005) and two large were cohorts based in England (ELSA; n = 5458; 
and Whitehall II; n = 3400).  In total, genotype and cognitive data were available for 
14033 participants, age range between 60 to 80 years. In all studies cognition was 
assessed on three cognitive domains: memory, executive functioning and information 
processing. Compatibility of cognitive data allowed for calculation of a general 
cognitive factor ‘g’ that was comparable between all cohorts. The instrument 
variables consisted of 61 fibrinogen-related polymorphisms within 13 different loci. 
These were identified through a detailed literature search as well as through search of 
relevant, genetic databases.   
 
 
Results – in the ET2DS, the age and sex-adjusted analyses revealed statistically 
significant associations between raised plasma inflammatory markers and poorer ‘g’ 
at follow-up; this was observed  for all biomarkers, with the strongest associations 
detected for IL-6 and the general inflammation factor (p values <0.001). These 
findings persisted in linear regression models of baseline biomarker levels with four-
year cognitive change as well as estimated life-time change – here the general 
inflammatory factor and plasma IL-6 levels were the strongest predictors. 
Adjustment for conventional vascular risk factors and cardiovascular disease 
attenuated the associations of cognitive decline with fibrinogen, CRP and TNF-
associations were largely attenuated in analyses assessing IL-6 and the general 
inflammation factor and tended to remain statistically significant.   
Meta-analysis was conducted in order to explore associations between pre-selected 
fibrinogen-related SNPs and impairment in general cognitive ability as indexed by 
‘g’. The analysis identified five plasma fibrinogen-related SNPs that were 
significantly associated with impaired ‘g’ at the nominal threshold level of p < 0.05. 
These were: rs2070016 (FGB gene); rs2070016 (FGA gene); rs1800497 (ANKK1 
gene); rs4251961 (IL1RN gene) and rs1130864 (CRP gene).   
Discussion – the results of the ET2DS indicate that in an elderly diabetic population, 
there is a significant relationship between baseline levels of circulating inflammatory 
markers and four-year cognitive change as well as estimated life-time cognitive 
decline. These associations were generally independent of common cardiovascular 
risk factors and events, suggesting a possible pathway where cytokine-induced 
activation of glial cells may be responsible for the consequent neuro-inflammatory 
 
 
processes resulting in declined cognitive ability. The lack of some associations may 
be due to a relatively short follow up period. The main strength of the ET2DS was 
the availability of prospective cognitive data, the large sample size and the use of a 
comprehensive cognitive battery, including a vocabulary test for crystallised 
intelligence and thus calculation of estimated life-time cognitive change.   
Genetic association analysis indicated a significant association between five pre-
selected SNPs each located within different genes (in general, genes associated with 
inflammation), and impaired general cognitive ability. This provides some support 
for a causal role of inflammation in age-related general cognitive impairment. One of 
the major strength was the use of a large dataset and the applied methodological 
approach. Meta-analysis was conducted on raw, prospectively generated data, 
allowing determination of the cognitive phenotype variable. 
The main outcomes of this thesis suggest that systemic inflammation may indeed be 
involved in aetiology of age-related cognitive decline, possibly via neuro-
inflammation. Further epidemiological investigation should involve a measurement 
of biomarkers trajectories in modelling cognitive change. Use of a stronger genetic 
instrument for inflammatory biomarkers, modeled against cognitive decline rather 
than cognitive ability as in the current study could further advance knowledge of the 
bio-pathological mechanisms underlying age-related cognitive decline. Results could 
ultimately inform subsequent investigations in the form of a randomised control trial, 
testing an evidence-based anti-inflammatory clinical intervention in diabetic 
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Chapter 1: Cognitive Ageing, Systemic 
Inflammation, and Genetics 
Ageing, specifically cognitive ageing, is an extremely complex and dynamic process 
with a great deal of heterogeneity in the rate of age related cognitive decline, 
reflecting the multifactorial nature of cognitive ability and is thus considered as a 
life-long trait. In light of the demographic changes resulting in the growth older of 
the older population, cognitive ageing and consequences of neuro-degeneration are 
increasingly becoming a major public health concern. This is particularly important 
as along with a growing proportion of the ageing population, there is also an 
increasingly higher prevalence of type 2 diabetes; epidemiological observations 
implicate type 2 diabetes as one of the major risk factors in development of age-
related cognitive dysfunction. To complicate matters further, brain-related neuro-
degeneration is a complex, gradual process. It has now been well established that 
cerebral damage might occur well before a clinical manifestation of cognitive 
impairment. Identifying preclinical, potentially modifiable markers that contribute to 
patho-physiological mechanisms resulting in altered age-related cognitive change is 
therefore an urgent matter in order to develop effective clinical interventions. 
The primary aim of this thesis was to investigate the relationship of elevated markers 
of systemic inflammation and change in cognitive performance in older people with 
type 2 diabetes. The use of prospective data and vocabulary-based estimator of pre-




life-time change in cognitive performance. A genetic association study was 
conducted on data collated from seven population-based studies, the aim of which to 
determine the associations of pre-selected single nucleotide polymorphisms (SNPs) 
with cognitive functioning. 
This chapter provides a review of some of the key details and background 
information. It commences with an introduction to cognitive functioning, including 
general intelligence, followed by an overview of the main neuro-biological processes 
and pathologies, age related changes in cognitive ability, including mild cognitive 
impairment and main types of dementia. This chapter will discuss the concept of 
cognitive reserve and concludes with main evidence with regards to prevalence of 
age-related cognitive dysfunction. The second part of this chapter consists of two 
main sub-sections; first, information and facts relevant to systemic inflammation are 
discussed. Four circulating inflammatory markers are discussed in more detail in 
terms of their biological properties. Epidemiological evidence supporting the inter-
relationship between inflammation and vascular risk and cardiovascular disease and 
between inflammation and type 2 diabetes conclude this section. The third part 
provides an overview of T2DM, defining the disease, its risk factors and current 
prevalence of this condition.  The following section is an introduction to genetics, 
describing DNA stricture as well as it components, and main issues in genetic 
association studies. It concludes with information of genetic determination of plasma 
fibrinogen levels and relevant biological mechanisms involved in disturbed plasma 




Many studies have examined the role of systemic inflammation in age-related 
cognitive impairment and decline. A literature review on epidemiological studies of 
inflammatory circulating biomarkers in cognitive decline is presented in Chapter 2. 
The literature review only included studies in the English language. Only prospective 
studies, recruiting dementia-free subjects and with a sufficient follow-up period 
cognitive assessment were included. Animal studies or basic biological studies were 
not included. Studies on genetic epidemiology were only included if the above 
criteria were met. It concludes with the summary of the main findings and 
description of the aims of the presented thesis.  
The following two chapters introduce the studies and populations that were analysed. 
Chapter 3 addresses the Edinburgh Type 2 Diabetes Study (ET2DS), Chapter 4 
commences with an overview of the seven collaborating cohorts, details about 
particular cohort description, including methods of cognitive assessments.  The 
second part of this chapter provides detail of method that was used to identify the 
pre-selected, fibrinogen-related SNPs that were required for the genetic association 
analysis. Chapter 5 presents results of the ET2DS longitudinal analysis, and in 
Chapter 6, the results of the genetic association study are described. A discussion of 
these findings are presented in Chapter 7; including summary and interpretation of 
the ET2DS, followed by summary and interpretation of the genetic meta-analyses 
findings and evaluation of strengths and limitations of this evidence. It concludes 






1.1 Cognitive Functioning, Cognitive Impairment 
and Cognitive Decline 
The changes in mental abilities that are observed as people grow older are commonly 
referred to as cognitive ageing. The brain undergoes age-related patho-physiological 
changes that are clinically manifested in decline of one or more cognitive domains. 
The neurology of cognitive ageing is a complex and complicated process. The focus 
of this section is on defining cognitive function and age-related cognitive changes, 
describing main neuro-patho-physiological changes. It also provides background 
information of cognitive ageing research. In the literature, there is a considerable 
overlap in terminology referring to age-related cognitive processes. In this thesis, the 
term cognitive impairment refers to ‘one-off’ measures, i.e., assessment of cognitive 
ability. Cognitive decline, on the other side, refers to a change of cognitive ability 











Cognition, or cognitive functioning, is defined as a mental activity with a 
multifactorial property, encompassing functions such as an acquisition, 
memory/storage of information, thinking and selection, visual-spatial functions, 




Interest in brain function dates back approximately 5000 years to a medical 
document from ancient Egypt that described observation of behavioural changes as a 
result of head injury
3
; nevertheless, despite the work of Aristotle (who proposed a 
direct functional link between heart and brain function
4
), there was a little interest 
and understanding of mental (cognitive) processes until the 19
th
 century, when 
intelligence and cognition, its determinants, mechanisms and functionality through 
the human life became a of scientific enquiry. Although some advocate the notion of 
holism which claims that even though some lesions may have a local effect, the brain 
functioning must always involve  multiple structures
5
, generally. most current 
research is guided by the doctrine of localisation
4
 where specific location/structure of 
brain correspond with specific cognitive function. The majority of work following 
this doctrine is based on observation and studies of patients with localised brain 
lesions, accompanied by sets of clinical symptoms and patterns of behaviour
6,7
. 
Approach of localisation of particular cognitive domain/function along with 




has allowed for understanding of increasing specific experimental measures of 
intelligence and cognitive functioning, i.e. neuropsychological assessments
8
.  
1.1.2 Domains of Intellectual Abilities, the General 
Cognitive Factor ‘g’ 
Understanding of human cognition, both functional and neuro-cognitive has 
advanced insight of many facets and patterns of intellectual ageing. Different 
domains of cognition can be conceptualized and assessed via validated 
neuropsychological tests. Cattell-Horn theory of intelligence
9,10
 proposed 
multifactorial, multidimensional and multi-directional nature of intellectual ageing 
trajectory
11,12
.  In this explanation of human cognitive functioning, two broad 
categories of intelligence were identified, each presenting different profile in terms 
of onset, speed and pattern of decline; crystalized and fluid intelligence
13
. This is 
commonly referred to as the ‘Dual component theory of intellectual development’
14
 . 
Crystallized intelligence reflects experienced and culture-based general knowledge 
and is linked to cognitive abilities such as general knowledge and vocabulary 
ability
15
. Typically, it shows very little age-associated decline, remaining relatively 
stable across a life-span
16
. As such, validated (usually vocabulary-based) assessment 
of crystallized intelligence provides an estimate of a person’s peak cognitive ability, 
i.e., cognitive proficiency prior to the onset of age-associated neuro-pathological 
processes
17
; this provides comparative data for longitudinal design where the change 




side, is affected by biology-based processes accompanying brain ageing. As such it is 
susceptible to neurological damage and there is a great degree of heterogeneity 
between individuals
18
. Determination of the speed and pattern of decline is 
conducted by a set of standardized tests that are sensitive to cognitive domains such 
as memory (range of sub-types), reasoning, speed of information processing and 
executive functioning
7,19
. Furthermore, evidence suggests a strong inter-correlation 
between decline on individual tests; this suggests the presence of the general 
intelligence component
19
. Since it was first proposed by Spearman
20
, it has received 
a great deal of support from a great deal of epidemiological evidence
2
 as well as 
experimental support, including evidence for specific neuronal function associated 
with performance on a diverse set of cognitive tests
21
.  One of the most compelling 
pieces of evidence was proposed by John Carroll; The Three Stratum Theory
22,23
.  
Factor analysis of approximately 460 data sets resulted in the identification of three 
layers of cognitive abilities: narrow, broad and general. The narrow stratum consists 
of 69 cognitive abilities that are grouped into 7 categories within the broad stratum. 
These domains are: crystallized and fluid intelligence; general memory and learning; 
broad visual & audio perception; retrieval ability; cognitive speediness and 
information processing speed
22
. Consistent with the ‘Dual Component Theory of 
Intellectual Development’ outlined above, Carroll also identified differences in 





1.1.3 Neuro-Biological Process and Pathological 
Determinants of Cognitive Ageing 
Commonly, cognitive ageing is associated with later life brain-related biological 
processes. Whereas some brain structures remain relatively intact until much later in 
a person’s life, some specific structures and volume brain alternations can commence 
as early as in third decade of person’s life. The location, degree and speed of 
anatomical degeneration are closely linked to brain development in two ways: the 
phylogenetic (evolutionary) and ontogenetic (life-time) development.  
The brain consists of multi-layered structures: phylogenetically the oldest is the 
subcortical structure; followed by relatively young cortex, further subdivided into 
two hemispheres. The evolutionary youngest subdivision is the neocortex
24
. From 
this point of view, the brain is dominated by one grand theme – the gradual transition 
from hard-wired structures to evolutionary younger open-ended structures. In terms 
of ageing, the younger cortical subdivisions suffer most from the detrimental effects 
of ageing. In particular, in the neocortex, the hetero-modal association cortex (the 
region that receives multiple sensory input requiring integrated cognitive activities
25
) 
including the infero-temporal, infero-parietal and particularly the (evolutionary) 
youngest prefrontal cortex are most affected. In contrast, the oldest parts receiving 
raw sensory information and the motor cortex are least affected, remaining relatively 
intact till the final stages of person’s life
1
. Similar principle applies when we look at 
the brain anatomy processes associated with the ontogenetic development and decay 




affected by age-related changes; in this respect, it is the frontal lobe, especially the 
prefrontal cortex that generally doesn’t reach the fully functioning development until 
the age of 16-18
26
. In an otherwise healthy brain, age-associated anatomical changes 





, age-related vascular events
29




On average, the weight and volume of the brain decreases about 2% every decade of 
the adult life. This brain atrophy is linked to the progressively increasing size of the 
ventricles whilst sulci become more prominent. The exact mechanism of this is yet to 
be determined, nevertheless, a few mechanisms have been proposed. It has been 
argued that decrease in dendritic synapses and loss of synaptic plasticity might be 
responsible for brain shrinkage. Synaptic plasticity is a term referring to the ability of 
synapses to adapt to overall neuronal activity.  Synapses are either strengthened by 
combined pre- and postsynaptic neuronal activity or they are weakened by non-
coincidental neuronal firing.  Research has found that synaptic plasticity is facilitated 
by specific ion channels
31
.  Further, there is an evidence for a key role of several 
kinds of neurotransmitters in this process
31
.  Moreover, neurotransmitter levels relate 
to age related decline in cerebral dopamine receptor density, with a central role 
implied in modulating responses to contextual stimuli and regulating attention
31
. 
Generally, there is an ‘anterior-to-posterior gradient’ with the pre-frontal cortex 
being the most, and the occipital lobe being the least affected
30
. Furthermore, age-
related brain atrophy occurs faster in cortical thickness and grey matter rather than 
white matter
16




36% of reduction in the  nucleus accumbens (mood regulation), 37% in the thalamus 
(sight, hearing, sleep-awake cycle) and 33% in the hippocampus (episodic 
memory)
7,31
; these are some of the most notable age-related changes, affecting 
person’s ability to carry out the activities of daily living as they once used to.  
In terms of the white matter age related anatomical changes, hyper-intensities (small 
focal lesions), usually reflect vascular illness as well as demyelination of pathways. 
Chronology of myelination is a great marker for both development and decline; 
pathways that require the longest time to myelinate are most susceptible to effects of 
ageing
31
. Again, it is the prefrontal cortex, and, within that, the dorsolateral 
subdivision in particular
32
.  This region plays a vital role in information transfer 
between cortical areas, a process that is crucial for higher and/or comprehensive 
cognitive proficiency
16,33,34
. However, there is no linear/causal relationship between 
white matter lesions and cognitive decline. Indeed, the damage to white matter 
integrity can be seen as have a threshold nature: up to a certain level it is benign, and 
beyond that it affects speed of cognitive decline. 
In summary, the exact evidence of association between age-anatomical brain changes 
is yet to be determined; age related anatomical changes account for 25-100% of 
variance in cognitive ability
15
 between young and aged individuals, with a decline in 
some cognitive abilities commencing in a third decade of life, others maintained until 








1.1.4 Age-related changes in cognitive ability 
Age-related cognitive impairment is commonly subcategorised into ‘normal’ (non-
pathological) or ‘pathological’. With respect to the former one, changes in cognitive 
performance are anticipated and within the norm for the person’s age and education.  
This is distinguished from the pathological cognitive impairment and/or decline 
where the decreased ability in cognitive function that is greater than expected for the 
sex and age matched population norm and where it presents with clinical 
manifestation of cognitive impairment/dementia
15
.  
As an alternative to the distinction between normative and pathological ageing, it can 
be argued that since decline in cognitive performance is always due to a set of neuro-
pathological changes, as described in section 1.3, cognitive ageing should be viewed 
as a continuum where the degree of damage is manifested in tandem with clinical 
symptoms and that this might be, in certain circumstances, accelerated by a whole 
array of risk factors and events. For example, one of the most prominent risk for 
declined performance in cognitive functioning is the presence of systemic 
inflammation; research indicates that decline of both cognitive ability and the 
immune system might commence as early as the 3
rd
 decade of life
36
, thus suggesting 
an inter-related effect on cognitive performance that is pathology-loaded. This 
approach better accounts for the gradual shift from mild cognitive changes to a 
detectable subclinical impairment (i.e. mild cognitive impairment) and, in some 




there is a great of heterogeneity between individuals with respect to the speed and 
trajectory of domain specific decline. Some remain relatively stable
37
 and some 
might even show improvement
1
, including emotional stability
37
. Lastly, the presence 
of Alzheimer’s Disease neuropathological facets was detected in brains of otherwise 
clinically asymptomatic individuals
38
. Therefore, classification of ‘normal’ brain 
ageing might be too narrow and potentially misleading.  
Typically, memory functioning is one of the first domains to decline; specifically, it 
is the delayed recall of verbal information, working memory, and short term recall
39
. 
Most memories are formed and stored in the neocortex; certain memories require the 
support of few subcortical (non-neocortical) structures and these are extremely 
vulnerable to decay and neuro illness
1
. Greater quantitative changes usually occur in 
episodic memory than semantic memory (episodic memory or autobiographical 
memory refers to memory of events that have occurred in our personal past. 





episodic memory, it is the ability to recall that deteriorates faster than 
recognition/familiarity
40
. Furthermore, performance on task assessing executive 
functioning is often detected at earlier stage of ageing
26
.  Given the high, superior 
role of the frontal lobe functioning, particularly its importance managing and 
organising the complexity of individual cognitive functions, it can be reasoned that it 
can mediate domain specific decline
33
. Moreover, there is also a strong possibility 
that domain specific decline occurs as a result of a general decline in information 
processing speed
41
. This might also (partially) explain why when we get older we 




evidence accounting for an exact bio-pathological mechanism is so far inconclusive, 
currently under ongoing investigation.  
1.1.5 Mild Cognitive impairment Cognitive Decline and 
Dementia 
The meaning of the word dementia is “the loss of mind” 
1
; term that refers to a 
gradual process, affecting certain faculties progressively faster than others
26
 and that 
results in notable disturbance to intellectual and personality functioning and 
communication. Therefore, cognitive ageing should be perceived as gradual 
continuous processes with certain distinct, measurable points.  
 
Mild Cognitive Impairment 
On the continuum of the ageing process, MCI is considered an immediate or 
transitional state of cognitive impairment. Typically, an fMRI scan can detect brain 
pathology in a form of neurofibrillary tangles (NFT) in temporal or temporal-parietal 
lobes, which corresponds with clinical symptoms including objective impairment in 
memory function greater than expected for an individual’s age and education 
(amnestic MCI)
42
. Other cognitive faculties remain intact, i.e., presentation is 
according to expectations of matched age and education person. The clinical criteria 
and clinical profile associated with dementia symptoms and measures are not 




impairment are classified; i.e., non-amnestic MCI. It is, however, the amnestic MCI 
that shows the highest conversion rate to dementia, particularly into Alzheimer’s 
Disease
43
. In fact, the presence of apolipoprotein ApoE 4 allele, associated with 
sporadic AD
44
, is also significantly higher in the amnestic subtype of MCI suggesting 
a possible explanation for this relationship
45
. 
Figure 1 below demonstrates the progressive stages of neuro-pathological changes; 
compared to control, some changes are detectable in MCI patients (the three middle 
images), whereas other regions and consequently other cognitive faculties remain 
relatively preserved; a scan of a brain at AD at the far right shows spread 
neuropathological changes in the form of massive reduction in hippocampal volume. 










Cognitive Decline and Dementia 
Currently, there are approximately 50 dementia aetiologies proposed
15
, with differing 
degree of severity of associated deficits and differing clinical profiles. Furthermore, 
the duration of this condition also differs between types, ranging from chronic to 
gradually more progressive to a final, detrimental stage; always it is represented by a 
cluster of dementia-type specific symptoms. With ongoing progress, the affected 
person experiences gradually increasing difficulties related to the affected cognitive 




 are also extremely common in 
dementia diagnosis.  
Among the identified types of dementia, the most common causes are Alzheimer’s 
disease (AD) and vascular dementia (Vad). Biologically, the precise mechanism of 
AD is yet to be fully determined; definite diagnosis can only confirmed by post-
mortem examination
15
. Nevertheless, a number of brain pathologies are shared in AD 
patients; neurofibrillary tangles (NFT) and - amyloid plaques. Intra-cellular NFT 
consist of a hyper-phosphorylated form of micro-tubule, associated protein tau. 
Hyperphosphorylation (among other processes) is crucial to the molecular 
pathogenesis of neurofibrillary degeneration of AD. Also, abnormal filaments are 
seen in soma and proximal dendrites of specific neurons
48
. Once a cell is affected, it 
basics mechanism is disturbed, which leads to a cell death, leaving the tangle 
behind
31
. Over production - amyloid protein leads and disturbance to its natural 
function of down regulation of excitatory synaptic transition and plasticity; as a 
result an extra-cellular deposit of - amyloid plaques are formed by a dense core of 




astrocytes. Once the degenerating tissue has been destroyed, only a core of β-
amyloid remains
31,49
. Clinically, standardised diagnostic criteria include significant 
memory impairment accompanied by impairment in at least one other domain, most 
typically aphasia, apraxia, agnosia and executive functioning
50
 
In terms of VaD, most commonly it is caused by a range of vascular lesions; cerebral 
small vessel diseases, associated with lacunar infarct
51
 and damage to myelin in a 
form of white matter lesions
52
. Large vessel VaD is usually associated with trombo-
embolic, either localised (single infarct dementia) or infarctions spread throughout 
the brain (multi-infarct dementia
53
. The former commonly leads to a progressive 
deterioration of the frontal lobe, linked to decline in executive functioning
53
. This 
multi-pathological origin of VaD complicates a definite diagnosis; rather a set of 
clinical criteria are commonly applied. At present, clinical diagnosis of VaD requires 
detection of significant cognitive impairment (as described in AD diagnosis), along 
with confirmation of relevant vascular profile.  
Definite diagnosis of each type of dementia can be further complicated by the 
possible co-existence of symptoms
54
.  Furthermore contrary to the previous view 
distinguishing between aetiologies of AD and VaD, there is increasing evidence of 
the vascular nature in development of AD
55
. Lastly, clinical diagnostic criteria rely 
heavily on research evidence assessing a change in cognition over time associated 
with a whole range of inter-related, multifactorial determinants as well as protective 
factors. Both cross-sectional and longitudinal designs have their pros and cons, 




1.1.6 Cognitive Reserve  
For decades it was assumed that cognitive deterioration, accompanied by specific 
clinical symptomatology was an inevitable and irreversible attribute of the overall 
ageing process.  In other words, if one lives long enough, s/he will exhibit age-
specific symptoms and consequent difficulties. Such people were commonly 
described as ‘senile’
7
. Nevertheless, in recent years growing evidence suggests an 
alternative hypothesis that postulates a certain degree of resilience to age-related 
neuro-pathologies.   
There is a great degree of heterogeneity between individuals in terms of pattern and 
speed of the trajectory of cognitive decline. Within the ‘reserve hypothesis’ there is a 
large degree of individual variation in the extent of how much the cognitive 
functioning, defined by results of psychometric testing and observed ability to cope 
with activities of daily living, can be protected against the influence of age-related 
brain neuro-pathological changes
56
. There is a wide-ranging spectrum of putative 
indices for cognitive reserve.  
By definition, the concept of cognitive reserve maintains that aspects of brain 
structure and function, such as neural plasticity and efficiency of the neural network, 
buffer the effects of either age-related neuropathological changes, such as formation 
of - amyloid plaques and neurofibrillary tangles, vascular damage, etc
38
.  There are 
currently two possible explanations for the concept cognitive reserve: neuro-




reserve, defined as the brain‘s capacity to buffer the effects of insults, is closely 
linked with neural regeneration and functional brain re-organization that can prevent 
cognitive ageing and/or preserve cognitive function despite chronological age
57
. The 
explanation based on the neuro-compensation mechanism is centered around the 
hypothesis that the ageing brain may compensate structural losses in functional areas 
by recruiting previously unrelated parts of the brain to take over cognitive function 
roles
34
. For example, hippocampal atrophy is significantly correlated with stronger 




Epidemiological evidence indicates the role of childhood intellectual performance
59
, 
educational attainment and occupational status
60
 plays a role in preserving cognitive 
proficiency. Pre-morbid intellectual functioning is considered as a chief factor; in a 
longitudinal study of ageing, 43.4% of variance in old-age cognitive ability (in a 
middle 70s) is determined by an early life (11 years of age) cognitive performance
61
. 
Valenzuela found that educational level was significantly associated with the 
preservation of cognitive skills but only in combination with occupational 
complexity and social engagement
56
. 
Interestingly, recent systematic literature review indicate that high level of cognitive 
reserve, i.e. high pre-morbid intellectual ability was positively correlated with far 
faster decline after proposed diagnosis of AD
38
. This is possibly due to a concise 
constellation of strongly connected neurons in people with rich factual and 
procedural knowledge. It is reasoned that the advanced cognitive faculty enables an 






. Neurofibrillary tangles, one of the most typical attribute of 
AD, occurs in varying quantities in the brains of non-demented subjects
62
. 
Substantial amount of studies reported autopsy detection of neurofibrillary tangles in 
individuals who were diagnosed with MCI who had not progressed to frank dementia 
as defined by Diagnostic Statistical Manual-IV
63,64
. It is reasoned that in subjects 
with advanced pre-morbid cognitive ability, greater pathological alternation and 
damage is required prior to manifestation of clinical symptoms of dementia
1
 and 
prior a formal neuropsychological and clinical assessment. Therefore in these 
subjects, frank dementia is diagnosed at higher level of severity when the rate of 
decline is steeper. At this stage of dementia it is also less likely that clinical 
intervention can effectively manage inevitable consequences of dementia
65,66
.  
The exact mechanism of the cognitive reserve concept is yet to be established. 
Attempt to explain how, in the face of normative age-associated structural brain 
changes, individuals vary greatly in the process of cognitive ageing is imperative – 
identification of modifiable risk factors for accelerated age-related cognitive decline 
as well as protective factors that might reduce the otherwise inevitable age-related 
cognitive impairment and decline will provide a major platform for targeted clinical 






1.1.7 Cognitive epidemiology - Prevalence of age related 
cognitive impairment and cognitive decline – 
overview  
Life expectancy has changed radically over the last century. Whereas in 1901, it was 
49 years of age for women and 45 years of age for men, in the 2005 healthy life 
expectancy at 65 years of age is 15 years for women and 13 years for men
67
. 
However, approximately 15% people of 65 have been classified as disabled, of those 
62% need care at some point on daily basis and 21 % on a continuous care basis
68
. In 
Scotland specifically, the majority of over 65 years of age have been diagnosed with 
two or more conditions and the majority of over 75s with three conditions with a 
multi-level and multi-factorial relationship between them all; either directly or 
indirectly contributing to accelerated cognitive decline and/or dementia. In particular, 
those diagnosed with dementia can also suffer from any combination of the 
following conditions: coronary heart disease: hypertension heart failure; stroke/TIA; 
T2DM; COPD; clinical depression or other detrimental conditions
69
. 
However, the difficulties in distinguishing between age-related cognitive changes 
and accelerated cognitive decline and the inconsistencies in defying mild cognitive 
impairment (MCI) and dementia present a severe issue in establishing prevalence and 
incidence of these conditions. In particular, a unique criterion for diagnosis of MCI 
has not yet been postulated; rather, diagnosis incorporates a set of clinical judgments. 




of prevalence and incidence of MCI and/or dementia. Estimates of MCI in 
population of 65 years of age was fluctuating between 3% up to 19%, estimates for 
cognitive decline ranged from 21% in 60 
70
 and older to 27% in 65 and above years 
of age 
71
. The incidence rates of MCI have ranged greatly from 8 to 58 per 1000 per 
year in the general elderly population
43
, depending on diagnostic criteria, sample 
structure, follow-up and cognitive measures. Furthermore, annual conversion rates 
from MCI to dementia have been found to be high in clinic samples ranging from 




Similarly, establishing the precise number of incidents of AD and VaD, and 
distinguishing them from other dementia types, is complicated by shared aetiologies 
as well as the possibility of both conditions co-existing.
54,68
. Despite the use of 
different methodologies for case identification and definition between studies, 
increases in the prevalence and incidence of dementia with age have been 
consistently reported. In terms of world-wide prevalence of dementia,  whereas at 
2001, there were 24 million dementia sufferers, at 2010 it leaped to 35 million with 
an estimated increase to 65 million in 2030 and 113 million in 2050
75
. A similar 
trend is observed in the UK; currently dementia affects approximately 700 000 
people above the age of 65 years and it is expected to double by the year 2051
76
. 
Specifically, data in the UK indicate that prevalence of dementia of all types ranges 
from 1.3% to 2.9% in 65-74 years of age, 5.9%-112.2% in 75-84 years of age and 
from 20.3%to 32.5% in 85 and above years of age
76
. An age-related trend in 




AD was the dominant type of dementia, accounting for 62% of all cases (and was 
more common in women), while VaD and mixed dementia, accounting for nearly 
one third (27%) of all cases (and was more common in men). Similarly, among 
participants in the Cardiovascular Health Study, a steady increase in the incidence of 
dementia with age was noted in both men and women
77








1.2  Risk Factors – Determinants  
In the previous chapter a number of determinants and risk factors have been 
mentioned that might play a role in age-related cognitive decline. To date, research 
has identified the relationship of increased levels of circulating inflammatory makers 
in relation to cardiovascular co-morbidity and type 2 diabetes that themselves are 
significant risk factors for age-related cognitive impairment and cognitive decline. 
The focus of the following sections will be on an overview of biological mechanisms 
of inflammatory and haemostatic markers. Epidemiological evidence of association 
between elevated systemic inflammatory markers and cardiovascular disease and 
type 2 diabetes will be discussed. The last part will focus on type 2 diabetes, to 
define the disease, its diagnosis and relevant risk factors. This section will conclude 
with discussing evidence of relationship between prevalence of type 2 diabetes and 
age-related cognitive decline.  
1.2.1 Inflammatory and Acute-Phase Response Markers 
Inflammation is an integral first line of defence response to injury or a disease-
causing stimulus with the primary attempt to restore and maintain homeostasis after 
injury
78
. Although inflammation is essentially beneficial, an excessive or prolonged 
inflammation can cause harm. Most of the body’s defence elements are located in the 
blood; inflammation is the means by which body defence cells and chemicals leave 






Principally, inflammation can be subdivided into acute and chronic phases, each 
manifesting with specific components and processes. In terms of an acute 
inflammation, it can be subdivided into three interrelated components: vascular 
dilatation (vasodilatation), endothelial activation and neutrophil activation
80
. 
Visually, the characteristic signs of inflammation are redness, heat and swelling; 
indeed, the literal meaning of the word inflammation is “setting on fire”
81
.   
Vasodilatation is the earliest inflammatory response, followed by relaxation of the 
vascular smooth muscle. This results in an increased permeability and blood flow 
(i.e., hyperaemia). Hyperaemia causes redness and the entry of the fluid into the 
tissues (erythema and oedema, respectively)
82
.  Acute inflammation can present with 
varied outcomes, such as resolution, where normality is restored, scaring (fibrosis) 
and abscess formation or progressing into chronic inflammation. Therefore, typically 
chronic inflammation is prolonged type processes, caused either by persistent 
inflammatory stimulus or ineffective inflammatory mechanism
82
.   
On a microscopic level, it involves responses in the immune system by a number of 
different chemical substances, called acute phase protein and cytokines, which are 
elevated and released by the rather complex immune system
83
. Specifically, sentinel 
cells, e.g. macrophages that are derived from blood monocytes, detect threats from 
infection or other environmental factors, such as food or chemicals, due to pattern 
recognition receptors
81
.  Activated microglia produce the potent pro-inflammatory 
cytokines interleukin-6 and TNF-alpha
84
. These inflammatory cytokines are the main 
mediators of a hepatic acute-phase response, causing an elevation of acute-phase 




response is accompanied with systemic and metabolic changes, specifically increased 
blood viscosity, platelet number and activity
83
 in order to restore body haemostasis 
and to remove the cause of disturbance to the system
83,85
.  Therefore on a molecular 
level, these inflammatory markers mutually affect production and regulation of other 
cytokines and acute phase reactants.  Specifically relevant to this study, IL-6 is 
known to inhibit an expression of TNF-alpha
86
, which plays a key role in the hepatic 
production of CRP
87
 and, apart from a host of other acute-phase reactant, also 
influences the production and synthesis of plasma fibrinogen
88
.  Furthermore, IL-6 
on its own
88
 and together with TNF-alpha have been shown to stimulate both 
fibrinogen and CRP production
81
. This biologically tight and mutually compatible 
mechanism provided rationale to assess associations between cognitive scores and 







Figure 2: Innate Immune System 
 
A bi-directional relationship between the brain and the immune system allows for a 
an interactive coordination where the brain is informed about peripheral process by 
the immune system, acting as a diffuse sense organ
89
. At the same time, the brain 
itself is immunologically active, actively communicating with the immune system, 
forming an integrated connection between brain and body, thus systemic 
inflammation influences brain function. Typically, elevated levels of cytokines are 
associated with sickness behaviour
90
. This term commonly used to explain a bodily 
strategy that is triggered by mechanisms of brain actions to elevated levels of 




produced by activated microglial cells of the innate immune system, play a pivotal 
role in the acute-phase response. Sickness behaviour is also characterised by 
activation of hypothalamic-pituitary-adrenal (HPA) axis
91
. As a response to 
psychological stress, activation of the sympathetic nervous system as well as 
activation of the HPA axis leads to release of stress-specific hormones, such as 
adrenocorticotrophic and glucocorticoids
92,93
.  Cytokine IL-6 is particularly known to 
affect activation of the HAP axis during an individual’s exposure to a psychosocial 
stress
85
.  The term sickness behaviour therefore encompasses psychological and 
biological components of the bodily response to pathogen-associated processes.  
The next part of this chapter will provide an overview of the cytokines Interleukin-6, 
TNF-alpha and acute-phase protein fibrinogen and C-reactive protein. The following 
sections will then discuss epidemiological evidence addressing the role of systemic 
inflammation in cardiovascular disease and in T2DM. 
1.2.2 Interleukin - 6 
Interleukin 6 (IL-6) is a pleiotropic cytokine known to influence a number of cellular 
processes, such as a cell growth and regulation as well as activating inflammatory 
cells to induce a process of inflammation. It is produced by several cell types, 
including activated monocytes and macrophages, T cell lymphocytes, endothelial 
cells and adipose cells
94,95
. As well as TNF-alpha, its primary tissue of origin is the 
adipose tissue and typically it circulates at s low level; IL-6 has a short half-life (2-4 






IL-6 expression, specifically its anti-inflammatory properties, are mediated as a 
reaction to stimuli of other inflammatory markers, such as pro-inflammatory TNF-
alpha, IL-1, IL-4, for example
88,96
.  It plays a fundamental role in regulation of the 
immune responses, making it a crucial component in inflammatory cascade process. 
IL-6 can induce both pro and anti-inflammatory response, and it has both, 
inflammatory and haemostatic properties. IL-6 has a role in up-regulating a number 
of haemostatic variables that includes fibrinogen as well as an inflammatory role that 
leads to an increased endothelial cell adhesiveness
85,97
.  
Due to its pleiotropic effects, IL-6 affects a majority of peripheral-to-brain immune 
responses by modulating neural, neuroendocrine and behavioural systems
98
.  Animal 
studies provide experimental evidence of an IL-6 altering role linked to the brain 
function due to its ability to cross the blood-brain barrier (BBB) 
99
. The blood-brain 
barrier is selectively permeable with some substances passing through.  IL-6 is one 
such a marker. This cytokine is able to by-pass the BBB and bind to the receptors on 
macrophages, activate them consequently modulate the BBB permeability. As a 
result, the compromised BBB disruption is the hallmark of neuroinflammatory 
disease state, linked to an activation of glial cells. Glial cells form approximately 
two-thirds of the brain cells, the remaining one third is formed by neurons. The main 
function of the glial cells is providing support and nourishment to neurons. There are 
two types: astrocytes that directly participate in neural computations by modulating 
the work of neurons and oligodendrocytes that wrap around axons, forming a fatty 
protective coating (myelin). Myelin facilitates signal transmission along the axon, 




neuronal network. Therefore the role of fully functioning glial cells is vital for a 
healthy brain function
1,31
. During a chronic inflammation state, all glial cells remain 
active for an extended period during which the production of mediators are 
sustained; this leads to neuronal death and particular molecular and cellular 
mechanisms that are known to underlie cognitive function, such as synaptic 
plasticity, long term potentiation, neuro-genesis and memory consolidation. Animal 
experimental studies also show that IL6 can enter the blood with the reabsorption of 
the cerebral-spinal fluid
99
. It was demonstrated that whereas mice with an over-
expressed IL 6 showed 63% reduction in cognitive ability and those mice that did not 
express IL-6 improved their cognition (maze learning and reduced amnesic effect), 




1.2.3 Tumor Necrosis Factor –  
Tumour Necrosis Factor – alpha  (TNF-alpha) owes its name to its ability to destroy 
malignant tumour cells in mice, as described by Carswell
101
. The TNF-alpha primary 
role is pro-inflammatory with its a vital role in maintaining immunity. As a potent 
mediator of pro-inflammatory process, it plays an important role of a whole range of 
(patho) physiological mechanisms: an induction of cell death leading to a cell 
removal is one of the key role of TNF-alpha. The production of TNF-alpha 
predominantly occurs in mononuclear cells and activated by a tissue injury and 
tumour cells
102




in the brain, unlike IL-6, it lacks the ability to penetrate the blood-brain barrier
99
. 
Nevertheless, increased concentrations of TNF-alpha are known to have an injurious, 
damaging effect on neurons
103
.  
Along with IL-1 and endotoxin, TNF-alpha induce in vivo IL-6 production and is a 
powerful responder to bacterial infection
104
; along with IL-6, it is directly involved in 
a hepatic activation of the acute phase response
81
. TNF-alpha increases vascular 




1.2.4 Fibrinogen  
Fibrinogen was first named by Rudolf Virchow (1821-1902), who identified three 
components necessary for thrombogenesis: i) endothelial dysfunction ii) blood 
constituents and iii) blood flow
106
.  Fibrinogen is synthesized in the liver through 
hepatocytes
107
. Alternative production is also possible in a bone marrow cells 
(megakaryocytes) that are mainly responsible for the production of blood platelets, 
required for normal blood clotting
108,109
. It has a biological half-life of approximately 
100 hours
108
. Fibrinogen is a complex, multifunctional and large (340 kD
110
) plasma 
glycoprotein, composed of two identical halves
109
. Each consist of three pairs of 







Fibrinogen is the main coagulation protein in plasma, less susceptible to acute 
changes than C-Reactive protein; fibrinogen circulates in plasma in concentrations 
between 1.5 g/L to 4.5g/L 8. Hepatic synthesis and production of fibrinogen is 
regulated by a number of cytokines and other molecules, mainly by IL-6, where 
evidence supports that IL-6 production is dependent on prior stimulation by fibrin 
degradation products. Additionally, fibrinogen production is also stimulated by IL-1 
and TNF-, whereas the synthesis is suppressed by IL-4, IL-10 and IL-13 
109
.  
As forming a part of the process of haemostasis, haemocoagulation is formed by the 
cascade of enzymatic reactions with the key aim to transform fibrinogen into 
insoluble fibrin. This process comprised of two pathways, the intrinsic and extrinsic, 
eventually combined into a single pathway. The final product of the cascade fibrin 
follows by combining aggregated platelets into a final product is the clot – the 
thrombus. Particular substances called coagulation factors are mainly plasmatic 
proteins, synthesised in the liver. Traditionally they are marked by Roman numerals; 
allocation of the letter ‘a’ indicates that this factor has been activated. Following 
from the stage of the common pathway, thrombin (factor IIa) has a catalytic 
influence which results in separation of several monomer-type peptides, resulting in 
fibrin that, through polymeric reaction with other monomers leads to formation of 
fibrin mesh. An activation of the factor IIIa along with positively charged calcium 
ions Ca
2+
 must occur to stabilise and strengthen the fibrin mesh
107,111
.  




The first detection of C-reactive protein (CRP) as an inflammatory marker was in 
1930 in the sera of patients who were acutely ill with pneumococcal pneumonia. It 
was named because its reactivity with polysaccharide ‘C’ of streptococcus 
pneumonia
79
. CRP is a calcium-binding pentameric protein. It consists of five 
identical non-glycosilated polypeptides 23-kd subunits. It is an acute phase reactant. 
Hepatic production occurs within a few hours after the injury or in the presence of 
inflammation. As plasma fibrinogen, CRP activation occurs under activation of IL-6; 
IL-1 and TNF-alpha also paly role in this
112
. Normal, physiological CRP level is 
considered to be a value <10mg/L with healthy individual generally having <1 mg/L. 
In comparison to other inflammatory markers, CRP has a longer half-life (19-20 
hours), therefore it also has a greater stability over a longer time period. Levels of 
CRP remain increased throughout the whole acute phase response until normal tissue 
function is restored 
79
.  
There are two main functional roles of CRP. It is able to modulate the function of 
phagocytic cells and it plays an activation role in the classic complementary 
pathway
82
. Additionally, CRP participates in an induction of inflammatory cytokines 
and tissue factors in monocytes and it also activates endothelial cells in order to 









1.2.6 Markers of Inflammation and Cardio-Vascular 
Comorbidity  
Elevated inflammatory mediators have been associated with coronary heart disease 
(obstructed blood supply to the heart), with cerebrovascular disease (obstructed 
blood supply to the brain) and with peripheral artery disease (obstructed blood 
supply to the lower limbs)
82
. These atherosclerotic conditions are collectively 
referred to as ‘macrovascular disease’. Large-vessel atherosclerosis often leads to 
cerebral hypofusion that may result in artery-to-artery embolism that can also be 
associated with higher risk of cerebrovascular event. There is evidence of coronary 




There is convincing evidence from clinical as well as biological studies that in the 
presence of macrophages, inflammation leads to the localised recruitment of 
neutrophils, monocytes and the presence activated macrophages in the cap of the 
atherosclerotic plaque
85
. Atherosclerosis is a systemic disease that affects the 
majority of the vascular system. Lesions in arteries supplying blood to the brain, i.e. 
carotid arteries and extra-cranial arteries are of greater clinical importance. The 
pathogenesis of atherosclerosis is a complex, cascade process that includes 
development of chronic inflammatory processes. The haemodynamic damage to the 
artery leads to dysfunction of the endothelium along with activations of cytokines, 






The selection of factors contribution to endothelial dysfunction is rather complex. 
The process includes haemodynamic issues, formation of reactive forms of oxygen 
and nitrogen, elevated artery pressure, genetic variants coding for inflammatory and 
respiratory responses, elevated homocysteine levels, hypertension, diabetes, 
hyperlipidaemia and smoking. As a response to the endothelial damage, normal 
(physiological) arterial properties are altered. Responding to leucocytes and palates 
increased levels, adhesive endothelial cells are affected and there is an increase in 
walls’ permeability. Consequently, endothelium adopts pro-coagulant (instead of 
anti-coagulant) properties and cytokines and adhesion molecules are elevated, which 
results in further damage that eventually leads to focal necrosis
115
. Endothelial 




Contrary to the previous assumption that atherosclerosis is caused by cholesterol 
diseases and consequently obstructing arteries
116
, the predominant role of 
inflammation and haemostasis in the aetiology of atherosclerosis is now generally 
acknowledged and accepted
117
. In fact, approximately half of the people who 




The infusion of IL-6 and TNF-alpha induces systemic inflammatory response as well 
as activation of coagulation. In laboratory experiment with mice, blocking the TNF-
alpha did not affect coagulation, unlike blocking the IL-6 expression
119
, suggesting 
the central role of IL-6 in the mechanism of activation of the coagulation cascade. 




promotes atherosclerosis due to its pro-coagulant as well as pro-inflammatory 
properties
110
. It plays a key role in the clotting cascade through to conversion to 
fibrin that stabilizes blood clots fibrinogen, which induces platelet aggregation, 
forming a clot, which reflects the thrombotic potential of blood
107
. During the 
development of the atherosclerosis, the disease is often asymptomatic but there is an 
increased risk of atherosclerotic plaque rupture and activation of the coagulation 
system, due to a complex mechanism. Specifically, fibrin is known to moderate 
endothelial cells. It is an adsorptive surface for LDL cholesterol; its breakdown 
during the process called fibrinolysis results in aggregation of lipids and plaque 
growth. When the plaque eventually ruptures, it results in an inflammatory response 
that, in turn, initiates the atherothrombotic cycle
107
.  
Cytokines IL-6 and TNF-alpha and acute-phase proteins fibrinogen and CRP have 
been identified as prominent, contributing factors in the development of both stable 
and unstable atherosclerotic diseases
120,121
.  In cognitively healthy, community-
dwelling subjects, systemic inflammation was significantly correlated with 
hypertension, including those on prescribed anti-hypertensive medication
122
. 
Significant correlation between fibrinogen, IL-6, CRP and TNF-alpha and angina 
was detected, with CRP and TNF-alpha recognised as the strongest predictor of 
coronary event
123
. IL-6, TNF-alpha and CRP interfere directly as well as indirectly 
with the endothelial function,TNF-alpha and  IL-1 were found in atherosclerotic 
lesions
124
 and also directly linked to hypertension
102
 . 
Elevated plasma fibrinogen levels have been described as one of the major risk 
associated with cardiovascular disease
125




been supported in relation to elevated plasma fibrinogen levels
126
.  A comprehensive 
review of studies that investigated the role of plasma fibrinogen and cardiovascular 
co-morbidities was conducted (Fibrinogen Studies Collaboration
127
).  Findings from 
a meta-analysis of 154211 adults, collated from 31 prospective studies with a 
minimum of a 1 year of follow-up time period. This report summarised that 
increased levels of plasma fibrinogen were significantly associated with 6944 cases 
of non-fatal myocardial infarctions or strokes and 13210 cases of death. In terms of 
evidence gathered from genetic association studies investigating relationship of 
fibrinogen-related gene variants with incidence of CVD
128-130
, the current results are 
largely inconclusive, suggesting the need for larger, epidemiological studies.  
In terms of CRP and its role in the process of atherosclerosis, CRP has been 
suggested to be a valuable diagnostic marker; elevated levels of plasma CRP are 
known to precede clinical symptoms of atherosclerosis
131
. Evidence of a direct role 
of an increased CRP levels in development of atherosclerosis is conflicting
132
. CRP 
elevation was associated with a 10-year risk of development of coronary heart 
disease in middle aged adults, independently of presence of the conventional 
vascular risk factors
133
. Findings from the Edinburgh Artery Study, population-based 
cohort of men and women aged 55 to 74 years, reported significant association 
between hsCRP levels and increased severity of peripheral arterial disease
134
. 
However, in vivo mice models provide inconclusive results of a causal role of CRP 
in development of vascular disease
135
. It therefore seems that the role of CRP in 
development of atherosclerosis is indirect, related to vascular damage along with 




TNF-alpha, evidence shows an involvement of these cytokines in the development of 
cardiovascular condition. In a large study of middle aged men and women, after 
adjustment for conventional cardiovascular events and risk factors, the risk ratios for 
the highest tertile of these markers and myocardial infarction was 1.27; 95% CI, 1.10 
to 1.48; for congestive heart failure 1.72; 95% CI, 1.40 to 2.12 and for stroke it was 
1.45; 95% CI, 1.12 to 1.86
120
. Nevertheless, findings from the Rotterdam Study 
found no significant association between IL-6 and carotid IMT or carotid plaques
136
. 
In general, studies tend to report reasonably consistent evidence of significant 
associations between IL-6 and CVD, independently of adjustment for major vascular 
risk factor
82
. The role of TNF-alpha appears to be mainly in terms of activation of 
expression of IL-6 (along with IL-1)
85
 and thus inducing the inflammatory cascade 
(described above), rather than a direct role in aetiology of atherosclerosis. Over-
expression of TNF-alpha has been detected in the adipose tissues of obese adults and 
is associated with reduced activity of the insulin receptors
137
.   
In summary, epidemiological evidence suggests significant association between 
elevated inflammatory markers and increased risk of atherosclerotic disease. The 
relationship between inflammation and atherosclerosis can be seen as bi-directional 
with multiple and multifactorial role of these markers in inflammation as well as 
coagulation processes. In recent years, increasing evidence from prospective studies 






1.2.7 Markers of Inflammation and Type 2 Diabetes 
The relationship between low-grade inflammation and development of type 2 
diabetes was first proposed in 1987
81
 and since then it has received an increasing 
attention. It has been proposed that inflammation induced insulin resistance and 
impaired insulin secretion might be an integral part of the pathogenesis leading to 
diabetes. T2DM and insulin resistance are closely correlated (approximately 90% of 
diabetic population
138
), which is the preceding signs of the disease.  
It is well acknowledged that there are a number of possible mechanisms in which 
inflammation, cytokines in particularly, contribute to insulin resistance, impaired 
insulin secretion dyslipidemia and progressive atherosclerosis
82
. This suggests a 
possible ongoing cytokine mediated acute-phase response that is closely involved in 
the pathogenesis of the T2DM. Prospective evidence suggests that elevated acute-
phase proteins, such as plasma fibrinogen and CRP are significantly associated with 
development of insulin resistance in T2DM
112
. This would suggest that the 
consequence of atherosclerosis is not only inflammation but also insulin resistance.  
The role of both, obesity and atherosclerosis has been implied in this relationship. 
Obesity, particularly truncal obesity, is strongly related to increased levels of 
inflammatory markers, in particular plasma CRP levels
85
. However, the increased 
levels of cytokines, most notable IL-6 and TNF-alpha activate the hepatic production 
of acute-phase protein, resulting in increased levels of circulating inflammatory 




atherosclerosis. Interestingly, not all people with increased levels of inflammatory 
markers and T2DM present with sub-clinical vascular co-morbidity
139
. It can 
therefore be questioned whether atherosclerosis develops as a result of activated 
inflammatory marker or whether both conditions (atherosclerosis and T2DM) 
develop in parallel, whilst sharing the activation of the innate immune system. In the 
majority of studies investigating the relationship between markers of inflammation 
and T2DM, detected associations remain after adjustment for body mass index
140,141
, 
which supports the relationship and provides a convincing evidence for the role of 
increased levels of inflammatory marker in this process.  Nevertheless, the exact 
mechanism of the relationship between obesity and the activated innate immune 
system in the diabetic population is yet to be determined. Another alternative 
explanation postulates that the possible mechanism is linked to a chronic 
hyperglycaemia that is involved in increased concentrations of glycation end 
products 
142
. These are known to activate macrophages, increase oxidative stress and 
activate the whole innate immune system, as presented in the Figure 2, above.  
Although these associations shows a strong evidence of the relationship between 
elevated inflammation and incidence of T2DM, it is yet to be established whether 
inflammation really lies on the causal pathway between these conditions. One 
possible approach is to select genetic variants known to control the synthesis and 
production of a particular inflammatory marker (or group of markers). Gene variants 
can then model the exposure variable against the defined outcome (Mendelian 




majority of this evidence produced conflicting or null findings. Nevertheless, the 





1.2.8 Type 2 Diabetes Mellitus - Definition, Clinical 
Manifestation and Diagnosis and Risk Factors  
Definition, Clinical Manifestation and Diagnosis 
Type 2 diabetes mellitus (T2DM) is a life-long, chronic, progressive, complex 
metabolic disorder with multiple aetiologies. In terms of classification and diagnosis, 
criteria for diagnosis of diabetes has been revised number times, with the current 
generally accepted classification is presented in the American Diabetes Association 
(ADA
143
) and the World Health Organization (WHO
144
). Whole range of diabetes 
presentations, as well as relevant factors (e.g. age of onset and occurrence of obesity) 
are covered. 
The most common types of diabetes with distinct diagnostic criteria: insulin 
dependent, type 1 diabetes and non-insulin dependent type 2 Diabetes
138
. Other types 
might develop as a response to medication (iatrogenic diabetes), due to illness of the 
pancreas or due to genetic coding
145
. Approximately 90% of diagnosed cases follow 
into the type 2 diabetes sub-category143. This thesis is primarily concerned with the 
role of inflammatory markers in accelerated cognitive decline in type 2 diabetes 
sufferers, which will be the main theme of the following subsection. This type of 
diabetes is referred to as non-insulin dependent diabetes mellitus (NIDDM)
138
. Type 





In healthy organism, preproinsulin is secreted from the  cells of the pancreas and 
when blood level glucose rise, it is subsequently converted to insulin. Insulin (the 
main hormone for the regulation of blood glucose levels) stimulates glucose transport 
into muscle and adipose cells and reduces glucose production in the liver and overall 
reducing the glucose levels in the blood; this process is defined as the glucose 
metabolism 
146
. In the early stages of the type 2 diabetes the insulin production 
remains intact for most people and so the sufferer is able to produce insulin.  But due 
to the metabolic alternation in the glucose homeostasis, the person’s body insulin 
dependent tissues fail to respond sufficiently, leading to impaired transition of 
glucose for energy
138,147
. Consequently, increased plasma glucose (chronic 
hyperglycaemia) with disturbances of carbohydrate, fat and protein metabolism 
occurs as a result of insulin resistance leading to a bodily response termed 




Main clinical manifestation is comprised of a group of specific symptoms, such as 
thirst whilst passing a large volume of urine (polyuria), possible sustained ketosis 
(elevated levels of ketone, which is a blood compound that the body uses as an 
alternative to glucose in order to sustain required energy levels). Unintentional 
weight loss also occurs, especially in T2DM.  If a patient presents with a prolonged 
occurrence of one or more of these symptoms, random testing is required to confirm 
or exclude a possible diabetes diagnosis
138
. 
The diabetes specific diagnostic criteria might vary between institutions
149
.  The 




7.0 mmol/l or plasma glucose above 11.1 mmol/l two hours following an oral 
glucose tolerance test (OGTT). According to the American Diabetes Association a 
single reading of fasting glucose levels above 7.0 mmol/L (no caloric intake for at 
least eight hours), a casual reading of above 11.1 mmol/L (without regard to time 
since last meal), or a reading of above 11.1 mmol/L in an oral glucose tolerance test 
(OGTT) during which the effect of an ingested glucose solution on fasted blood 
levels is tested, is sufficient for diagnosis. Recently, both ADA and the WHO 
extended their criteria to accept glycated haemoglobin levels (HbA1c), which reflect 




In the fasting plasma glucose (FPG)  after an overnight fasting, at least 8 hours, the 
patient is asked to take 75 g of glucose (diluted in approx. 250 ml of water) with the 
concentration of blood glucose being measured 2 hours after. Impaired glucose 
tolerance (IGT) is defined  by fasting plasma glucose levels that fall below the 
diagnostic criteria for diabetes (<7 mmol/l) but the two-hour post OGTT results are 
7.8 mmol/l to 11.1 mmol/l.  Impaired fasting glucose (IFG) is proposed as fasting 
glucose levels between 6.1 and 6.9 mmol/l, with two- hour post-OGTT below 7.8 
mmol/l if measured
145
. For the purposes of epidemiological studies, the WHO 
recommends applying the 2 hour repeated glucose measure; in this way 








Epidemiology of type 2 diabetes, risk factors 
Approximately one third of individuals with IGT or IFG remain pre-diabetic, one 
third revert to normoglycaemia, and one third progress to diabetes
151
. 
In terms of a worldwide estimate, there is a progressively growing trend in the 
prevalence of type 2 diabetes. Whereas in 1935, 15 million people worldwide were 
estimated to be suffering from a form of diabetes (1% of the world population of 2 
billion), this number exploded to 220 million in 2010 (over 3% of a world population 
approaching 7 billion) and it is expected to rise to 336 million (4.4%) of people by 
the year of 2030
152,153
. Changes in diagnostic criteria since 1965 and improved case 
ascertainment partly account for this development. However, actual increases in 





According to the Department of Health, in the UK, it is estimated 4% of population 




There are a number of issues with establishing incidence, prevalence and thus 
estimating further trend in those. In particular, these are hindered by methodological 
issues linked to differing diagnostic criteria as well as due to variability of age and 
other factors in populations.  Furthermore, since the diseases, especially T2DM can 
remain asymptomatic for a number of years it may go unnoticed/undiagnosed or 
masked by other comorbidities; cases of no symptoms at all during the whole 






Despite the fact that precise biochemical pathological processes leading to diagnosis 
of T2DM are yet to be fully determined, multiple risk factors associated with insulin 
insensitivity hence been proposed, are broadly divided between genetic and 
environmental. From the genetic point of view, evidence suggests a possible 
monogenetic determinant of T2DM
159
.  However, incidence of multi-genetic 
(different combination of several gene defects) origin has also been documented, 
although comparatively this is rather rare
160
. In general, the majority of T2DM cases 
are due to polygenetic (simultaneous action of several genes) influence, showing a 
clear familial aggregation.  Though not in a typical Mendelian fashion, having one or 
more parent or sibling with T2DM is an identified risk factor
161
. Nevertheless, 
despite progressively more convincing evidence of genetic determinants of diabetes 
onset, complex inter-relationship between genotype and environmental factors is a 
probable pathway in the explanation of this condition.  
In particular, an advanced age is a strong risk factor; generally, the most affected 
proportion of population is formed by these above 65 years of age. Although T2DM 
is less likely to be diagnosed at an age of 40 and above, increasingly lower age 
ranges have been documented and thus presenting an additional NHS and other 
resources cost
157
. Comparatively, in developing countries, onset of T2DM is 
generally lower, approximately 45-64 years of age
155
. Worldwide, there is a trend in 
gender that  more women than men are affected, most likely due to differences in life 
expectancy
155
. However, this figure is not age or ethnic specific and only represents 
the overall sum. In this respect, ethnicity was also shown to be an associated risk 




followed by the United States in terms of African Americans, Mexican Americans 
and Native Americans
138,157,162
. In a recent years a growing trend has been observed 
among younger ethnic populations, in particularly South Asian and African 
Caribbean
157,163
.  In general, there has been a rise in prevalence of T2DM in younger 
populations. Since physical exercise tends to increase insulin sensitivity
164
, it is 
reasoned that the decreased physical activity and co-occurring increased rates of 
obesity among children and young adults are the key factors are responsible for the 
increasing prevalence of T2DM in this age group
165
. 
In terms of additional environmental factors, primary concerns are smoking, lack of 
physical activity, dietary factors, ethnicity and inter-connectivity
138,166
. A cluster of 
risk factors, such as obesity, central/abdominal obesity in particular, dyslipidaemia, 




1.2.9 Association with Cognition 
One of the most pronounced risk factors for age-related cognitive impairment and 
age-related cognitive decline is the presence of type 2 diabetes. Epidemiological 
evidence indicates that, in comparison to the non-diabetic, age and sex matched 
population, people with T2DM are at 1.5-2.5 fold greater risk of dementia. In 
particular,  there is a 2-fold increased risk of vascular dementia and up to 2.3-fold 
greater risk of dementia of the Alzheimer’s type
168
. The reason for this is thought to 




Both hypoglycaemia and chronic hyperglycaemia have been implicated in the 
development of cognitive deficits in the diabetic population.  Also, Draelos
169
 reports 
overall impairment in cognitive function in patients with insulin-dependent diabetes 
mellitus during hyperglycaemia and hypoglycaemia events. 
In terms of the hypoglycemic events, the majority of contemporary evidence is based 
on retrospective results and cross-sectional data. This evidence reports the 
relationship between incidence of (severe) hypoglycaemia and impaired cognition. 
However, the direction of this relationship cannot be assessed in cross-sectional 
design, leaving a scope for speculation about reverse causation, in that person with 
reduced cognitive ability might be at higher risk of (severe) hypoglycaemia. Also, 
the majority of studies focused on type 1 diabetes or they report inconclusive 
evidence with varying results
169
. Recently, we have showed a significant relationship 
between severe hypoglycemic events (i.e. self-reported incidence of hypoglycemia 
that required external help
170
) and impaired general cognitive ability at baseline as 
well as accelerated decline detected at four-year follow up measures. At the four-year 
follow up, prevalence of severe hypoglycemia was also linked to a significantly 
higher risk of declined performance in tests assessing non-verbal reasoning, working 
memory, attention, mental flexibility and executive functioning
171
.  
Recently published reviews by Cukierman et al
168
 and Kodl and Seaquist
172
 concisely 
summarised the evidence of association between T2DM and cognitive decline. 
Convincing evidence for the relationship between T2DM and deficits in domain-
specific cognitive dysfunction was detected, in particular memory, executive 




retention, attention and motor functioning
172
.  Cukierman et al reported an overall 
greater risk as well as decline in information speed processing and attention and a 
greater risk of future dementia. Examination of evidence from longitudinal studies 
fully support these findings. Furthermore, one identified study reported a significant 
relationship between T2DM and vascular dementia in a population-based study
173
. 
Recent findings from the Epidemiology of Vascular Ageing (EVA) Study suggests 
that ageing individuals with diabetes were two times more like to suffer from overall 
four-year cognitive decline, independently of conventional cognition-related 
confounding factors, such as smoking, alcohol and relevant co-morbidities
174
. Brain-
imaging studies provide further support suggesting that diabetes-related brain 
pathology result in impairment of the majority of cognitive functioning, with 
memory performance being the least affected
175
. 
In a recent study, demographic analysis of 232 participants from The Austrian Stroke 
Prevention Study demonstrated that the presence of metabolic syndrome was 
associated with less physical activity, more CHD, higher frequency of each 
component of metabolic syndrome, higher levels of C-reactive protein and also with 
a lower educational attainment. Perhaps not surprisingly, compared to age and sex 
matched counterparts, those with the metabolic syndrome performed worse on all 
cognitive tests. The discrepancy between these groups was most visible at memory 
test and executive functioning tests; difference on psychomotor skills reached a 
marginal level of significance
176
. These findings are supported by results based on 
large data set of 1969 ageing men and women that reported the metabolic syndrome 




elevated levels of plasma CRP, increasing the risk for the non-amnestic mild 
cognitive impairment 2.31 times
177
. Another large study, comprising of 959 
randomly selected older adults, reported a significant relationship between metabolic 
syndrome and prevalence of Alzheimer’s disease, irrespective of major risk factors, 
including APOE, 4
178
 (which itself is a major risk factor for development of 
Alzheimer’s Disease). 
Further evidence suggests that older people with good glycaemic control are less 
likely to experience the same impact on their cognitive ability as older people with 
poor glycaemic control. However, this has only been observed in relatively younger 
subjects. Beyond the age of 70 years, interaction between T2DM and cardiovascular 
conditions likely results in accelerated cognitive decline, possibly converting into 
frank dementia of either Alzheimer or Vascular type
138,179
.  
Epidemiological observations provide a robust evidence of the type 2 diabetes and 
cognitive decline relationship. The exact biological mechanism, however, is yet to be 
determined, which has proven methodologically complicated
173
.  Evidence of a direct 
relationship between microvascular association with cognitive impairment and 
decline is scare, mainly due to difficulties in assessment of microvascular status
180
 . 
Furthermore, there is a lack of longitudinal data on a reasonably large samples, many 
studies use only limited selection of neuropsychological tests that might allow for a 
comprehensive assessment of the whole range of cognitive domains. Lastly, there is 
a great inconsistency in selection of covariates, with age and sex, being the most 
common. However, as discussed above, diabetes is a complex condition, almost 




vascular, cardiovascular disease and/or elevated systemic inflammatory status, each 








1.3 Chapter Summary 
Systemic inflammatory responses are complex, encompassing a wide range of 
mechanisms and pathways. Among the main inflammatory-related changes are 
vascular and metabolic changes. Inflammation causes endothelial dysfunction and 
through a cascade of circular mechanisms leads to development of atherosclerosis. 
Inflammation also affects lipid metabolism, which is associated with insulin 
resistance; as such, insulin resistance can be seen as a metabolic expression of 
inflammation
82
. Epidemiological evidence is largely supporting the role between 
inflammation, cardiovascular disease and T2DM. However, there are some 
conflicting or inconsistent results, suggesting the need for further investigation. Such 
investigations are methodologically complicated due to the multi-directional 
relationship between each aspect; distinguishing what is causal, confounding, 
mediating or co-existing factor is complicated due to the lack of risk specificity. 
Therefore further support of causality is warranted. Genetic association studies have 
been proposed as one of the possible approach. The next section will focus on issues 
relevant to genetics, genetic association studies and it will also focus specifically on 




1.4 Genetic Epidemiology 
1.4.1 Genetics – basic principles 
Genetics (from the Greek ‘ghenno = procreate
181
) is a science that is concerned with 
inheritance and variability between species. The primary aim of genetics is to 
determine mechanisms of inheritance and differences and similarities in genetic 
profiles between generations by examining the contribution of particular gene 
(genes) to completion of a particular trait, or group of traits, commonly referred to as 
phenotype. All living organisms are made of cells within which most chemical 
reactions and processes take place. The genetic information is essential for the 
maintenance of the existing cell and the production of new cells. Genetics is 
therefore the essential biological discipline, arguably one of the most important 
sciences.  
There are approximately 25 x10
15
 cells in one human organism. The control center of 
the cell is the nucleus; this is where the genetic information is stored in the form of 
DNA
182
. Each cell contains forty-six chromosomes, coming in twenty-three pairs 
(with the exception of sex cells). Chromosomes are formed by thin strands of 
deoxyribonucleic acid (DNA); each chromosome contains hundreds of genes. Genes 
are the segments of DNA with the primary function as hereditary units. They are 




bodily mechanism. An alternative pair (or group) of genes that is positioned in a 
specific loci of the chromosome is called allele
183
.  
The next subsection of this chapter describes the basic principles of genetics.  
1.4.2 DNA, Gene, Chromosome, Allele, Haplotype, SNP 
The structure of the DNA (deoxyribonucleic acid) was discovered and first described 
by James Watson and Francis H. C. Crick in 1953 and since then provided the basis 
of further scientific activities
184
.  
DNA is the essential blueprint of inheritance; it is the primary carrier of the genetic 
information in all living organisms (with the exception of few viruses where RNA 
plays this role
183
). The DNA molecule is organized in the form of a double-stranded 
helix that consist of 5-carbon sugars (deoxyribose) and two groups of simple units 
called nucleotides, each composed of nitrogen bases. In DNA, these represent purine: 
adenine (A) and guanine (G) and pyrimidine: cytosine (C) and thymine (T). 
Interaction between nucleobases always occurs according to the complementarity 
rule, i.e., only two specific bases are attached, one purine and one pyrimidine (i.e. 
adenine & thymine and cytosine & guanine). The two strands in the double helix are 
positioned in opposite directions. As the two polymer strands align, bind and twist, 
they give the DNA its classical double helical shape. Human DNA is comprised of 








DNA (in eukaryotes) is organised into 46 chromosomes; 22 pairs of autosomal 
chromosomes and two sex chromosomes. A gene, from the molecular genetic point 
of view, is a specific sequence of nucleic acids which determines the structure and 
function of the gene. It is located on a fixed point of the chromosome, called the 
locus. Genes can be defined as units of specifically stored, inheritance information 
for specific proteins, corresponding to a range of biological mechanisms and traits 
(figure 3). 
 




Furthermore, genes can also contain ‘non-coding’ regions that are involved in 
determining its expression in the process called transcription, which uses 
information from both coding and non-coding parts of the gene. The part of the gene 
that eventually transcribed into a protein, is called the exon, the non-translated 
regions are called introns; the length of these varies between genes. 
Allele 
The specific form of gene, occurring in a specific locus, is called the allele 
(allomorphic gene). The combined information from both alleles represents the 
person’s genotype. Alleles are crucial in determining the final form of the 
individual’s genetic trait. Various combinations of alleles also result in variability of 
phenotypic presentations. Inside of a diploid cell, there are always two alleles for one 
gene; this can be in the form of a homozygous individual (individual has two same 
alleles for a trait) or a heterozygote (two different and distinct alleles for the same 
trait).  
If one allele is dominant , an allele is producing the same phenotypic effect 
regardless of homozygous or heterozygous inheritance. Complete dominance occurs 
when the dominant allele (commonly referred to as ‘A’) masks fully the function of 
the recessive allele (commonly referred to as ‘a’); the recessive allele i.e., an allele 
that is masked by the dominant allele, does not produce a phenotypic effect if 





Genetic variability is primarily determined through genotype frequency. From this, 
we can calculate the allele frequency; this represents a contribution of specific allele 
or genotype within specific loci. Allele frequency is occasionally mistaken for gene 





The human genome, of a total length of three billion base-pairs, is made of haplotype 
‘blocks’; group of alleles on the same chromosome, within which alleles at different 
loci are strongly associated. This group is commonly referred to as ‘haplotype’ (a 
combination of the phrase ‘haploid genotype’). The average block length for 
Europeans is 25kb. Blocks occur as the results of constraints on population size 
during the history of our species. Within a block, two-four common haplotypes 
typically account for >90% of all allelic variations.  
1.4.3 Genetic variation 
As mentioned above, a gene, as a hereditary unit, is a stretch of DNA sequence that 
encodes information in a combination of nucleotide bases. This information is 
subsequently expressed as another class of bio-polymers, called proteins. Depending 
on the mutation location and whether the protein structure is altered, genetic variants 




Genetic variation happens through a several different types of mutation altering the 
structure of the genes. Two individuals share 99.9% of the DNA sequence with the 
0.01% defining variability between individuals. The phenotype variability is based 
on the genotype variability that is determined by the role of numerous gene variants. 
i.e., polymorphism.  Polymorphism refers to a situation where two alleles determine a 
specific trait. Whereas polymorphic alleles are frequent, meaning that the frequency 
exceeds 1% any lower frequency is referred to as a mutation. The smallest possible 
change/variance in DNA sequence is replacement of one nucleotide, a so called the 
Single nucleotide polymorphism(s) (SNP, plural SNPs). 
The ‘coding’ part forms only a small proportion of the DNA sequence whereas the 
remaining part of the genome is formed by non-coding and extra-gene sequences. 
The manifestation of DNA sequence in phenotype presentation is also determined by 
degeneration of genetic coding when during the process called translation, in the 
coding sequence, the substitution of one nucleotide is not into amino-acid, 
determined by the messenger RNA (mRNA). This means that in the sequence of 
nucleotides there is a substantial amount of polymorphisms that might not affect 
phenotype. One way to detect this is through methodology linked to molecular 
genetics.  
In terms of medical genetics, genetic methodology and public health, the most 
important polymorphisms is the single nucleotide polymorphisms
182
. 
The frequency of SNPs in one genome is approximately one in every 1000 base-pairs 






SNPs affect the structure and role of proteins only to a degree; this depends on the 
type of mutation
186
. Even a relatively small change, i.e., of one nucleotide, can result 
in a wide spectrum of different effects. However, SNPs in the coding regions form 
approximately 5% of genetic diversity the remaining part of genetic variability is 
therefore in extra-gene and non-coding regions. Recently, contrary to previous views, 




Commonly, detection of individual SNP is carried out via polymerase chain reaction 
- PCR.  Increasingly common is the use of DNA microarrays in SNP analysis, which 
allows for detection and identification of a very large number of SNPs at one time 
(on the order of hundreds of thousands/one million).  
1.4.4 Genetic Epidemiology 
There is an increasing amount of evidence providing understanding of 
biological/pathological mechanisms of complex conditions; this includes an 
identification of a wide range of modifiable risk factors, determinants, protective 
factors and the multi-directional relationship between them. However, traditional 
epidemiological studies suffer from the effect of confounding and/or mediating 
variables which constrains the interpretation of their findings. Further, bias can occur 
in measurement of predictor as well as outcome or exposure variables; in particular, 
measurement of exposure may be affected by the disease onset and elimination of 




Epidemiological studies, despite using the same or similar methodological 
approaches, often provide inconsistent, or even conflicting results and identification 
of a robust causal factor/determinant for a given disease is not possible.  
Extensive documentation of the human genome allows for an alternative approach 
that can at least partially resolve these limitations by the use of an instrumental 
variable in the form of genetic variant(s) that can be modelled against the defined 
outcome. 
188
. This approach is part of the discipline known as genetic epidemiology. 
Primarily, the approach does not differ from the traditional epidemiological approach 
– once the potentially causative genetic determinants of the predictor(s) are 
identified, they can be modelled directly or via an intermediate phenotype against the 
outcome of interest.  
Genetic epidemiology is “the study of the joint action of genes and environmental 
factors in causing disease in human populations and their pattern of inheritance” 
(Thomas, 2004, p. 3
189
). Genetic association studies can either focus on an individual 
gene or gene variants candidate or on examination of mutations through the whole 
genome. Genetic association studies aim to map and investigate regions of linkage 
disequilibrium containing the causal variant(s). As these investigations identify a 
smaller region of the genome, they have a greater power to detect smaller effects
189
. 
This methodology has a number of advantages. In correctly designed studies, there is 
a limited chance of bias in measurement of exposure (i.e., the genotype) and the 
selection bias is usually less serious as it can be dealt with by controlling for 
population stratification.  In the case of haplotypes, the use of tagging SNPs can deal 




1.4.5 Causal Inference in Genetic Epidemiology 
Genetic association studies are one of the most popular approaches to the 
identification of genetic propensity of organisms to a specific trait. Primarily, the aim 
is to test the strength of a correlation between genetic variation and a specific 
condition to identify either candidate genes or a genome region that might contribute 
to the diseases status or increased prevalence of such conditions
190
. The frequency of 
SNPs is most widely investigated in candidate association studies; alternatively, with 
the HapMap (discussed below), it is now possible to detect and/or test  novel 
associations through genome wide association studies (GWAS) where a large 
number of individuals are examined for a commonality of genetic variants associated 
with a specific trait
182
.  The candidate gene study can take the form of a case-control 
study with a comparison of allele frequency of candidate gene(s) prevalence. 
Linkage studies, which are family-based, aim to identify particular regions of 
genome that contain a non-random inheritance pattern. Typically, these regions are 
very large with millions of base-pairs. In comparison, association studies focus on 
narrower region of the genome; there are more suitable for fine-mapping due to a 
greater power to detect effects smaller than the linkage investigation
183
.  
To date, candidate gene studies for a wide range of diseases
191
 as well as GWAS
192
 
have detected direct associations and thus true causal SNPs for increased disease 
vulnerability. However, as with any other research method, genetic association 
studies suffer from a number of limitations that differ from conventional 






Specifically to GWAS, testing a large selection of genetic variations, the risk of type 
I error is considerably high; this can be addressed by multi-stage replication studies 
that might eliminate the risk of missing (potentially important) SNPs that did not 
reach the significance level in the original genome-wide association study
194
. Further 
problem affecting GWAS include SNPs is in linkage disequilibrium (LD) to the true 
causal SNP resulting in indirect association, population stratification presenting a 
potential confounding variable with the risk of false-positive results, and interaction 
between genes (epistasis)
192,195
. The following section of this chapter will discussed 
this in greater details.  
1.4.5.1 The HapMap 
The International HapMap Project was designed to cover the ‘entire’ human genome 
through using commercial DNA microarray-based methods, identify common 
haplotypic variants, and this facilitate examination and identification of genetic 
variance in common disease
196,197
 The project was completed in 2000 with the first 
study published in 2003. By 2005, HapMap completed a haplotype map of the 
human genome and determined allele frequencies for about 1.3 million SNPs (The 
International HapMap Consortium, 2005
198
); this led to documentation of regions 
that are difficult to study as well as it identified linkage disequilibrium patterns
199
. 
Subsequently, by 2007, a further 2.1 million SNPs (25-35%) were identified
200
. 
Currently, at the time of writing this thesis, almost all mapping information for 10 





1.4.6 Methodological issues of genetic-association study 
design and in meta-analysis of genetic association 
studies 
There are number of limitations and methodological obstacles that impact on 
interpretation of gene-association study results, particularly when the aim is to 
determine causal relationship in a complex condition, such as age-related cognitive 
changes.  
1.4.6.1 Linkage Disequilibrium (LD) 
Linkage disequilibrium (LD) essentially describes the non-independence of alleles at 
two or more loci (making up a haplotype). 
Non-random associations are caused by physical proximity (linkage) in a way that 
the two alleles happen to occur together in the same gamete. This happens more 
often than expected from their allele frequencies. As every new mutation occurs in a 
haplotype, it becomes more frequent with that particular background. The magnitude 
of LD depends on the amount of recombination between the loci that breaks down 
the haplotype over time. The LD will persist for many generations between tightly 
linked loci. Linkage equilibrium is attained gradually through random mating.  
LD can also be caused by population stratification where the sample is a mixture of 
sub-populations with different allele frequencies or by admixture where the 




genome from different populations. Causal factors/reasons that disturb HWE (see 
below) seem to lie on the same causal pathway for the LD.  
The genome consists of blocks of high LD, separated by hotspots of recombination; 
in the genome of non-Africans, the LD typically extends for ~100 kb. Only a few 
different haplotypes can commonly be found within each block. Only three to four 
markers can ‘tag’ all the present variations. LD mapping is therefore important as it 
is one of the possible ways to map the entire genome, which has over 10 million 
common variants.  
1.4.6.2 Hardy-Weinberg Equilibrium (HWE) 
Allele and genotype frequencies may be related according to Hardy-Weinberg law, 
i.e., the ordered genotype frequencies in offspring are the product of the allele 
frequencies in the parental generations through a random mating. Non-sex cells 
always carry two alleles; paternal and maternal. Assuming that the population is 
large, mating is arbitrary, and that no mutations or migration occurs and there is an 
average fertility, then the probability of an individual with allele AA is p[A] times 
p[A]; the same rule applies to probability of individuals with two alleles AA, Aa, aa. 
Therefore the expected frequencies of the 4 ordered genotypes are:  
p
2 
[AA] = p[A] x p[A] 
pq
 
[Aa] = qp[aA] = p[A] x q[a] 
q
2 





This equation allows for a calculation allele frequency in future generations, that is: 
p
2 
+ 2pq/2 = p (p+q) = p 
a
2 
+ 2pq/2 = q (q+p) = q 
Therefore estimated frequency of both alleles remains the same across generations. 
As a typical example of the Hardy-Weinberg law is the prevalence of blood group 
with a negative Rh in European population where a prevalence of just under 17% 
prevalence remains constant
201,202
.  However, conditions necessary to satisfy the HW 
law are very seldom possible; possible explanations for deviation of frequencies from 
HWE include non-random mating, allele frequencies change from generation to 
generation as the population evolves, through mutations due to arbitrary 
environmental interactions, genotyping error or random fluctuations in allele 
frequency (gene drift)
189
. Whether the sample, i.e., the estimates of genotype 
frequencies within a chosen population, follows the HWE law can be checked 
mathematically (goodness of fit, chi-square) or through software developed 
specifically for this purpose (e.g., www.wbiomed.curtin.edu.au/genepop).  
1.4.6.3 Epistasis  
Epistasis, the interaction between different genes, is one of the major obstacles in 
gene association studies. It was first described in 1909 by William Bateson who 
referred to the complexity of the mapping relationship between genotype and 
phenotype, using the example of hair colour, specifically dominance of alleles within 
the same pair, i.e., the same locus
203
. He noted that regardless of the genotype (i.e., 






effect of gene interaction, in particular interaction between alleles at different genes, 
can occur at the same step or at different stages of the same biological pathway.  
In the case of a simple, ‘Mendelian’, disorder it is less difficult to identify specific 
loci. However, in complex traits, such as diabetes, asthma, multiple sclerosis, etc. 
this is particularly complicated due to factors such as increasing numbers of 
identified loci and contributing alleles, and, to an extent, contributing environmental 
factors. Additionally, detection is complicated by masking effects of one gene on 




By definition, heterogeneity refers to detectable systematic differences between 
studies, predominantly occurring due to study design, measurement of phenotype, 
differences in effect sizes or any combination. In meta-analysis, this is a particular 
issue as it can lead to underestimation of meta-analysis results
204
. When results from 
collated studies present with different study characteristics and/or different effects, 
the use of a random effects model, rather than a more rigid fixed effects model, is 
recommended. In meta-analysis, random effect models operate on the assumption 
that there are substantial differences between individual studies’ magnitude of effect 
and thus statistical heterogeneity is assumed.  
 
 




Bias can occur as a result of population heterogeneity when the study population is 
formed by a mixture of individuals with varied genotypes, and different populations 
present with a specific disease caused by non-genetic factors
205
.  Differences in allele 
frequency due to systematic ancestry differences presents a major issue as it can 
produce false associations. A possible way to address population stratification is to 
perform a principal component analysis to model ancestry differences
206
 as well as 
infer genetic ancestry
207





DNA methylation is a process that involves addition of methyl group to the cytosine 
and adenine nucleotides 
182
 and that is also associated with the ageing process
209
. 
Recent evidence suggests that age-dependent methylation changes play a role in 
autoimmunity and cancer incidence. Also, in some tissues, age-related demethylation 
(decreased levels of methylated cytosines) can be responsible for chromosomal 










1.4.7 Fibrinogen  
Fibrinogen gene, location, normal function and gene variants 
Fibrinogen is a plasma glycoprotein, produced by the liver. It consists of three units, 







.  Molecular location of the genes is on the short arm of the 
chromosome 4; cytogenetic location 4q23-q33, covering an area of 50kb, arranged in 
order FGG-FGA-FGB .  
1http://ghr.nlm.nih.gov/gene/FGA; 2http://ghr.nlm.nih.gov/gene/FGB;  3http://ghr.nlm.nih.gov/gene/FGG 
 
The FGA, FGB and FGG genes function is to instruct a production of the fibrinogen 
A, fibrinogen B, and fibrinogen  (gamma) individual chains of the fibrinogen 
protein that, combined together, forms the functional fibrinogen
212
  
The fibrinogen protein is a fundamental element in the formation of blood clots, a 
process called coagulation. Additionally, the beta gene is known to be involved in 
fibrinogen synthesis
213
.  Mutations in either of the fibrinogen genes may results in 
numerous bleeding conditions, such as congenital afibrinogenemia (excessive 
bleeding), hypofibrinogenemia (decreased fibrinogen in the blood), 
dysfibrinogenemia (abnormal functioning of fibrinogen) or combination of these 






Circulating fibrinogen levels can be partially accounted for by SNPs across these 
three fibrinogen genes, aalthough only limited evidence supports this explanation for 
variability in plasma fibrinogen levels; only 20 to 51% of variations in circulating 
fibrinogen levels can be explained through heritability
109
 and even large, GWAS 
investigations, such as the Framingham Heart Study
215
 could not detect such 
association. Instead, locations on chromosome 2 and chromosome 10 were linked to 
the highest LOD (logarithm of odds score; a statistical test applied in genetic linage 
analyses to test the probability if the two loci are not linked
183
). The discrepancy may 
be due to an increased frequency of alleles that are associated with elevated plasma 
fibrinogen levels, as well as can be due to non-random associations of alleles – those 
potentially located on different chromosomes. The potential for masking the true 
causal allele was considered to be high.  
 
Non-genetic factors associated with plasma fibrinogen levels  





Common cardiovascular risk factors have been positively correlated with elevated 
plasma fibrinogen levels, namely smoking (including passive smoking
216
), obesity, 
waist-hip ratio, diabetes, hypertension and elevated LDL-cholesterol levels
107
. 
Specifically, a number of components of metabolic syndrome, such as decreased 
HDL-cholesterol, glucose ≥ 5.5 mmol/L., diastolic BP ≥ 90 mm Hg, have been 







In terms of hormonal status, data provided by both cross-sectional and longitudinal 
evidence have not been consistent. The use of oral contraception
218
, menopause and 
hormone replacement therapy
219
 have been associated with elevated plasma 
fibrinogen levels. However, studies also suggest an inverse relationship between the 
latter two factors and increased fibrinogen concentration
107
. Interestingly, positive 
interaction has been observed between the use of oral contraceptive and smoking
220
; 
conversely, within approximately 3 months of discontinuation of oral 
contraceptives
221
, relatively rapid reduction of plasma fibrinogen levels have been 
detected after cessation of smoking; although the duration of an average of 10 years 
is required to return to the state of healthy never-smokers
109
. In terms of alcohol 
consumption, a U-shaped relationship has been observed between alcohol units and 
plasma fibrinogen levels amongst men
222
 and independent of gender
223
. In a large 
epidemiological study; higher concentrations of the plasma fibrinogen were detected 
in non-drinkers or >60g/day of alcohol. The association was stronger in men again; a 
possible explanation might be linked to the type of alcohol but the precise 
mechanism is yet to be determined
224
.  
Psychosocial factors have also been strongly associated with plasma fibrinogen level 
with stress being one of the strongest candidates
225
. Childhood environment, father’s 
social class and levels of education have also been inversely associated with elevated 
fibrinogen concentration
226
, postulating plasma fibrinogen levels as a possible 
explanation of an inverse relationship between socio-economic status and coronary 
heart disease
227
. In large population-based studies (Caerphilly and Speedwell 




of low socio-economic status on increased risk for CHD
228
. Other factors correlated 











Chapter 2:  Literature review 
2.1 Aim  
The purpose of this literature review is to systematically identify and critically 
discuss the available prospective epidemiological evidence on the association of 
inflammatory and acute-phase proteins with cognitive decline in elderly populations. 
For this purpose, published articles that investigated the nature and strength of 
association between the systemic inflammation and late-life cognitive ability were 
identified using a systematic literature search carried out with adherence to a 
predefined set of inclusion and exclusion criteria. The rationale for the selection of 
studies and the details of the final search are outlined at the beginning of the chapter. 
This is followed by a summary of the identified literature search, also including a 
brief outline of the excluded studies. A critical appraisal of the eligible evidence 
focuses on methodological aspects of the included studies. Finally, a summary of the 
appraised evidence and implication for the original work presented in the remaining 





2.2 Literature Review Methods 
Search strategy 
The electronic databases Medline, EMBASE and PubMed were used to search for 
prospective evidence on the inflammation-cognition relationship. Searches were last 
run on these databases, October, 2013.  
Key search words included: “Cognition.mp/cognit$.ti,ab./cognition disorders/cognit$ 
impair$.mp/”, exploration of reported inflammatory markers included: 
“Fibrinogen/fibrin$.ti,ab./Interleukin-6/IL-6.ti,ab./C-Reactive Protein/C-Reactive 
Protein/CRP.ti,ab./Tumor Necrosis Factor-alpha/TNF-alpha.ti,ab./biological 
markers/ or exp inflammation mediators/”.  The search was restricted to an ageing 
population by:”(elderly or aged or "old age").ti,ab.”, and in terms of methodology 
the key words were: ”prospective.mp. or Prospective Studies/ or Aged/ or 
prospective.mp./Cohort Studies/Longitudinal Studies/ or longitudinal.mp.”. Pre-
determined inclusion criteria included studies that reported findings from 
investigations on living human participants and for which a full text paper was 
published in English language.  
Inclusion and Exclusion Criteria 
Many of the neuropsychological tests commonly administered in epidemiological 
studies have been shown  to be domain-sensitive
19
. Furthermore, some of the 
individual cognitive tests are deemed as not sufficiently sensitive for detecting 




particular alteration in brain anatomy (for example, vascular damage to one 
particular area only
4
) or in cognitively healthier subjects
232
. This applies specifically 
to the Mini Mental State Examination, a test that was designed for screening 
purposes only and therefore is not sufficiently robust to confirm an overall cognitive 
decline
233
.  Therefore, only studies with a comprehensive cognitive battery, 
consisting of multiple testing, were selected in order to allow for a review of findings 
that are comparable to the presented ET2DS results. To ensure that findings were 
comparable to the ET2DS, at least one of the markers of inflammation assessed in 
the ET2DS must have been present in the reviewed articles.  
Cross-sectional data are undoubtedly a valuable source of evidence for cognitive 
impairment relating to cognitive performance at one given time; nevertheless, unlike 
longitudinal evidence, this does not allow us to observe changes in cognitive ability 
and to subsequently assess the potential predictive value of measured markers of 
inflammation
173
. A longitudinal design is therefore better suited for the investigation 
of a complex, over-time developing condition. For this reason and also to collate 
evidence comparable with the prospective design of the ET2DS, only prospective 
evidence was eligible for the current review.  In summary, studies must have 








 Original research only, full text available (reviews scanned for additional 
relevant references) 
 Prospective design 
 At least one of the circulating inflammatory marker investigated in the 
ET2DS analysis (i.e. plasma fibrinogen, CRP, IL6 and TNF-alpha) 
 The cognitive neuropsychological battery contained at least one assessment 
of at least one cognitive domain that was compatible with ET2DS cognitive 
assessment   
 Articles reported results gathered from live adult/human, age 60 and above 
 Articles published in the English Language 
 
Exclusion criteria 
 European ancestry  
 Post-mortem findings 
 Animal studies 
 Baseline sample consisted of either solely or comparison of healthy subjects 
and subjects with clinical manifestation/diagnosis of any kind of MCI or 
dementia of any type, including any type of a motor-neuron disease; 
cerebrovascular disease (any type); cardio-vascular disease (any type); 





A range of information was extracted from the studies included. In terms of methods, 
this included: details of sampling; population characteristics; baseline sample size; 
sub-sample as reported in this review; age (mean and/or, SD and/or range); 
percentage of male subject; which of the four inflammatory markers were 
investigated; what cognitive/neuropsychological tests were administered, and if the 
pre-morbid intellectual ability was estimated. Methodological details of included 
studies are summarized in Table 2. Co-variants used in multivariate analysis were 
recorded along with all relevant results; this is presented in Table 17, Appendix A. 














The aim of this review was to critically appraise epidemiological, prospective 
evidence to ascertain the role of inflammatory markers in the pathogenesis of steeper 
cognitive decline. Meta-analysis was therefore not intended. In fact, due to a high 
degree of heterogeneity - in particular in baseline characteristics of selected 
populations, length of follow-up, selection of cognitive assessment tools, varied 
combination of the four identified circulating inflammatory markers and selection of 
co-variants - meta-analysis would not be appropriate. Therefore a narrative, critical 
approach to the relevant evidence review was adopted.  
 
2.3 Main findings  
The primarily aim of the search was to identify original articles reporting single, 
population-based studies with sufficient selection of inflammatory markers and a 
sufficient selection of cognitive test battery. It was structured to avoid anything other 
than prospective/longitudinal studies that focused on the (trajectory of) cognitive 
decline in relation to levels of inflammation, rather than clinically defined diagnosis 
(MCI, dementia). Even so, the search also identified four systematic literature 
reviews; these were examined for additional relevant references if not identified 
already independently through the search strategy. Additionally, seven conference 
reports were identified, deemed as relevant to the proposed subject; the original 
paper was sought, assessed and reviewed according the inclusion criteria stated 




clearly stated in a particular article’s abstract, the methods and result sections were 
nevertheless examined to ensure that no prospective data were lost. After careful 
consideration, one study was accepted, since it presented results that were adjusted 
for childhood (age 11) IQ levels. 
Excluded studies 
Of the identified articles, 1001 were removed due to duplicate entry in more than one 
database and 204 were removed as the paper was either not published in English 
language, or the study was concerned with non-human or post-mortem data. This left 
2533 titles and abstracts to be reviewed. A further 2441 were removed at this stage as 
the studies were not relevant for the presented review. This left 92 full text detailed 
review. From the reviewed full text papers, 81 articles were excluded as the studies 
failed to meet essential criteria for inclusion: primary reasons and the corresponding 
number of articles excluded are presented below:  
 
Table 1: Distribution of principal reasons for exclusion of studies from review 
Reason Number of Articles 
No inflammatory marker of interest/IM only as covariates 6 
IM-personality with cognitive performance as covariant  1 
Restricted Cognitive Battery 4 
Non-Caucasian 7 








Reason Number of Articles 
AD (one post-mortem and one AD at baseline and depression as  
an outcome measure) 
13 
Parkinson’s Disease   1 
Post-stroke/TIA 2 
CVD condition 6 
Subcortical ischemic VD 1 
inflammatory status as an outcome measure 1 
Depressed (case-control study; healthy controls) 1 
Rheumatoid arthritis 1 
Asymptomatic Intracranial Atherosclerosis 1 
Dialysis 1 
Gene-variants-cognitive ability with no cogn results available 3 
Duplicate publications 3 
Cross-sectional design 8 
Conference abstract, no article available  1 





Brief examination of the evidence generated through the initial search revealed a 
remarkable heterogeneity in terms of methodologies, range of investigated 
biomarkers and neuropsychological assessment of cognitive ability. Also, there was a 
great inconsistency in adjustment for relevant co-variants. There were also marked 
differences between the studies, in the style of reporting results, with the majority of 
studies failing to report effect size and/or exact p values except for Luciano et al and 




Nine studies (in 11 publications) were identified which met the full eligibility criteria 
and were therefore included in the review. Included studies are considered below in 
chronological order of their publication date. For the MacArthur Study of Successful 
Ageing, two publications that were eligible for this review were identified and these 
are considered together. Two publications were also identified for the PROSPER 
Stud). One study was included despite an apparent cross-sectional design – this study 
presented analysis in which the cross-sectional association between CRP levels and 
cognitive ability at age 70 was adjusted for IQ measures in childhood and therefore 




The MacArthur Study of Successful Ageing (MASS)
235
 is a population-based cohort 
study of healthy men and women (aged 70-79 at recruitment in, 1988) based in East 
Boston, Durham and New Haven, USA.  At baseline, relevant demographic data as 
well as plasma IL-6 and CRP biomarker levels were collected under standard 
operational procedures. Cognitive functioning was assessed at baseline and again at 
two subsequent follow-up clinics. After 2.5 years (first cognitive follow-up in 1991), 
71 of the initial 851 participants (8% of the original cohort) had died. At the second 
follow-up assessment that was carried out 7 years after baseline, 273 people had died 
(32% of the original cohort). Subjects lost to follow-up were more likely to be men, 
more likely to have higher plasma IL-6 levels and tended to have lower cognitive 
scores at baseline (by 7 years follow-up, subjects lost to follow-up also had lower 
baseline physical activity scores and were more likely to be current or ex-smokers). 




up assessments respectively reached conventional levels of statistical significance 
(p<0.05). 
In initial analysis from the MASS (Weaver et al., 2006
236
), which reported findings 
for 779 participants, linear regression analyses were used to investigate the baseline 
plasma IL6 levels in relation to change in scores for two waves of cognitive 
assessment. Median IL-6 were on average 4.55 pg/mL (ranged from 0.10 to 3.8 
pg/mL) at baseline. For the purpose of non-linear association analyses, tertiles of IL-
6 were defined, with values of <2.13 pg/mL in the lowest tertile, followed by any 
values between 2.13 and 3.8 pg/mL falling into the middle tertile and the highest 
tertile containing values  ≥ 3.8 pg/mL of plasma IL6 levels. Results suggested an 
association between baseline cognitive ability and IL-6, independently of all 
covariates; although marginal, subjects in the highest tertile of plasma IL6 presented 
with impaired, baseline cognitive ability (OR for summary cognitive test score below 
median = 1.46; 95% CI: 0.97, 2.20). During follow-up, tertiles of cognitive decline 
were defined according to change in a summary cognitive test scores (follow-up 
score minus baseline score). The first wave of the follow-up testing supported the 
role for IL-6 in cognitive decline, i.e., both the second and third tertile of IL6 levels 
were significantly associated with cognitive decline (OR for change in summary test 
scores falling in bottom tertile of distribution of change scores =2.21; 95% CI: 1.44, 
3.42 and OR=2.03; 95% CI: 1.301, 3.19, respectively). However, at the 7 years 
follow-up assessment, only subjects in the third, (i.e. highest, tertile showed declined 




The second analysis of MASS, in 2008
237
, included all 851 study participants. The 
investigators used growth curve modelling in order to assess change in cognitive 
ability in relation to baseline levels of IL-6 and CRP levels. As previously, cognitive 
scores were available from three time points over a period of 7 years.  Both 
biomarker values were subdivided into tertiles, from the highest to the lowest: for IL- 
6 tertile values in pg/m were <2.15; 2.15 - 3.80 and > 3.80. For CRP tertile values in 
mg/L were: <1.24; 1.24 - 2.65; >2.64. At baseline, a cross-sectional association 
between increased biomarker levels and cognitive ability was detected. In terms of 
follow-up results, an increased risk of cognitive decline was detected forthe top 
tertile of IL-6 ( p< 0.05). However, neither the CRP nor the IL-6 levels significantly 
predicted decline in any cognitive ability before or after adjustment.  
In the Longitudinal Ageing Study Amsterdam
238
,  comprising 998 participants (age 
range 62 to 85 (male=47.3% ), comprehensive cognitive batteries were administered 
at baseline and at a 3 year follow-up clinic, assessing general cognition (MMSE, no 
other determination of general cognitive ability), immediate and delayed recall, 
speed of information processing, and non-verbal reasoning (Dik et al, 2005). Among 
other biomarkers, baseline measures of CRP and IL6 were obtained.  Both markers 
were log-transformed for regression analysis, although extreme values were not 
removed. It can be argued that this might have introduced a potentially bias to the 
analysis; comparison of results with extreme and without extreme values were not 
presented .  No significant association was detected between biomarkers and 





A possible contribution to this null result might be the loss to follow-up testing; 
whereas the mean age of the total baseline sample was 75.4 years (SD 6.6), the 
subjects who attended for follow-up were on average 74.6 years old (SD 6.2) at 
baseline and generally healthier (although, interestingly, there was no significant 
difference between the baseline and follow-up groups in alcohol consumption and 




Another study conducted in Holland (Schram et al, 2007
239
), published data collated 
from two population-based cohorts: the Rotterdam Study and the Leiden 85-plus 
Study. For the Rotterdam Study, levels of baseline IL-6 and CRP were available for 
3874 subjects ( mean age 72 years, average follow up  4.6 years). The Leiden 85-plus 
Study comprised 491 subjects (age range 85 to 90 years, average follow-up 5 years). 
IL-6 and CRP levels were entered into linear regression modelling to assess change 
in global cognition, executive functioning and memory performance. Participants 
from the Rotterdam Study with higher baseline measures of CRP and IL-6 presented 
with lower baseline cross–sectional global cognitive ability and executive 
functioning (p<0.05); furthermore, accelerated decline in global cognitive ability was 
observed in relation to elevated IL-6 baseline levels. However, this effect was 
observed only in APOE 4 allele carriers (p<0.05). Otherwise, no significant 
associations were observed.  
In the Leiden cohort, associations of similar magnitude and direction were observed 
but power was less, affecting the statistical significance of the findings; higher 




baseline but similar findings for CRP were not statistically significant. In terms of 
cognitive decline, the only significant association was between higher baseline IL-6 
levels and poorer performance in memory function. Steeper decline in global 
cognitive ability, as predicted by IL-6 levels, was observed only in APOE 4 allele 
carriers (p<0.05). Therefore results from both cohorts suggested that IL-6 may only 
significantly influence cognitive performance at advanced age in APOE 4 allele 
carriers. 
In a Scottish cohort consisting of 1053 community-dwelling participants (the Lothian 
Birth Cohort 1936, age range 67 to 71 years 
234
), the availability of childhood IQ data 
allowed investigation of life-time estimated change in cognitive ability in relation to 
late-life measurements of plasma fibrinogen and CRP levels. The results suggested 
the possibility of a reverse association; i.e., suggest a strong possibility that 
childhood IQ levels predict elevated levels of these two inflammatory markers at the 
age of 70 (p<0.001). However, the results also indicated that levels of plasma 
fibrinogen level were a significant predictive risk for late-life decline in general 
cognitive ability and speed of information processing. 
A further Scottish study (Marioni, et al., 2009
240
) reported finding from the Aspirin 
for Asymptomatic Atherosclerosis Trial, a study that consisted of a baseline sample 
of 2321 cognitively tested community-based adults (age range 50 to 80 years) of 
whom 504 underwent repeat cognitive testing at a 5-years follow up clinic. For all 
participants, pre-morbid peak cognitive ability scores were also available from the 
Mill Hill Vocabulary Test (MHVT). Therefore, two sets of results from this study are 




actual change in cognitive ability (504 subjects).  Baseline plasma fibrinogen and 
CRP levels were significantly associated with decline in general ability (p<0.05), 
non-verbal reasoning (p<0.05), with information processing speed (p<0.01), attention 
and mental flexibility (p<0.01). Adjustment for common cardiovascular risk factors 
attenuated these associations only partially; the CRP-general cognitive ability 
relationship became non-significant as did the relationship between both plasma 
biomarkers and non-verbal reasoning. Plasma fibrinogen, adjusted for plasma 
viscosity, was significantly associated with mental flexibility performance, 
independently of the CV risk factors.  With respect to 5-year cognitive decline, 
plasma fibrinogen levels significantly predicted decline in executive functioning 
(p=0.046) and CRP levels predicted decline in non-verbal reasoning (p=0.037), also 
independently of the common CV risk factors. The authors also observed an 
interesting finding in so far as higher baseline CRP levels significantly predicted 
improvement in verbal memory test score (p=0.029). 
A third Scottish cohort study (Rafnsson et al., 2010
241
) was based on the Edinburgh 
Artery Study, a population-based cohort of 1592 subjects. Blood sampling was 
carried out in 1987-88 with two subsequent cognitive assessments; in 1998/99 with 
717 subjects (mean age 73.1 years; SD 5.0) and four years later when 452 
participants agreed to return for a follow-up assessment. For these people, mean 
value of plasma fibrinogen was 2.53 g/L; SD = 0.61 and median value of CRP was 
2.0 mg/L (range 0.92-4.39). In terms of the 5-year cognitive change, plasma 
fibrinogen predicted decline in executive functioning only, also independently of CV 




associated with a 5-year decline in non-verbal reasoning only (p<0.05). However, 
there was a much more consistent association of biomarkers with cognitive decline 
measured in terms of estimated lifetime cognitive change (calculated using results of 
the National Adult Reading Test, NART). Plasma fibrinogen levels were 
significantly associated with lifetime decline in general cognitive ability (p<0.01), 
non-verbal reasoning (0.05), speed of information processing (p<0.001) and attention 
and mental flexibility (p<0.001). A very similar pattern of findings was observed in 
for CPR levels, which were associated with a decline in general cognition (p=0.05) 
and in the majority of individual cognitive domains: non-verbal reasoning (p<0.05) 
speed of information processing (p<0.001), attention and mental flexibility (p<0.01) 
and general cognitive ability (p<0.05). 
In the Framingham Study (Jefferson, et al., 2011
242
), circulating levels of CRP, IL-6 
and TNF-alpha were modelled to investigate their association with cognitive decline 
on a comprehensive test battery. The follow up cognitive assessment was conducted 
with 1352 subjects (mean age 60 years, SD 9, range 35 to 85), all of whom were 
community-dwelling citizens in Boston, USA. IQR values for plasma CRP, IL-6 and 
TNF-alpha were 2.0 (0.9-4.9), for IL-6 2.6 (1.8-4.2) and for TNF-alpha 1.2 (0.9-1.6), 
respectively. In linear regression models of cognitive change over 6.3 years, the only 
significant associations detected were between CRP and naming and lexical retrieval 
ability (B=-0.02; p=0.044), TNF-a and attention and mental flexibility (B=0.04; 
p=0.004) and TNF-alpha and verbal reasoning and abstraction) (B=-0.08; p=0.046).  
The most contemporary study was the Pravastatin in the Elderly Individuals at Risk 
of Vascular Disease
243




conducted in Scotland, to investigate the efficacy of statins in the reduction of 
coronary and cerebrovascular morbidity and mortality in an older-aged adults. 
Prospective collection of cognitive data was also undertaken. Two publications 
eligible for this review, one assessing the relationship of CRP levels
244
 and one 
assessing the relationship of IL6
245
 levels  in relation to accelerated cognitive ageing, 
have been published. At baseline, 5680 participants (mean age 75.3 years, SD 3.4; 
range 70-82 years) from Scotland, Ireland and the Netherlands were recruited. 
Cognitive assessment was carried out over an extended period of 36 to 48 months 
(averaged for 42 months). Higher plasma CRP levels were significantly associated 
only with a decline in immediate and delayed memory, assessed by a 15-Picture 
Learning test; this association persisted after adjustment for conventional CVD risk 
factors (both associations, p<0.05). No other significant associations with cognitive 
decline were detected. With regard to IL-6 levels, this circulating biomarker 
predicted decline in memory and executive functioning, both at the 0.002 level of 
significance; as with the CRP levels, here too these associations persisted at analyses 
adjusted for CVD risk factors. Interestingly, even though concentration of IL-6 was 
not associated with a significant decline in attention (Stroop test), its polymorphism 








2.3.1 Discussion of main findings  
Although overall evidence from prospective studies supports some form of link 
between systemic inflammation and late-life cognitive skills, it only partially 
confirms the hypothesis that elevated levels of circulating inflammatory markers 
have a negative impact on cognitive decline in advanced age. Evidence was 
inconsistent among the reviewed studies, with some reporting no significant 
associations, especially after adjustment for conventional cardiovascular risk factors 
and vascular events. Also, there was evidence of a reverse relationship between 
concentrations of some biomarker (CRP) and general cognitive ability and in one 
study improvement on memory test was detected (the AAA trial). 
There may be a number of reasons for this lack of consistency between studies. Most 
notably, there was a great degree of between-study variability in the selection of 
cognitive tests, in the length of follow up, in population characteristics and the choice 
of co-variants.  
With regard to the cognitive assessment, the inclusion criteria for this review 
excluded studies with too narrow an assessment of cognitive performance. For 
example, global cognitive ability, or ‘g’, is generally understood as a factor derived 
from suitable, comprehensive cognitive batteries that accounts for a certain level of 
variability
246
. Whereas some studies conducted appropriate statistical analyses to 
determine ‘g’ (such as a principal component analysis), some researchers claimed 




possible lack of sensitivity to mild cognitive impairment (MCI)
247
, MMSE has failed 
to detect differences between the MCI and dementia and MCI and healthy adults
248
. 
Furthermore, it may fail to detect true cognitive impairment in well educated, 
mentally and physically active people and there can be an increased rate of false 
positives among people with lower educational attainment
249
.  
Included studies reported all reported administration of, to a greater or lesser degree, 
a comprehensive neuropsychological battery that was comparable to that used in the 
Edinburgh Type 2 Diabetes Study (ET2DS), thus enabling direct comparison of their 
findings with my own.  All reviewed studies assessed memory function. Almost 
always, verbal and non-verbal, prospective and/or semantic memory was assessed; 
one study assessed immediate and delayed memory via Picture Learning Test; this 
differs from the ET2DS where verbal memory test and faces recognition test was 
administered. Most studies used some test assessing ability to process information. 
Executive functioning was also frequently examined. Even where 
neuropsychological tools differed considerably from those used in the ET2DS, the 
reliability and robustness of all tests was always clearly considered.  
In terms of cognitive change or decline over time, it was not always reported whether 
cognitive decline was examined via ‘absolute change’ (calculated by subtracting 
baseline from follow up respective cognitive scores) or adjustment for respective 
baseline cognitive test score. Both approaches have their own advantages and 
limitations 
250
, which will be considered in the interpretation of my own ET2DS 
study findings. When discussing aspects of cognitive testing, it is also important to 




‘extremes’ of follow-up are follow up time points for cognitive assessment in the 
MASS investigation). The average follow up period at all included studies was 3.5 
years which is relatively short to detect change in cognitive performance that might 
be associated with bio-pathological degeneration of the brain. In fact, Dik et al noted 
that their negative results might be due to an insufficient follow up period, 
commonly associated with an observation of a practice effect
238
. The effect of 
practice was also possible in the MASS investigation and both authors admit that two 
sets of follow-up cognitive assessment with a space of just over three years in 
between is too short a time period to detect noticeable change in cognitive 
performance. Likewise, the PROSPER investigation allowed just 39 months in 
between baseline and subsequent testing.  
Another issue which limits the interpretation of findings from the included studies is 
that approximately half of the studies lacked data on baseline characteristics and did 
not compare these in subjects who were lost to the follow-up assessment. Only the 
MASS
235
, the Longitudinal Aging Study Amsterdam
238
,  Edinburgh Artery Study
241
 
and the Aspirin for Asymptomatic Atherosclerosis Trial
251
 provided such data.  
Generally, subjects lost to follow up assessment tend to be more frail and cognitively 
less able; this might contribute to health-related choices, leading to generally worse 
physical health and also higher prevalence of risk factors and/or disease associated 
with an accelerated cognitive decline
252
. This may produce potentially serious bias in 
results and needs to be taken into account during interpretation of findings.  
In terms of selection of inflammatory circulating markers, the majority of studies 




fibrinogen levels, and only one publication reported the role of TNF-alpha. 
Furthermore, sample size varied from several hundred to several thousand with the 
majority of studies being of small to average size. 
There was also considerable overlap in the selection of covariates, based on a 
rationale/evidence of the relationship between these confounding and mediating 
variables either with elevated levels of circulating inflammatory markers and/or 
cognitive ability at advanced age. In general, adjustment was made for the following 
covariates: age and sex, education attainment (years spent in formal education or 
highest education attainment) and socio-economic status. An adjustment for 
conventional cardiovascular risk factors and/or events was common to all studies 
with slight variation between each (i.e., myocardial infarction, angina, stroke, TIA, 
hypertension, type 2 diabetes, HbA1c levels, cholesterol levels, smoking status and 
alcohol consumption). Three studies also considered mental health (depression as 
defined by a standardised assessment) as a potential confounder of the relationship 
between inflammatory markers and cognitive performance
238,241,253
. Additionally, the 
MacArthur Study of Successful Aging analyses were also adjusted for marital status 
and, given the variability of sample population, also ethnicity
236,237
.  A couple of 
studies carried out an additional assessment to investigate whether adjustment for the 
presence of APOE, 4 allele
238,239
 or the presence of APOE, 4 allele and the country 
of origin (Scotland, Ireland or the Netherlands) 
244
 attenuated the strength of the 
inflammation-cognition relationship. Additionally, adjustment was made for various 
other medical conditions, such as tumor, thyroid disturbance, allergy, asthma, 
rheumatic diseases, fracture/osteoporosis
253






Only the Scotland-based cohort studies reported adjustment for prior peak cognitive 
ability defined by a standardized test, such as the National Adult Reading Test
241
 or 
the Mill Hill Vocabulary Scale
240
 and one article provided results from analyses 
adjusted for childhood IQ levels
234
. All the reviewed studies reported adjustment for 
variables that were comparable with those undertaken in the ET2DS, which helped 
subsequent comparisons and ultimate interpretation of findings from my own study.
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Aging (1988)   
East Boston; 1189 
subjects 
Prospective; 2.5 
years and 7 years;  





IL 6 (880 participants) 
median; 4.35pg/ml; split 
into tertiles 
Screening (Mental Status Questionnaire)  
Immediate and delayed memory (Boston Naming 
Test1) 
Language comprehension (Boston Naming Test2) 
Spatial memory (delayed recognition span test)  
Abstraction: Similarities (WAISR) 
Spatial ability (copying geometric figures) 








IL6 (median): 2.77 pg/mL 
(1.86-4.64) 
CRP (median): 1.79 
(0.95-3.13) 
 








998 (47.3%) 74.6 (6.2) 
CRP: 3.2 (5.0) 
IL6: 1.9 (2.1) 
 
General cognition (MMSE) 
Immediate and delayed recall (AVLT) 
Information processing (Alphabet Coding Task) 
 
Schram 




Leiden Study (2) 
prospective  
1: 4.6 years 
2: Max 5 Y. 
1: 3874 




   IL6: 2.11 (1.44-3.32) 
2.CRP: 3 (1-7) 























Cognitive Measures (tests) 
Lucciano, 
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4-10 mg/L: 398 
>10mg/L:120 
FIB: 3.28 (0.64) 
MHT – pre-morbid IQ 
Verbal Memory (LM) 
Spatial Span (Verbal Paired Associates) 
Non-verbal memory (Ravens’ Matrices) 
Executive Function (Verbal Fluency) 
Working Memory (LNS) 
Information Processing (DST) 
Spatial ability (Block Design) 
Executive Function (Symbol Search) 
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5 years follow up 
+ pre-morbid test 
504 (27%) 63.0 (6.85) 
Fibrinogen: 3.36 (0.72) 
CRP: 1.98 (0.89,4.18) log 
transformed 
 
Memory (Logical Memory) 
Non-verbal reasoning (Raven’s Matrices) 
Info speed process (DST) 
Executive Function (VFT) 
Mental flexibility (TMT-B) 
 
Rafnsoon, 
















Follow up:  
Fibrinogen (BL) = 2.53 
(.061) 
Screening (MMSE) 
Verbal declarative memory (Logical Memory) 
Non-verbal memory (Faces) 
Executive Function (BVFT) 
Information Processing (DST) 
General cognitive ability factor ‘g’ 
 


















Cognitive Measures (tests) 
Jefferson, 


















CRP: 2.0 (0.9-4.9) 
 IL-6: 2.6 (1.8-4.2)  
TNF: 1.2 (0.9-1.6) 
Memory verbal (Logical Memory) 
Memory-visual spatial (Visual Reproductions 
Delayed Recall) 
Executive Functioning (TMT-B) 
Language (Boston Naming Task – 30 item) 
Visual perceptual ability (Hoope visual organisation 
test) 
Verbal reasoning (Similarities Subtest) 
Reading (WRAT-3 reading subtest) 
 
       
       
Mooijaart, 










5680; 48% 75.3 (70-82) CRP: 3.1 (4.9) mg/L 
Screening Test (MMSE) 
Executive Function (Stroop test) 
Executive Function/working memory: (Letter-Digit 
Coding test) 




SP., et al., 
2013245 
Total: 5653 N; male % Age (SD) Il 6pg mL-1 Screening test - MMSE 
Executive Function – calculated fro as a z-score from 
Attention (Stroop test) 
Processing Speed (Letter Digit Coding) 
Memory Immediate (picture-learning) 








75.5 (3.4) 1.94-3.19 
3rd Tertile 1884; 56% 75.5 (3.4) 3.19-26.81 
 
1 entire study population, baseline 
2 samples investigated in the presented article, in prospective studies referring to FU variables  
3 only biomarkers of interest reported here (Fibrinogen, CRP, IL6, TNF-alpha), mean levels (SD) provided where available 






Even though the strength of detected associations between inflammatory biomarkers 
and cognitive decline differed considerably between studies and the overall evidence 
was not conclusive, the available prospective evidence does seem to indicate that 
elevated inflammatory markers are associated with accelerated late-life cognitive 
decline, occurring after measurement of the circulating biomarkers. Inconsistency in 
methodologies, particularly in the selection of neuropsychological tests, variation in 
cohort size and characteristics, and selection of potentially mediating variables that 
require consideration, most likely account for the current mixed evidence. 
Furthermore, insufficient length of the follow-up period might not allow for 
detecting significant brain-related pathological changes that would be subsequently 
manifested in declined cognitive scores and therefore indicate whether inflammation 
is, indeed, potentially influencing late-life cognitive ability. 
A great deal of evidence suggests that the association of inflammation with late-life 
cognitive decline occurs independently of common cardiovascular risk factors and 
conditions, pointing towards the possibility of a direct effect on the brain, most likely 
in the form of neuro-inflammation. However, this does not provide a sufficient 
explanation of whether a cardiovascular condition confounds the investigated 
relationship or mediates the effect of elevated inflammatory markers in these 
processes. 
On the other hand, the magnitude of some results suggests that the pathway by which 




Certainly there is a need for larger, prospective studies with a long-term follow up, 
ideally with repeated, multi-wave measures using the same, comprehensive 
neuropsychological battery. This will add to evidence on the pattern and speed of 
changes in cognitive performance, highlighting the main factors in the trajectory of 
cognitive decline.  
The complexity of the gradual, progressive change in cognitive performance, 
influenced by numerous factors that interact with each other, points towards multiple 
bio-pathological processes in which systemic inflammation alters cognitive 
performance. From the result of even prospective observational studies, it is not 
possible to determine whether systemic inflammation lies on the causal pathway 
towards defined cognitive decline (and potentially dementia). One possibility for 
further research in this respect is investigation of association between cognition and 
biomarkers’ related genes and gene variants (i.e. those genes variants which affected 
the circulating levels of the biomarkers). 
As these are not confounded by the main associated factors, such as CV conditions, 
association between gene variants and defined cognitive phenotype could help 
determine whether associations between biomarkers and cognition are causal. 
The ET2DS was designed with the first wave (baseline) assessment providing data 
for cross-sectional analysis
255,256
 but with the advantage of subsequent prospective 
phase scheduled for re-assessment four years after the baseline. The cohort is also of 
a sufficient size to detect meaningful changes in cognitive performance in relation to 




neuropsychological assessment provides cognitive scores across all main domains of 
cognitive functioning as well as general cognitive factor (derived using all cognitive 
scores) and estimated peak, pre-morbid cognitive performance.  
The most likely inflammatory candidates, upstream markers (IL-6 and TNF-alpha) 
and downstream markers (plasma fibrinogen and CRP) were measured at baseline; 
these scores can be modelled independently or can be used in further analysis as a 
‘inflammation factor’ (derived using scores from all four markers).  
As Type 2 Diabetes is one of the strongest risk factors for many conditions 
associated with more rapid deterioration of the brain – potentially making people 
with this condition to decline faster than general population – the investigation 
undertaken in the first part of this thesis (on the association between plasma 
inflammatory biomarkers and cognitive decline) represents investigation of an 




2.5 Study Aims 
People with type 2 diabetes are at a greater risk of age-related cognitive decline. In 
light of the current evidence, the aim of this thesis was to test whether higher plasma 
levels of circulating biomarkers are related to the four-year change and to the life-
time change in performance in general cognitive ability and in specific cognitive 
domains in the diabetic older population. For this, data from the baseline and four-
year follow up phase of the Edinburgh Type 2 Diabetes Study was used (detailed 
description is presented in the following chapter).  The following baseline levels of 
circulating inflammatory markers were examined: cytokines IL-6 and TNF-alpha and 
acute-phase proteins fibrinogen and CRP. Additionally, the general inflammation 
marker, derived using baseline measures of the four markers, was examined. The 
main outcomes were the follow up scores of seven neuropsychological tests, 
providing data for cognitive domains of memory, executive functioning and 
processing of information. The score of general cognitive ability ‘g’ was derived 
using follow up scores of the seven neuropsychological tests. Four-year cognitive 
decline was assessed by using the respective baseline cognitive scores as covariates, 
and the life-time cognitive change was estimated by adjusting for a score of the Mill 
Hill Vocabulary Test. 
To examine the mechanisms of the underlying, potential causal relationship, genetic 
association analysis was conducted.  Gene variants (SNPs) known to have an effect 
on circulating plasma fibrinogen levels were selected via literature search and 




For this purpose, data from seven population-based cohorts were collated, providing 
genetic and cognitive data for 14033 subjects. General cognitive ability factor ‘g’, 
based on cognitive scores for mutually compatible data of three cognitive domains 
(memory, executive functioning and information processing) was calculated for each 
study. Results from individual studies were further used for meta-analysis, 
determining the relationship between fibrinogen-related SNPs and general cognitive 
ability.  
The following chapters describe in detail the methodology of the ET2DS and the 
information on the seven collaborating cohorts, statistical analysis and the results 




Chapter 3:  Methods – The Edinburgh Type 2 
Diabetes Study 
This chapter describes the design of the Edinburgh Type 2 Diabetes (ET2DS), study 
investigating the association of circulating inflammatory markers with cognitive 
impairment and decline in adults with type 2 diabetes. Methods of data collection 
and analysis are reported, both for the baseline and follow up phases of the study, 
where these are relevant to the research described in this thesis.  Baseline data for the 
study were already available when I started my PhD (methods published in detail 
previously
257
); I was responsible for collecting follow-up cognitive data, assisted by 







3.1 The Edinburgh Type 2 Diabetes Study  
The principal aim of the ET2DS was to investigate the role of potentially modifiable 
risk factors, such as circulating inflammatory markers, vascular disease and other 
potential risk factors involved in aetiology of cognitive impairment and cognitive 
decline in elderly people with Type 2 Diabetes.  The Edinburgh Type 2 Diabetes 
study is a prospective, population based study that commenced in 2006-07 and has 
continued as a longitudinal study with cognitive follow up in 2010-11.  
 
3.2 Study Recruitment, Selection Criteria and 
Population 
Baseline Sampling Frame 
ET2DS participants were selected from an elderly population of Lothian, Scotland, 
with diagnosed Type 2 Diabetes via Lothian Diabetes Register (LDR), a 
computerized database containing clinical details of approximately 20,000 diabetic 
inhabitants. Through comparison of the prevalence of diabetes on the LDR with that 
calculated from other sources data in Scotland, it has been established that the LDR 
captures almost everyone diagnosed with this condition in Lothian
257
.  
To ensure the validity of T2DM diagnoses recorded on the LDR, the ET2DS team 
performed confirmatory checks according to several conventionally accepted 




treated with oral anti-diabetic medication or insulin and if those receiving dietary 
treatment alone had a research clinic HbA1c measurement >6.5%. Clinical records of 
subjects with HbA1c below 6.5% and those who may have forms of diabetes other 
that type 2 were reviewed by a consultant diabelogist for validation of a correct 
diagnosis.  
Exclusion Criteria 
Exclusion criteria were as follows: 
 subject not confirmed diagnosis of T2DM (i.e. T1DM) 
 subject not willing to consent to the study or unable to provide a fully 
informed participation consent form 
 subject was not physically fit to complete clinical and cognitive assessment 
 subject confirmed to be non-native English speaker 
 subject did not have normal (corrected) visual acuity – corrected visual acuity 
was below 6/36 for distance vision and/or sufficient to read large print 
 
Baseline Study Population 
A total of 9.464 men and women were identified from the LDR on the 20
th
 July, 
2006, within the study age range of 60 to 74 years as of the 1
st
 August, 2006. Of the 
5.561 randomly selected people, 107 people were no longer on the LDR list by the 
time invitations were ready to send, therefore an invitation for participation was sent 
to 5,454 people. A total of 3,286 people (60.2%) replied to the invitation letter with 




band was carried out to replace those who declined or did not reply to an invitation. 
Of those, 1,252 (23%) people who declared an interest in participation, 1,077 
(19.7%) ultimately attended the baseline clinic. Failure to meet the essential study 
inclusion criteria further reduced the number of the final study participation to 1,066 





Figure 5: Recruitment for the ET2DS and attendance at baseline clinic  
 
Follow Up Clinic Study Population  
All ET2DS participants were considered for follow up clinic assessment in 2010/11. 
Of the initial 1,066 participants, 88 (8.3%) had died, 26 (2.4%) were deemed unfit 
for the follow up examination and 9 (0.08%) had declined further clinic participation. 
Of the remaining 943 (88.5%) subjects invited to the follow up clinic, a further 98 
persons (9.2%) declined to participate and 14 (1.3%) could not be contacted. The 
Follow up Clinic was therefore attended by 831 (77.9%) participants; of these 3 
(0.3%) people were deemed unfit or refused to proceed with cognitive testing. 
Therefore cognitive data were available from 828 (77.6%) of the initial baseline 
study population (Figure 5).  
Of the 235 (22%) people who did not attend the follow-up clinic; 88 (8.3%) had died 
and of the remaining 147 participants, a small group of 6 (0.6%) had declined any 
further contact with the research team. A questionnaire investigating health and 
personal circumstances was sent to all remaining participants (returned by 67 
subjects) and/or their General Practitioners (returned for further 42 subjects). The 
main reasons given for not attending the follow up clinic were poor health and time 
constraints due to duties as a family carer. In addition to questionnaire data, further 
information on all study participants was gained from record linkage to hospital 




diagnoses, including dementia. Over all, information from 32 (3%) participants could 
have not been obtained. 
 






3.3 Sample Size  
When the ET2DS was designed in 2005
257
, the targeted sample size of 1,000 was 
estimated on the basis of the number required to conduct a baseline assessment with 
sufficient statistical power of 90%; =.05 at two-sided significance level to detect a 
standard Pearson correlation of 0.10 and above between the cognitive test scores and 
the independent variables. Estimated targeted sample of the follow up wave was 800 
subjects in order to retain power of 90%; =0.05 at two-sided significance to detect 
correlation 0.12 or greater. At the four year follow-up of the study with 828 
participants, the regression analyses remained powered over 95% with a=.05, two 
sided significance, detecting 0.01 increase in multiple correlation coefficient.  
 
3.4 Ethical Approval 
Ethical permission was obtained for the ET2DS from the Lothian Medical Research 
Ethics Committee. Informed consent was obtained from all participating patients 
attending baseline, follow up clinics and for the record linkage use. Data collection at 






3.5 Clinical Assessment at Baseline and Follow up 
Clinics 
The primary aim of the 2010-11 follow up clinic was to repeat the baseline cognitive 
assessments in a manner that would provide comprehensive and comparable data 
required for assessment of 4 year change in cognitive function. The project presented 
in this thesis aimed to determine the relationship between baseline circulating levels 
of the acute-phase proteins and central pro-inflammatory cytokines with 4 year 
subsequent change in cognitive performance and estimated cognitive decline. 
Therefore the following section provides information on baseline measurement of the 
inflammatory markers and potential confounding and mediating variables considered 
in subsequent analyses as well as both, baseline and follow up cognitive assessment 
(including derivation of general intelligence factor ‘g’). It also reports on data 
management and data analyses. 
Importantly, all data collection at both baseline (BL) and follow up (FU), was carried 
out by trained nurses/researchers, in accordance with standard operating procedures 
257
. All forms and questionnaires were created or chosen with an aim of ensuring 
reliability between and within nurse/researcher assessments. The self-administered 
questionnaire contained validated questions on a range of demographic, personal and 
clinical characteristic, including age, sex, marital status, participant and their spouse 
educational attainment and their employment/occupation status), current socio-




history and control of diabetes (age of onset, HbA1c levels) and current and previous 
medical diagnoses of cardiovascular and other relevant comorbidities.  
 
Inflammatory Markers Measurement  
A baseline fasting venous blood sample provided measures of a range of biomarkers, 
including plasma levels of fibrinogen, CRP, IL-6, and TNF- , as well as high-
density lipoprotein cholesterol, total cholesterol, HbA1c and also blood samples for 
DNA extraction. Blood samples were processed at the research clinic and plasma 
stored at -40
0
C. Assays for inflammatory markers were performed in the University 
Department of Medicine, Glasgow Royal Infirmary. Plasma fibrinogen was 
determined from stored plasma, anti-coagulated with trisodium citrate, using the 
automated Clauss assay (MDA-180) coagulometer, Organon Teknika, Durham, NC). 
Plasma CRP was determined by  a high-sensitivity immunonephelometric assay 
114
. 
IL-6 and TNF antigen levels were determined by high-sensitivity ELISA kits from 




Assessment of Baseline Cardiovascular Disease and Risk Factors 
Questionnaire 
The self-reported questionnaire contained questions on current and previous medical 




stroke and transient ischaemic attack (TIA) and also the presence of cardio-vascular 
risk factors. Information was gathered about the year of diagnosis/event and the 
diagnosing general practitioner/hospital. This facilitated confirmation of a clinical 
diagnosis using scrutiny of medical records and/or record linkage to Scottish hospital 
discharge data (SMR01 scheme) obtained from Information Services Division (ISD) 
of NHS Scotland.  The WHO Chest Pain Questionnaire 
258
 was also completed.  
Data on smoking and alcohol consumption were collected using standard 
questionnaire as used in previous epidemiological studies259.  The smoking variable 
used in subsequent analyses was the estimated pack per year of smoking.  This 
variable was derived by multiplying the number 20 (estimated cigarettes smoked per 
day) by the number of years as a smoker. For non-smokers, zero value was entered. 
Alcohol intake was estimated on self-reported alcohol units consumed in a typical 
week in last 12 months before the clinic visit. 
 
Physical Examination  
Systolic and diastolic brachial blood pressure was measured in the right arm (± 2 
mmHg) using a standard stethoscope and an aneroid, 6 inch dial, desk standing 
sphygmomanometer (Acceson 
TM
, AC Cossor & Son (Surgical) Ltd, Harlow, 
UK).Patients remained in the supine position with their arm resting at the level of the 




A standard 12-lead ECG was taken to assess evidence for myocardial ischaemia; this 
was coded as evidence of coronary heart disease if Minnesota codes were 1.1. to 1.3; 
4.1 to 4.2; 5.1 to 5.3; 7.1 and as indicating definite MI, if Minnesota codes were 1.1.1 




Definition of Cardiovascular Disease 
Cardiovascular disease was defined according to pre-specified criteria, using 
evidence collected from the questionnaire (including the WHO chest pain 
questionnaire), the ECG, hospital discharge codes from record linkage and, if 
necessary, review of medical notes. 
In terms of myocardial infarction (MI), this was recorded if two out of the first three 
of the following criteria were met, or if the first and last criteria were met: 
i. Self-reported history of heart attack (subject recall of doctor’s diagnosis) 
ii. MI indicated by WHO chest pain questionnaire for MI 
iii. ECG evidence of ischaemia  
iv. Prior hospital discharge  ICD10 code for MI (I21-I23; I252) 
In terms of angina this was recorded if two out of the first three of the following 
criteria were met, or if the first and last criteria were met: 
i. Self-reported history of angina (subject recall of doctor’s diagnosis) 
ii. Angina indicated by WHO chest pain questionnaire for angina 




iv. Prior hospital discharge ICD10 code for ischaemic heart disease (I20- I25) 
For stroke, two out of the first three of the following criteria had to be present: 
i. Self-reported history of stroke (subject recall of doctor’s diagnosis) 
ii. Prior hospital discharge ICD10 code for stroke (I61; I63-66, I679, I694)  
iii. Review of clinical notes confirmed history of stroke as opposed to TIA 
For transient ischaemic attack, two out of the first three of the following criteria had 
to be present: 
i. Self-reported history of TIA (subject recall of doctor’s diagnosis) 
ii. Prior hospital discharge ICD10 code for TIA (G45, G659) 
iii. Review of clinical notes confirmed history of TIA 
 
3.6 Cognitive Assessment at Baseline and Follow 
Up 
Assessment of cognitive function was carried out at baseline (2006-07) and the same 
battery of seven standardised, psychometric neuro-psychological tests was 
administered at the follow up clinic (2010-11). This provided a comprehensive and 
validated assessment of cognitive functioning allowing for comparison and thus 
assessment of a possible 4-year change across a range of cognitive domains as well 





 All nurses/researchers followed a standard operating procedure. 
 The ET2DS investigator with a high level of expertise in psychological 
testing completed observation for validation 
 Prior to commencing with cognitive testing, mood quality was assessed 
(assessment of anxiety and depression, using hospital anxiety and depression 




 Prior to commencing with cognitive testing, capillary blood glucose was 
measured to confirm that subjects were not hypoglycaemic. Any subjects 
with glucose < 4.0 mmol/l would be asked to return on a different occasion 
for testing. 
At baseline, cognitive testing was conducted by trained research nurses during one 
clinical session, approximately for one hour, after collection of blood and urine 
samples and a short break for breakfast. Due to resources available at the follow up 
clinic participants completed their clinical and cognitive assessments at different 
times during a total visit of approximately 4.5 hours. Sample of the cognitive test 
pack is provided as an Appendix B. 
 
Mill Hill Vocabulary Test 
Unlike the remaining part of the cognitive tests battery measuring current cognitive 
performance, the Mill Hill Vocabulary Scale (MHVS) test is designed to provide an 




‘crystallised’ intelligence, assessed via vocabulary test, is known to decline very little 
with age thus provide a valid pre-morbid, pre-clinical cognitive functioning 
17,232
. In 
this study the combined Junior and Senior Form A synonyms MHVS
262
. It is a 44-
items, self-administered test where subjects are presented with a key word and are 
required to select the closes synonym from six given words; overall score ranged 0-
44. Vocabulary assessment vary very little across the life-span; as such the major 
advantage of this test is that it allows a direct comparison between  population as 
well estimated premorbid assessment thus life time cognitive change, it provides a 





Mini-Mental State Examination 
Mini-Mental State Examination (MMSE) is a screening 30 item scale designed to 
detect severity of cognitive difficulties, particularly in elderly population; it 
comprises of 20 questions and task assessing functioning in those domains: 
orientation time and place, memory (immediate and recall), attention and calculation, 
praxis-ideational, praxis-copying and drawing and spontaneous praxis-writing. A 
single score is given for each correctly completed item, ranging 0-30. The cut off 
point for dementia is <24, which leaves 6 points for detection of MCI from healthy 
cognition.  Its major advantage is its practicality, only taking approximately 10 
minutes to complete
4
 and consistency between MMSE scores and outcomes of other 




test, it had lacked sensitivity to detect subtle changes in specific cognitive domains 
and to differentiate between people whose cognition deteriorated over 4 years and 
those whose cognition remained stable
233
 and also  differences between the MCI and 
dementia and MCI and healthy adults
263
. Furthermore, cognitive impairment might 
not be detected in subjects with high educational attainment and thus increased rate 
of false positive among people with lower educational level
264
 .  
 
Logical Memory Test (Immediate & Delayed Recall) 
Verbal declarative memory, measured by Logical Memory Test (LM), was assessed 
by immediate (subtest 1) and approximately 30 minutes delayed (subtest 2) recall of 
a short story of a 3
rd
 Edition (WMS-III, UK)
265
. A brief story of 25 elements is read 
aloud by to the participants. After reading, subject is encouraged to recall as much as 
they can (part I). Delayed recall is tested and recorded in identical way; participants 
are asked to recall as much as possible without hearing the story again. Each 
correctly recalled element is scored; the two sub-scores are summed and combined, 
providing a scoring range 0 – 50. Due to a high inter-ratter reliability, this test has 




Faces (Immediate & Delayed Recall) 
In a very similar manner, non-verbal, visual, memory was assessed by two subtests 




faces, each on display for approximately 2 seconds and with each photo subjects are 
reminded to remember the image. The ‘recall test’ collection contains 48 photos; the 
initial 24 photos (target) and 24 distractor photos. Subjects are required to indicate 
whether photo was already seen by yes/no answer at two time points, immediately 
(subtest 1) and approximately 30 minutes delayed recall (subtest 2).These are scored 
with 1 point for each correct answer; sub-scores are summed and combined, 
providing a range of 0-98. 
 
Letter-Number Sequencing 
Working memory along with attention, active maintenance and information 
organisation was evaluated by the Letter-Number-Sequencing subtest (LNS), another 
test utilised from the Wechsler Adult Intelligence Scale, 3
rd
 Edition (WAIS-III, UK).  
Participant is verbally presented with a string of numbers and letter in randomly 
alternating order and is required to re-schedule these according to certain criteria 
(numbers first is raising order followed by letters in alphabetical order).  Strings 
commence with three items and at successful completion of three strings per block, 
subject move toward longer, more complex collections up to the point of 8 items per 
string. The test is discontinued if participants fail to provide three consequent correct 
answers or at successful completion of all 21 strings. Participants score one point for 





Digit-Symbol Coding Test 
Digit Symbol Test (DST), WAIS-III, UK test was administered to assess speed of 
information processing of adults in age range 16-89
267
. It is another pen-paper task 
where participants are presented with a template of numbers 1-9, each corresponding 
with a specific unique symbol. This template remains present for the duration of the 
test. Participants are required to match symbols with numbers using a pen and 
predesign table of randomly allocated digits and empty boxes below for relevant 
symbols, as many as possible within allocated 120 seconds. Boxes must be filled in 
linear order, i.e. alternating across the sheet is not allowed. Prior the actual tests, a 
trial of 7 boxes is provided; this allows the examiner to confirm that subject 
understood the nature of the task. Score ranges between 0-93. DST has demonstrated 





The Borkowski Verbal Fluency Test 
Executive functioning was assessed by a phonemic, Borkowski Verbal Fluency Test 
(BVFT). This consists of 1 minute three sub-task where participant is required to 
name as many words as they can think of, beginning with three different letters with 
the exception of proper nouns, numbers and a repetition of words with identical 
semantics
19
.  As such it is orally presented test with the overall score calculated by 
sum of correctly named words form all three trials. Particular letters have been 




particular letter, i.e. ‘C’ being relatively common, ‘F’ less common’ and ‘L’ least 
common. Despite the test has well established reliability and validity
19,266
, however, 





Matrix Reasoning Test 
The Raven’s Matrices (MR), another subtest selected from the Wechsler Adult 
Intelligence Scale-III, allows for assessment of a person’s non-verbal reasoning, i.e. 
person’s ability  to reason by induction, therefore relies heavily on problem solving 
skills
19
. It consists of a sequence or group of 26 designs. In each there is a one block 
of the pattern missing and the participant is required to fill in a missing design from a 
6 choices provided below. Items/patterns are becoming increasingly difficult and 
complex, requiring higher ability to understand and apply the rules of the missing 
point of the matrix. Maximum score is 26. Both reliability and validity
270
, including 




Trial Making Test – B 
The Trial-Making Test, part B (TMT-B), selected from the Halstead Retain Battery 
has been administered to assess mental flexibility predominantly
272
; further, it shows 
to reliably assess other cognitive domains, such as executive function
273
, sustained 
attention and visual scanning and attention
4




circles, containing numbers (1-13) and letters (A-M) and required to connect these 
circles in numeric and alphabetical order, evenly alternating digits and letters in an 
upward order and it is measured in seconds. Throughout the completions, subjects 
are required to keep pen on the paper. Time to complete this test provides a final 
score, therefore the higher the score, the poorer performance on this task. Errors are 
not counted (unlike in part A of this test). TMT-B has demonstrated well above 




Hospital Anxiety and Depression Scale  
Also, to assess patients’ mood, every participant completed a self-reported Hospital 
Anxiety and Depression Scale (HADS) questionnaire
275
 [52] 
There are 14 questions in total, seven assessing anxiety and seven assessing 
depression. Each item is presented with a 4-multiple choice, allowing the person to 
indicate severity of the item with regards to last 3 days mood. Scores range 0-3, as 
follows: 
 Most of the time (3) 
 A lot if the time (2) 
 From time to time, occasionally (1) 
 Not at all (1) 
Therefore the maximum possible score on each scale is 21; evidence suggest 











3.7 Data Management 
A master Microsoft Access database was created for all baseline and follow up, 
coded data. Results of plasma assays were entered onto the same database, either 
from paper records (biochemistry and haematology) or from electronic files provided 
by participating laboratories. At baseline, the majority of data from paper records 
were double entered and possible discrepancies were resolved by referring to the 
original, paper format record. Remaining data were randomly sampled and double 
checked. In terms of the follow up cognitive data, an identical approach was applied; 
data were manually entered on a daily basis. On completion of all cognitive test, 
randomly selected 20% of records were double entered by any member of the 
research team except the member providing the initial scores. As at baseline data 
management, all discrepancies were resolved by referring to original paper records. 
At both time points, all data were handled only by the ET2DS research team and all 
sets of data, including the master database, were securely stored (password protected) 
on dedicated university computers and backed up securely on a dedicated university 






3.8 Data Analyses 
Prior to statistical analysis, data sets were examined for outliers and missing data. 
Specifically for outlier values in a cognitive dataset, the threshold was set at ‘>1.5 
interquartile range of distribution’; all values out-with this threshold were checked 
against a paper record and corrected where necessary. The intention was to preserve 
as much information as possible to satisfy the required sample size and retain 
statistical power. Therefore only the true outliers were removed from any subsequent 
analyses. 
All categorical variables were described according to their frequency 
(percentage/number). All continuous data were first explored for normality of 
distribution, assessing QQ plots along with descriptive statistics; majority of data 
followed a normal distribution except for positively skewed IL6, CRP and TNF- , 
smoking-pack-per-year and cognitive test TMT-B (both baseline and follow up 
scores). These values were transformed to their natural logarithm values; for these 
variables, median and inter-quartile range is reported for the raw values of all 
transformed variables; further analyses were carried with the transformed values.   
Prior to performing linear regressions a number of preliminary calculations and 
analyses were carried out, relevant to cognitive data. Two cognitive tests, Logical 
Memory and Faces, consisted of ‘immediate’ and delayed’ tasks; Pearson correlation 
between respective scores in each test showed a moderate to high coefficients, 
therefore immediate and delayed scores were combined into a single value, i.e. ‘total 




and follow up data sets. Further, standardised residual scatter plots were inspected 
visually for possible violations of homoscedasticity. Set of correlation analyses was 
run to assess potential issues of collinearity; this concerned with relationship between 
predictive variables and between cognitive tests. 
 
3.8.1.1 General intelligence factor –Principal Component Analysis 
One of the most common methods used in the area of epidemiological studies of 
cognitive ageing is Principal Component Analysis (PCA). It is reasoned that people 
perform consistently across a different cognitive domains
277
. PCA is a data reduction 
technique that condenses a multidimensional dataset by creating components 
(factors) that account for the correlated variance amongst the cognitive scores
278
.  In 
studies concerned with cognitive performances, the largest component that explains 
the largest single proportion of variability, i.e. the principal component factor, is 
commonly known as the general intelligence factor, or ‘g’
277
.  Derivation of this 
single dimension cognitive competence enables an interpretation of results from a 
variety of neuropsychological tests in a meaningful way that allows comparison of 
cognitive scores across varied cohorts. 
Prior to performing the PCA, set of Pearson correlations was run to assess 
associations between seven  cognitive test scores at each time point; moderate to high 
correlation coefficient were observed, therefore it was possible to determine the 
baseline and follow up 'g' as well as a follow-up ‘g’ that was adjusted for its 




In terms of calculation of the actual ‘g’ factor, firstly two single scores of ‘g’ were 
determined: baseline and follow up ‘g’, each combining respective seven cognitive 
scores (LM, Faces, MR, DST, LNS, BVFT and TMT-B). In terms of the baseline ‘g’, 
the principal component accounted for 44, 0% of the variance with each test loading 
strongly on the ‘g’ (range .0454 - (-.0794)).  All loading was of a positive value 
except for the TMT-B (measured in seconds), suggesting a higher scores and thus 
lower level of performance on this test. The follow up ‘g’, principal components 
accounted for 46.3% of the variance, each test again loading strongly on the ‘g’ 
(range .481 – (-.807)). As above, TMT-B negative value reflected higher time need 
to complete the task and thus a lower cognitive performance. Table 3 provides each 
test contribution to principal component ‘g’ (baseline and follow up data), that 
demonstrates the strength of loading onto the first component und thus the 
occurrence of the general intelligence factor. The consistency between all values, the 
pattern detected within each time point scores as well as the steadiness between those 
two time points, is in line with relevant evidence suggesting that performance on 

















LM_BL 0.530 28.1 1 44.0 3.08 
Faces_BL 0.456 20.8 2 13.0 0.91 
VFT_BL 0.678 45.9 3 11.2 0.78 
MR_BL 0.663 44.0 4 9.8 0.69 
DST_BL  0.753 56.6 5 9.3 0.65 
LNS_BL 0.710 50.4 6 7.8 0.54 
- ln_TMT-B_BL 0.793 62.8 7 4.9 0.34 
LM_FU 0.182 36.6 1 47.4 3.32 
Faces_FU 0.154 26.2 2 11.7 0.82 
VFT_FU 0.188 38.8 3 10.5 0.74 
MR_FU 0.207 47.4 4 10.2 0.71 
DST_FU 0.237 61.8 5 8.4 0.59 
LNS_FU 0.224 5.55 6 6.9 0.49 
- ln_TMT-B_FU 0.244 65.8 7 4.7 0.33 
BL - Baseline Scores;  FU - Follow Up Scores; DST – Digit Symbol Test; LM – Logical Memory; LNS – Letter Number 
Sequencing; MR –  Ravens’ Matrices; TMT – B – Trial Making Test- B; VFT – Verbal Fluency Test 
 
Final step was to determine a follow up‘g’ that was adjusted for a respective baseline 
‘g’ scores. A simple comparison of the individual (i.e. baseline vs. follow up) mean 
standardised scores would be uninformative because the means and standard 
deviation at both waves are approximately 0 and -1, respectively59.  Therefore to 
ensure that the comparison of the mean scores across time is meaningful, PCA was 
carried out on the age-adjusted residuals of each cognitive test in the following steps:  
 all data (baseline and follow-up) were combined into a single column; 
 standardised residuals from PCA were saved as composite ability score; 




 the follow-up composite residual was entered as an independent variable into 
regression analysis, with adjustment for baseline composite score.  
 residual from this analysis provided a variable indicating a cognitive decline 
over 4 years. 
This variable was further entered into all models that were set to establish the 
strength of association between baseline levels inflammatory markers and a change 
in general cognitive ability. 
 
3.8.1.2 Inflammation Factor – Principal Component Analysis  
Pearson correlation between baseline levels of biomarker values, carried out on 
results from the entire baseline sample, revealed a significant inter-correlation with a 
moderate effect size. Reduction to the attenders weakened these coefficients slightly; 
however, all values reached a significant level of p< 0.001. Also, the same pattern 
remained the same across the two time points, i.e. the strongest associations were 
observed between plasma fibrinogen and CRP levels (r=0.521 and r=0.497). Slightly 
weaker associations were observed between IL-6 and CRP (r= 0.433 and r=0.415) 
and between IL-6 and plasma fibrinogen (r=0.339 and r=0.344). Overall, TNF -  
showed the lowest magnitude of correlation values with the weakest relationship 
observed between CRP and TNF -  (r = 0.133; and r=0.126) (Table 4 and 5). These 
results supported previously identified biological (cellular and molecular) multi-
factorial relationship between these four specific biomarkers that mutually affect 
production and regulation of other cytokines and acute phase reactants
86,87




As mentioned above in a sub-section 5.1.7, principal component analysis reduces 
multi-variable measures into one principal factor that encompasses the correlated 
variance between individual variables. Provided the biological link and significant 
correlation coefficients between individual biomarkers, it was rationalised to conduct 
a PCA on values of baseline biomarkers values. 
PCA revealed that all loadings were of a positive value; Table 6 provides each 
biomarker’s contribution (percentage and factor loading value, baseline measures), 
that demonstrates the strength of loading onto the first component und thus the 
occurrence of common component. This principal component accounted for 48.6% 
of the variance, each biomarker strongly loading on it (range 0.789 to 0.435). This 
unrotated, saved component, referred here as an ‘inflammatory factor’, was later 
subjected to same multiple regression analysis as each inflammatory marker 
individually. 
Table 4: Pearson correlation of baseline inflammatory markers (whole study 
population) 
 Fibrinogen CRP IL6 TNF –  
Fibrinogen 1 0.521** 0.339** 0.146** 
CRP  1 0.433** 0.133** 
IL6   1 0.324** 









Table 5: Pearson correlation of baseline inflammatory markers (attenders sub-
sample) 
 Fibrinogen CRP IL - 6 TNF –  
Fibrinogen 1 0.497** 0.344** 0.133** 
CRP  1 0.415** 0.126** 
IL - 6   1 0.296** 




Table 6: Principal Component Analysis: baseline inflammatory markers 
 Component Variance (%) Eigenvalue 
Fibrinogen 1 48.62 1.95 
CRP 2 24.18 0.97 
Interleukin - 
6 
3 15.05 0.60 
TNF- 4 12.14 0.49 
 
 
3.8.1.3 Relationship between T2DM and baseline levels of inflammation, 
association with follow up cognitive scores 
Interaction between Type 2 diabetes and elevated systemic inflammation that is 
either mediated or confounded by vascular risk factors has been documented
94,280
. 
Provided the rationale and research question of this study, i.e. investigation into 
relationship between elevated levels of inflammatory markers and accelerated 
cognitive decline in solely diabetic population, a series of regression analyses were 




the baseline data) and the baseline HbA1c levels and all above listed inflammatory 
markers to confirm such associations in this particular cohort.  
Results, presented in Table 7 show a significant relationship between T2DM, as 
defined in the paragraph above, and inflammation status of all measured markers, 
including the inflammatory factor. In case of plasma fibrinogen and TNF - , here 
significant associations vanished in analyses adjusted for common cardiovascular 
factors. The remaining biomarkers showed significant relationship with T2DM, 
independently of cardiovascular factors and events.  
Table 7: Associations between baseline measures of inflammatory markers & HbA1c 
 Fibrinogen CRP IL – 6 TNF -  IF 
HbA1C, Age, 
Sex, 
.067 (.036)** .146 (.036)*** .113 (.035)** .092 (.035)** .168 (.035)*** 
HbA1C, 
Fully adjusted$ 
.037 (.043) .155 (.045)*** .091 (.045)* .049 (.045) .153 (.045)*** 
$ Age+ Sex + BP (S) + Total cholesterol + smoking + alcohol +HbA1c + MI + angina + stroke + TIA + duration of T2DM 
IF – Inflammatory Factor; BP(S) – Blood pressure (systolic); TIA – (transient ischaemic attack) 
 
 
3.8.1.4 Assessment of missing data, imputation of cognitive scores 
Missing data were present at both time points, in independent as well as dependent 
variables. For the purpose of this analysis, cognitive data were imputed for baseline 
and follow up. Specifically, adjusting for age and sex, missing cognitive score were 
imputed for any person where data were missing on one, two or three out of the 




performed separately for cognitive test scores at baseline and at year 4 follow-up. For 
participants with missing data on Faces or Logical Memory, the sum scores on the 
respective test were imputed. A potential for an underestimation of error following 
imputation may be problematic. In the present analyses, imputation of missing data 
outweighed by the increased statistical power, in particular in the analysis of the 
global ability factor g. The calculation of the factor, which is further described 
below, requires that data is available on each contributing test, so that any missing 
data on individual tests would severely restrict the number with participants with a 
value of g. The number of cases with data was imputed is shown separately for each 
cognitive test in Table 8, below. 
Table 8: Imputation of cognitive data collected at baseline and 4-year follow up 
 Baseline Cognitive Data (n=1066) Follow-up Cognitive Data (n=828) 
Cognitive 
Test 
Number of imputed 
cases 
Data missing after 
imputation (%) 
Number of imputed 
cases 




12 0.38 5 0.72 
Faces 2 0.47 3 0.72 
BVFT 2 0.38 4 0.60 
MR 9 0.28 1 0.72 
DST 4 0.47 21 0.96 
LNS 13 0.47 32 0.84 
TMT-B 9 0.47 21 0.96 
 
In terms of predictors and demographic variables, complete data were available for 




T2DM, SIMD, highest education attainment. Small amount of data were missing in 
the remaining variable sets (table 9) but except for the percentage representation, no 
other formal analyses of missing data was conducted on this data. 
 
Table 9: Percentage representation of missing data (predictors & covariates, 
baseline measures) 
 Number Missing %  Number  Missing % 
Age  0 0% BP (S) 2 0.2% 
Sex 0 0% Cholesterol 9 0.8% 
Fibrinogen 3 0.3% MI 0 0% 
CRP 30 2.8% Angina 0 0% 
IL-6 14 1.3% Stroke 0 0% 
TNF 61 0.8% TIA 0 0% 
HbA1c 38 3.6% Smoking 47 4.2% 
Dur_T2DM 0 0% Alcohol 49 4.6% 
Education  0 0% SIMD 0 0 
HADS_A 1 0.1% HADS_D 1 0.1% 
 
 
3.8.1.5 Multifactorial analyses 
To avoid possible violation and biased results, prior regression analyses a number of 
preliminary calculations were taken to assure that assumptions necessary for this type 
of analyses were met. Specifically, this concerned with data distribution and extreme 
values, linearity and homoscedasticity. 
The modelling was three-tiered process. Firstly, Pearson’s correlation, adjusted for 




biomarker and cognitive scores.  Next two cumulative steps, association between the 
baseline level of each of the four circulating biomarkers/cluster of biomarkers and 
cognitive function was assessed. At step one, the follow up cognitive scores were 
adjusted for respective baseline scores, determining a 4 year change in cognitive 
functioning.  Alternative to this approach would be modelling that would explore an 
effect of inflammatory markers on an ‘absolute’ change in cognitive performance 
(i.e. subtracting follow up score from the baseline, results being entered as dependent 
variable). An adjustment for baseline score ameliorates a possible bias caused by 
baseline scores exceeding the follow up measures, especially in case if the reliability 
of dependent variable measure is uncertain
250
. Though the neuropsychological 
battery of standardised tests used in this study has been specifically selected for its 
robustness, validity and reliability, in the case of subtest assessing a verbal (Logical 
Memory) and non-verbal (Faces) memory, follow up scores improved significantly. 
Therefore in regression adjustments, respective baseline scores were entered as 
covariates. 
Next, all potential confounding variables, measured at baseline, were introduced into 
the models; those included: age and sex, vascular risk factors (systolic blood 
pressure, cholesterol levels, alcohol intake and smoking), the presence of 
cardiovascular disease (incidence of MI, angina, stroke and TIA), and diabetes 
relevant variables (duration of diabetes and HbA1c levels). At the step two, all 
follow up cognitive scores were adjusted for the pre-morbid, estimated peak 
cognitive ability to determine a life-time cognitive ability (MHVS scores were 




for all variables in exactly the same manner as in the previous multifactorial analysis. 
This enabled a direct comparison of the predictive value of inflammatory markers on 
4 years and life time change in cognitive functioning of elderly diabetic population. 
Associations between socio-economic factors and performance on cognitive testing 
at advanced age has been well documented
59,281
. Therefore many studies assessing 
the strength of relationship between potential risk factor and cognitive performance 
include various forms of valuation of socio-economic status as a covariate in 
adjusted analysis
61,282,283
. In the ET2DS, socio-economic status was defined by 
SIMD value. SIMD, the Scottish Index of Multiple Deprivation is used to identify 
deprivation based domains, such as current income, employment, health, education 
skills and training, geographic access to services, and housing and crime
284
. 
Providing the significant relationship between SIMD and trajectory of cognitive 
ageing
15
, it would seem reasonable to include this variable in fully adjusted models, 
assessing change in cognitive performance in the ET2DS. However, the primary aim 
of this analysis was to assess the biological link between circulation inflammatory 
markers and cognitive scores in the diabetic population were a role conventional 
cardiovascular risk factor and event were assessed in fully adjusted models. Previous 
research indicates that cardiovascular risk factors and evens largely correlate with the 
socio-economic status
285
. Therefore it was reasoned that including SIMD values in 
the presented regression analyses would weaken the statistical power without adding 
any apparent benefits to the results and consequent interpretation.  
Lastly, consideration was made whether to conduct analysis determining a potential 




this study, scores on this test were obtained for screening purposes only. 
Furthermore, scores on MMSE are known to be influenced by intra and inter-tester 
variability; a previous study found that MMSE scores for identical subjects were 
dependent on testers
286
 and very sensitive to a ceiling-floor effect
287
.  In light of the 
methodological issues, it was therefore not included in the selection of cognitive tests 




Chapter 4: Methods – Collaboration of 
Seven Population Based Cohorts 
The second aim of the work presented in this thesis was to explore the relationship 
between fibrinogen - related single nucleotide polymorphisms (i.e. SNPs associated 
with altered plasma fibrinogen levels in previous studies) and general cognitive 
ability. The rationale was that if fibrinogen levels are casually associated with 
cognitive impairment in older age, then it might be possible to detect direct 
association between ‘g’ and SNPs affecting plasma fibrinogen levels. In order to 
explore this, it was recognized that a larger sample size than was available from the 
ET2DS alone would be required, and so collaboration between seven population-
based cohorts which were known to have cognitive data and at least some fibrinogen-
related SNPS was established. Plasma fibrinogen measures were also available in the 
collaborative cohorts. The procedures which I went through to obtain and collate data 
from these cohort studies and the characteristics of each of the studies are described 
in this section. Particular focus has been paid to studies description, collection of 
genotypic and fibrinogen data and cognitive test battery administered in each cohort. 
Furthermore, method of analyses, including calculation of general intelligence factor 
‘g’, details of analyses conducted in each cohort as we as well as the method of meta-
analysis is presented here.  
The last part of this chapter described methods of identification and selection of 
fibrinogen related Single Nucleotide Polymorphisms (SNPs). This section outlines 




International Human Genome Project (HapMap) and the National Human Genome 
Research Institute (NHGRI). Process of deriving to the final selection of fibrinogen 
related SNPs, subsequently used in analysis determining strength of relationship 
between these gene variances and cognitive functioning is outlined at the end of this 
chapter. 
 
4.1 Data collection from participating cohorts 
Data request 
Cohorts were identified as suitable for inclusion in this work if they contained the 
variables necessary for the proposed analysis, i.e. to explore associations between 
fibrinogen-related SNPs and cognitive functioning in older population. Studies were 
selected on the basis of comparable populations, availability of genotype and 
cognitive data and, provided the time scope available to complete the analysis, 
judged to be reasonably easy to access. This included studies in Edinburgh and two 
large studies based in London with which investigators of the Edinburgh studies had 
previously collaborated: 
 The Aspirin for Asymptomatic Atherosclerosis Study (AAA)*, $ 
 Edinburgh Artery Study (EAS)*, $ 
 English Longitudinal Study of Ageing (ELSA)* 
 The Edinburgh Type 2 Diabetes Study (ET2DS)*, $ 




 Lothian Birth Cohort 1936 (LBC 1936)$ 
 Whitehall II (WII)* 
*studies with previous history of collaboration and now part of UCLEB - Consortium of UCL (London) – Edinburgh – Bristol 
population based prospective studies288; $ Scottish population - based studies 
 
 
Firstly, all identified collaborative centers were contacted to discuss potential 
collaboration and conditions for data sharing. Subsequently, an appropriate Data 
Request Form was forwarded to each external center (ELSA, LBC 21, LBC36, 
ELSA and Whitehall II; Appendices C). Data from AAA, EAS and ET2DS were 
requested internally, no official form was required. Study objectives and aims were 
outlined and appropriate datasets necessary for analyses were requested as follows: 
 any person with genotype data including 1 or more fibrinogen-related SNPs 
(list of eligible SNPs described in section 5.3, Appendix D) 
 any person with cognitive test scores, regardless of missing values 









4.2 Studies description, Genotypic and Fibrinogen 
Data, Cognitive Test Battery and calculation of 
general intelligence factor ‘g’ 
This section describes the key characteristics of each collaborating cohort, relevant to 
the presented study.  All 7 studies are from the UK, population based with a 
prospective cohort design.  Two studies are birth cohorts (LBC 1921 and LBC 1936). 
The AAA trial was initially set up as a RCT; however, prospective data collection 
was conducted, hence this trial could have been identified and included as a cohort 
study. Each study has clearly defined sampling methods, inclusion/exclusion criteria, 
method and procedure of genotypic, biological and cognitive data collection that 
were necessary for the presented investigation. All studies have reasonable even 
gender representation (except for the AAA trial were approximately 2/3 were female 
and, reversely, Whitehall II with approximate 2/3 of male subjects), with all subjects 
falling into 7-8
th
 decade of life, mean age ranged from 60.8 (Whitehall II) to 79.1 
(LBC 1921). This is in line with recruitment criteria within those cohorts. Each study 
details, relevant to the presented analysis, are described below.  
Collating and sorting data according to the above stated criteria resulted in reduction 
in the number of subjects from each study that was included in the final analysis 
There was a substantial overlap between cognitive tests used in individual cohorts for 
the neuropsychological assessment; majority of those have been described in a sub-
section 5.1.5, Cognitive Assessment at Baseline and Follow up (ET2DS). Where 




Overview of all tests for which results were available in each collaborating study is 
provided in table 10. Calculation of general cognitive factor was conducted in each 
study independently. 
Collaborating centres were requested to share all available genotype data (all 
available according to the final fibrinogen related SNPs selection), cognitive data (all 
available scores that were obtained through standardized cognitive assessment) and, 
if available, plasma fibrinogen measures. For each variable, year/date of data 
collection was requested to assure consistency between cohorts in terms of time 
difference between each type of data collection. This resulted in receiving partial 
subsets of the original data from the each of the original cohort population.  For this 
reason, data were not always available for analyses assessing differences in sample 
characteristics between included and excluded subjects; therefore potential selection 
bias could have not been assessed. Furthermore, this inconsistency meant that 
adjustment for factors potentially mediating association between fibrinogen related 
genetic markers and cognitive outcome. From those, age and sex were consistently 
reported across studies and thus entered as covariates. However, demographic and 
laboratory data were available for the received datasets; description of each study 
characteristics is provided in a table 16, descriptive statistics was performed on a 







The Aspirin for Asymptomatic Atherosclerosis Study  
The Aspirin for Asymptomatic Atherosclerosis (AAA) commenced in 1998 as a 
placebo, double blind controlled, randomized trial. The primary aim was to 
investigate the effect of low-dose aspirin on cardiovascular events and cognitive 
ability in people with asymptomatic atherosclerosis, i.e. healthy subjects with relative 
risk of cardiovascular disease. Subsequently, the study has been analyses as a 
prospective, observational cohort to assess the relationship between inflammatory 
biomarker and cognitive performance at an advanced age, including cognitive 
decline and estimated life-time cognitive change.  The trial initially recruited 3350 
men and women (n= 2396), age range 50-75 years, all residents in central Scotland 
(Edinburgh, Glasgow and Lanarkshire), of whom 2312 underwent cognitive 
assessment (mean age of cognitively tested sample 61.6; SD=6.54, male = 27.4%). 
Detailed description of sample recruitment, baseline clinical and cognitive 
examination has been published previously
289-291
.  Ethical committees of 
Lanarkshire, Edinburgh and Glasgow granted the ethical approval for this study. 
Further, all subjects provided informed, written consent prior the start of their 
participation.  
Blood samples used for genotyping were collected at a clinic visit three months after 
recruitment (baseline). Genomic DNA was isolated by standard procedure at the 
Welcome Trust Clinical Research Facility Genetic Core, Western General Hospital, 
Edinburgh. Genotyping was carried out by KBioscience (Herts, UK) using their in-
house chemistry of Competitive Allele Specific PCR (KASPar). Assays for plasma 




Glasgow Royal Infirmary; this was carried out in the same manner as in the ET2DS, 
described above.  
Of the initial 3,350 subjects in the AAA Trial, 2312 undertook cognitive assessment 
at a 5-year follow up clinic, administered by a trained nurse in accordance with 
standard operating procedures. For the purpose of the current analyses, the sample of 
2,061 subjects who completed the entire cognitive battery was used. The battery of 
neuropsychological assessment included tests of immediate and delayed memory 
(Auditory Verbal Learning Test; AVLT, score ranged 0-75). In this test participants 
receive five presentations with recall of a list of 15 words, one presentation of an 
alternative list of 15 words and then they are presented with the sixth recall trial. 
Delayed recall is assessed approximately 30 minutes after the initial presentation. 
Furthermore, subjects in the AAA trial undertook a test of executive functioning 
(Verbal Fluency Test; VFT), processing speed (Digit Symbol Test; DST), non-verbal 
reasoning (Raven’s Standard Progressive Matrices; MR) and mental flexibility and 
attention (Trial Making Test, part B; TMT-B). Scores from all five tests showed 
moderate to high correlation (r= - 646 to r= 0.343; p<0.01) and were entered and 
used to conduct a principal component analysis to derive ‘g’. The principal 
component accounted for 55.83 % of the variance with each test loading strongly on 







Edinburgh Artery Study 
The Edinburgh Artery Study (EAS) commenced in 1988 with the primary aim to 
investigate the epidemiology of peripheral arterial disease – assessment of cognitive 
function was subsequently added. Initially, the cohort consisted of 1592 men and 
women, age range 55-74, randomly selected from age-sex register of eleven general 
practices in Edinburgh. Several follow up assessments clinics were organized with 
blood being sampled for genetic testing at a five-year follow up clinic (1992) and 
cognitive testing commencing in 1998; at this time point, 1209 subjects undertook a 
cognitive battery of 4 neuropsychological tests; for those, 717 full cognitive dataset 
was available. Out of this sub-sample, genotype and cognitive data were available for 
534 of subjects (male 50.7%), mean age 73.9; SD = 5.32.   A full description of study 
recruitment, clinical and cognitive assessment of this cohort has been published 
previously
114,292
. This study gained ethical approval from the Lothian Health Board 
Ethics of Medical Research Sub-committee for Medicine and Clinical Oncology. 
Written informed consent was provided by each person prior their participation. 
Blood assays were carried out according to relevant standards in accredited 
laboratory. Genotyping was carried out from five year examination blood samples, 
using a 5’-nuclease assay (TaqMan) by Helen Ireland in the laboratories of Professor 
Steve Humphries. Plasma fibrinogen levels were determined at baseline from a 
fasting blood samples, measured by a thrombin-clotting turbidometric methods
134
. 
A cognitive assessment consisting of battery of 5 neuropsychological tests was 




standardized operating procedures. It assessed immediate and delayed memory 
(Logical Memory; LM), executive function (Verbal Fluency Test; VFT), non-verbal 
reasoning (Raven’s Standard Progressive Matrices; MR), mental flexibility and 
attention (Trial Making Test, part B; TMT-B) and processing speed (Digit Symbol 
Test; DST). There was a slight variation in the administration and scoring the 
Logical Memory test compared with other studies; in EAS, two stories were read and 
scored for immediate and delayed recall, therefore scores ranged from 0-100. 
Correlation between individual cognitive tests ranged from r= 0.186 to r= 0.400; 
p<0.01); Principal component factor ‘g’ accounted for 49.61 % of the variance 
between tests with each loading strongly on the factor ‘g’, ranged 0.635 – 0.768.  
 
The English Longitudinal Study of Ageing 
The English Longitudinal Study of Ageing (ELSA) is a longitudinal, population 
study. It commenced in 2002 and was conducted by the Department of Epidemiology 
and Public Health, University College of London and the National Centre for Social 
Research.  The primary aim of this study was to explore and determinate a wide 
range of factors associated with an advanced age; cognitive functioning of older 
people being one of the outcome measures.  Detailed description of study aim, 
recruitment and clinical assessment has been published
293
.  Initial 12,000 participants 
formed a nationally representative sample of the English population, aged 50 years 
and above. For the purpose of this analyses, data from wave 4 (2008-09), available 




point, the largest number of subjects with both genotyped and cognitive data was 
available; also, as this was the most recent data provided by this collaborator, mean 
age of participants matched the closest with mean age of remaining cohorts. The 
ELSA has received an ethical permission from the London Multi-Centre Research 
Committee. All subjects provided a signed informed consent prior their participation.  
Analyses of blood sample for plasma fibrinogen concentration was conducted in the 
Royal Victoria Infirmary (Newcastle-Upon-Tyne). Detailed information of internal 
and external quality assessment for the laboratory was published elsewhere
294
 .  
Cognitive data for the presented analyses were available for 5,600 subjects; however, 
calculation of general intelligence factor reduced this sample to 5,458 subjects. The 
ELSA cognitive battery consisted of four neuropsychological tests: immediate and 
delayed word recall of 10-words recall list (words recall, scores 0.10; subjects 
presented with a random one to two syllables words and are required to recall in 
writing as many as possible), semantic fluency was assessed by a number of animal 
names that the subject can freely name within a 1 minute time limit (number of 
animals); ability to write initials after 20 minutes delay, i.e. when instructions was 
given (prospective memory, PM, range 0-5); lastly, unlike in other cohorts, literacy 
skill was assessed to determine subjects ability to memories and comprehend context 
relevant scenario (literacy, range 0-3, subjects were provided instructions with 
regards to medication administration and consequently tested on comprehension of 
it). Detailed description of neuropsychological battery is presented on 
www.ifs.org.uk/elsa/ Person correlations revealed moderate values, ranged between 




presence of principal component that accounted for 45.7% of variance between tests 
with each score loading sufficiently, ranged 0.528 – 0.768. 
 
The Edinburgh Type 2 Diabetes 
As detailed above, the ET2DS is a population based, prospective study of 1066 
randomly selected subjects with diagnosed T2DM, aged 60-74. For the presented 
analysis, the baseline data set of 1,066 subjects was reduced to 1045 of participants 
with both genotype and cognitive dataset available; mean age 67.9 (SD=4.2), of 
those 51.2% were male.  
Blood samples collected at the ET2DS baseline clinic were used for DNA extraction 
and subsequent genotyping. Genomic DNA was isolated from whole blood by 
standard procedure at the Welcome Trust Clinical Research Facility Genetics Core, 
Western General Hospital, Edinburgh. Genotyping was undertaken at KBioscineces, 
using their in house chemistry of Competitive Allele Specific PCR (KASPar).   
Fibrinogen assays were performed in the University Department of Medicine, 
Glasgow Royal Infirmary, using stored plasma anti-coagulated with trisodium citrate 
and automated Clauss assay (MDA-180 coagulometer, Organon Teknika
114
.  
Detailed description of collection of data cognitive scores at baseline was described 
above in a section 5.1.5.  PCA for the current analyses was calculated on raw (i.e. 
non-imputed data) in order remain consistent across cohort studies.  All scores 




Calculation of general intelligence factor revealed a principal component accounting 
for 44.09% of variance with each cognitive score loading strongly, ranged 0.530 – 
0.793. 
 
Lothian Birth Cohort 1921 and Lothian Birth Cohort 1936 
Lothian Birth Cohort 1921 (LBC1921) and Lothian Birth Cohort 1936 (LBC1936) 
are a unique epidemiological studies of cognitive ageing, both comprising of alive 
participants of the initial 1932 and 1947 Mental Health survey, specifically The 
Moray House Test, Number 12, a validated test of general cognitive ability
295,296
. 
Detailed description of background information has been published previously
61,296
.  
The LBC1921 study had commenced in 2000 with the primary aim to establish 
individual differences in genetic determinants in cognitive ageing. This cohort 
consisted of all living people who undertook the Scottish Mental Health Survey at 
1932. Then, it was completed by 87,498 children of both genders. Of those, sample 
of 550 relatively healthy man and women was undertook clinical and cognitive 
assessment at 2000,. For the current analyses, the required genotype and cognitive 
data were available for 517 participants, mean age 79.1 (SD=0.57) years, male 
representing 41.6%.  
The LBC 1936 study began at 2004 with the goal to investigate and establish a range 
of contributors associated with brain ageing and assess multidirectional relationship 




participants who completed the Scottish Mental Health Survey at the mean age of 11, 
i.e. in 1947. At the time of the first wave,); data required for this analyses were 
available for 1005 subjects, mean age was 69.6 (SD=0.83), male representing male 
50.6%.  
Ethical permission for the LBC 1921 and LBC 1936 was provided by the Multi-
Centre Research Committee for Scotland and the Lothian Research Ethics 
Committee. As above, prior the study all subjects provided a written informed 
consent indicating voluntary participation. 
In case of both cohorts, blood sample were used for genomic DNA and plasma 
fibrinogen extraction. Genomic DNA was isolated from whole blood by standard 
procedure at the Welcome Trust Clinical Research Facility Genetics Core, Western 
General Hospital, Edinburgh. Genotyping was carried out by KBioscience (Herts, 
UK), using the in-house chemistry of Competitive Allele Specific PCR (KASPar)
297
. 




At the follow up wave of the LBC 1921 study at 2000, participants completed 
assessment of immediate and delayed memory (Logical Memory; LM), executive 
function (Verbal Fluency Test; VFT) and non-verbal reasoning (Raven’s Standard 
Progressive Matrices; MR). Correlation coefficient between those three tests showed 
lower to medium values (r= 0.175 to r= 0.386; p<0.01). Principal component analysis 
was conducted and principal factor ‘g’ was saved; it accounted for 52.14% of overall 




The cognitive battery administered in the LBC 1936 provided scores for the 
following: immediate and delayed Memory (Logical Memory; LM); executive 
function (Verbal Fluency Test; VFT), non-verbal reasoning (Raven’s Standard 
Progressive Matrices; MR), mental flexibility and attention (Trial Making Test, part 
B; TMT-B) and processing speed (Digit Symbol Test; DST). Individual scores were 
correlated at a levels similar to the LBC 1921 (r= 0.181 to r= 0.400; p<0.01). A 
general intelligence factor ‘g’ was calculated; results indicated a principal component 
which accounted for 48.4% of variance, with individual tests loading at a high level 
(0.645 – 0.775). 
 
Whitehall II 
The Whitehall II study is a prospective cohort study of British civil servants. It 
commenced in 1985 with initial sample number of 10,308 men and women (men 
70%), aged 35-55. In comparison to remaining six cohorts, the population of 
Whitehall II was slightly younger (mean age 60.7, SD = 5.9); also, unlike other 
cohorts, here the criteria of recruitment included occupational status (civil servants), 
ethnic background (British) and residency (London). Furthermore, all enrolled 
participants were ‘white collar’ worker, despite some hierarchy of salary scale has 
been observed.   The primary focus of clinical examination is cardiovascular and 
metabolic risk factors and disease and provides a longitudinal evidence of inter-
relationship between wide range of these factors as well as their effect on cognitive 
ageing
299




total 3,431.  Of those, all subjects had SNP data available, however, sufficient data 
set to calculate  general intelligence factor ‘g’ reduced this sample slightly to 3,340 
valid cases, mean age 60.7 (SD=5.94), of those 75.6% being male participants.   
Genotype data were drawn from a blood samples collected in 2004 (approx. 6000 
subjects).   
Blood samples were used for an extraction of DNA, using magnetic bead technology 
(Medical Solutions, Nottingham). Medical Solutions used SNPLex (Applied 
Bioscinece) to determine relevant genetic variances
300
. For assessment of plasma 
fibrinogen concentration, blood samples were frozen immediately after venipuncture 
and stored until assays. Plasma fibrinogen was determined by an automated 
modification of the Clauss methods. Technical error was estimated by assaying 
blinded duplicate samples for 5% of subjects
301
. 
Though the study was established in 1985, collection of cognitive data was not 
conducted until the phase 5 (1997-99). Comparatively to other collaborative cohorts, 
the mean age of Whitehall II population was slightly lower. Therefore, to match as 
close as possible the mean age across all cohorts, data from wave 7 (2002-04) were 
selected. The battery of neuropsychological tests assessed immediate, short term 
memory (word list immediate, score range 0-20, subjects are required to freely recall 
in writing as many words as they can from a previously presented list of one or two 
syllable words); verbal and mathematical reasoning and test of ability to infer 
patterns, principles and rules (the Alice Heim 4-1; AH4-1, score range 0-65). The 




progresses with the test. Furthermore, phonemic verbal fluency (freely recalled 
words beginning with S, test identical to previously described Verbal Fluency Test 
with e exception of reduced presentation of three letter to single letter, in this case 
letter ‘S’) and semantic fluency (freely recalled names of animal; same principle 
applies as in a phonemic verbal fluency test), each allowed 1 minutes recall time.  
Detailed description of cognitive assessment procedure has been published 
previously
283,299
 and is also available at www.ucl.ac.uk/whitehallII/. Person 
correlation showed moderate relationship between individual test scores (r= 0.328 to 
r= 0.585; p<0.01). The general intelligence factor was derived from 4 cognitive tests 
with a strong principal component accounting for 59.7 % of the variance and each 
test loading strongly on the ‘g’, ranged 0.603 – 0.838.  
 
4.3 “Summary of data available for all 
collaborating cohorts 
Table10 below provides a breakdown of numbers of subjects in each collaborating 
cohort for which genetic, cognitive and/or plasma fibrinogen data were available. 
The aim of the analyses was to assess relationship between fibrinogen related SNPs 
and cognitive performance, therefore the final number subjects of each cohort was 






Table 10: Final number of subjects per individual cohort 
 AAA EAS ELSA ET2DS LBC 21 LBC 36 W II 
Initial cohort (n) 3350 1592 12000 1066 550 1091 10308 
Received (n)
1 
2312 852 5606 1066 517 1005 3413 
SNP data (n)
2 
2091* 852 5606 1060* 517 1005 3413 
Fibrinogen & 
SNPs data (n) 
1918 523 5532 1034 487 997 3187 
‘g’ & SNP data  
(n)
3 





1. Number of cases received from collaborative centers, based on availability of fibrinogen related SNPs (1 or more) 
from the requested list of pre-identified fibrinogen related SNPs and cognitive test scores 
2. Final number of subject with SNPs data after quality control; *additional cases above the requested dataset as 
according to selection criteria for all studies 
3. Final number of subjects with valid ‘g’ score and SNP data 





4.4 Data Management  
Data Storage 
Collaborative centers for ELSA and Whitehall II provided data in a password 
protected format; this was valid for a limited period of time. Data retrieved from the 
mail box were saved in a password protected University server with an appropriate, 
password protected backup. Data from LBC cohorts were received via email 
exchange; upon password protected saving, these email were deleted from the 
mailbox, therefore no unauthorized access could have been gained. Internally 
obtained data for the AAA, EAS and ET2DS are securely stored at the University 
server. At all stages of the study, all datasets were password protected, back up was 
on a secure university server, therefore only authorized access was possible.  
Cleaning and Preparation of individual data set 
The data files received from the collaborating studies differed considerably in 
format, layout and structure, therefore a direct synthetizing was not possible. To 
ensure compatibility of all datasets required for individual analyses and the meta-
analyses, studies were unified on the following variables: 
 ID unique subject identifier as defined by individual study 
 rs number SNPs  
 g general intelligence factor, derived via PCA 
 fib plasma fibrinogen levels, all available in g/L 
 sex male/female (categorical variable) 





Subjects were excluded if the following four conditions were not satisfied.  
 SNPs (i.e. at least one SNP from the required selection must be present) 
 SNPs satisfied a quality control check (details presented below) 
 European subjects only 
 Cognitive scores available for more than half of the possible cognitive results 
derived from a cognitive test battery specific to each particular cohort 
 
Genotype Data Cleaning  
The genotyping was carried out independently by each research team independently. 
The format of the received genotype data differed between cohorts. Specifically, 
ELSA genetic data were coded as ‘A’=major allele and ‘B’= minor allele, whereas 
the remaining files were received in the conventional format. Therefore the ELSA 
cohort genetic variables were recoded first to match the remaining cohort. In 
Whitehall II, LBC 1921 and LBC 1936 datasets, each SNP was presented in two 
separate columns, one for each allele; in such case, these were combined into one 
column. Lastly, the major allele frequency was calculated for each gene variable and 
coded as a ‘scale’ variable according to the major allele frequency, i.e. with the 
highest frequency assigned to highest number (2-1-0). This ensured consistency 
across all genetic data and thus allowed merging cohorts as well as conducting and 




A sample call rate threshold > 0.95 was applied in AAA, EAS, ET2DS, ELSA and 
Whitehall II in order to identify samples with a low DNA quality or problematic 
arrays. SNPs that were outside the Hardy Weinberg equilibrium threshold (HWE 
p<0.05) and duplicate SNPs were removed. The filter for Minor Allele frequency 
was set at MAF ≥ 0.5%, excluding rare SNPs. In terms of varied ethnic background, 
Principal Component Analyses was conducted to identify non-Caucasian subjects; 




In LBC 1921 and LBC 1936, quality control was as follows: individuals were 
excluded from this study based on unresolved gender discrepancy, relatedness, call 
rate (less than or equal to 0.95) and evidence of non-Caucasian descent. SNPs were 
included in the analyses if they met the following conditions: call rate greater than or 
equal to 0.98, minor allele frequency greater than or equal to 0.01 and Hardy–




Table 11 provides an overview of cognitive test batteries available used in each 
study. There was a substantial overlap between the Scotland based cohorts (AAA, 
EAS, ET2DS, LBC 21 and LBC 36); the two cohort of populations based in England 
differed. However, all tests were standardised for the population and purposes they 
were used for; also the three main cognitive domains were tested in each cohort. 
Pearson correlation showed a moderate to high correlation between test score in each 




were satisfied.  It was conducted in seven steps (one step for one study), this is 
presented in Chapter 6, Section 6.2.   
 
Table 11: Cognitive tests for which results were available in each collaborating 
study 
 AAA EAS ELSA ET2DS LBC 21 LBC 36 W II 










VFT VFT semantic 
fluency 





TMT-B  ‘literacy’ TMT-B   AH 4-1 
Processing speed DST DST  DST  DST  
Non-Verbal 
Reasoning 












AVLT – Auditory Verbal Learning Test; AH-4 – Alice Heim - 4; DST – Digit Symbol Test; LM – Logical Memory; LNS – 
Letter Number Sequencing; MHVS – Mill Hill Vocabulary Scale; MHT – Moray House Test; MR –  Ravens’ Matrices; 






4.5 Data Analyses 
The primary aim was to conduct meta-analysis of data collated from the 7 
collaborative cohorts in order to test the significance of associations between plasma 
fibrinogen gene variances (SNPs) and cognitive ability, indexed by general cognitive 
factor ‘g’. Prior to this meta-analysis, a number of consecutive steps were carried 
out. Firstly, individual associations were modeled in two steps, using a multiple 
regression analysis:  
 
 Plasma fibrinogen values ~ SNPs (+ age +sex) 
  ‘g’~ SNPs (+ age + sex) 
 
Age and sex are known to affect frequency of gene variants
183
. A set of linear 
regressions was therefore conducted before and after the adjustment for age and sex.  
Results of these regression analyses, i.e., unstandardized parameter values, standard 
error and p values for each of the 61 SNP for all collaborating study were further 
used to conduct a meta-analysis. In the first step, the relationship between plasma 
fibrinogen and selected SNPs was assessed. Although the nominated SNPs were 
selected especially for their effect on plasma fibrinogen concentrations, linear 
regression and meta-analysis were conducted in order to confirm the strength of this 




selected polymorphisms and the ‘g’. All steps of the meta-analyses were conducted 
using statistical package R 2.1.4. 
The meta-analysis technique enables combining results from different studies. 
Generally, three different approaches to meta-analysis are taken. Systematic reviews 
quite often depend on data that are extracted from the published trials. This can be 
rather problematic due to number of factors, such as lack of control over co-
ordination of data and analytical processes and bias towards publishing statistically 
significant results
194
. Alternative approaches are either individual data analysis (IPD) 
or aggregate patient data (APD)
302
.  Both IPD and APD share a scale of strengths and 
limitations, majority of currently published meta-analyses are conducted on APD, 
especially in gene-association studies and medical studies. In genetic epidemiology, 
these approach is particularly efficient, especially when raw dataset for each cohort is 
available and if the overall number of subjects exceeds 1000
194
.   In the data 
available for the presented meta-analysis, there were number of issues. Most notably, 
methodological rigor in terms of measurement of the outcome of interest, i.e. choice 
of neuropsychological tests assessing cognitive ability, lack of control over 
standardization of data collection and scoring, etc. was not feasible. Additionally, 
one of the key criterion for selecting the fibrinogen-related SNPs was availability in 
at least two of the seven collaborating cohort. Many SNPs were present in less than 
all seven cohorts (appendix E) and this would have introduced a major issue of 
missing data in the IPD approach. Therefore, the presented meta-analysis was based 





Correction for multiple testing 
One of the common problems in studies assessing multiple variables is the possibility 
of ‘false positive’ when the predictor is claimed to have an effect on the outcome 
when, if fact this has been a false positive finding (type I error)
278
.  In this study, for 
a 95% confidence level, the maximum probability that we have falsely identified 
positive association was 0.05. In other words, significant associations between 
fibrinogen-related SNPs and plasma fibrinogen levels and between fibrinogen-related 
SNPs and 'g' was set at the nominal level of significance of 0.05, expecting to find 
5% false positives.  
There are number of ways how the type I error can be controlled, which one of the 
most common statistical approach is the Bonferroni correction for multiple testing
278
. 
By dividing the alpha value by the number of associations, the cumulative type I 
error decreases below the set alpha level. In this study, 61 associations/hypotheses 
were tested. Bonferroni adjustment, calculated in the formula of 0.05/61 would lower 
the new critical p value at 0.0008197.  
Nevertheless, P-values are incredibly sample-size dependent
278
. Conceptually, if two 
identical underlying sets of effects are studied by one smaller and one larger study, 
for the smaller size study the multiple testing correction would eliminate evidence of 
any effects whereas it but make some impact in the second, larger study, despite the 
underlying situation is identical. Therefore it can be argued that placing more 
emphasis on presenting raw p-values, then considering the possible impact of 




studies often suffer from achieving sufficient power. Unlike any hypothesis-free 
analysis, such as Genome Wide Association Studies, where the nominal level of p 
value is set at much lower level, the presented, the presented analysis was hypothesis 
driven. It used a set of 61 SNPs that have been selected for their documented 
significant association with the predictor of interest, i.e. plasma fibrinogen levels. 
Therefore the conducted meta-analysis is a replication stage of a (conceptually) 
larger process. Thus, the underlying probability of a false positive in this analysis is 
somewhat reduced in a rather subtle way that isn't really satisfied in standard multi-
test methods. Bonferroni adjustment, resulting in p-value modification, has been 
evaluated and number of issues was pointed out
303
. Specifically, this adjustment is 
predominantly concerned with rejection of null hypothesis.  Artificially modifying 
probability level can result in misinterpretation of the analysis when true associations 
are deemed as no significant despite their true association with the outcome of 
interest (type II error)
303
. Many researchers argue that, especially in genetic-
association studies, cconfidence intervals are more informative than p values because 
they provide a range of values, which is likely to include the true population 
effect
193
. They also indicate whether a non-significant result is or is not compatible 
with a true effect that was not detected because the sample size was too small
189,194
. 
In light of these issues, i.e. hypothesis-driven analyses of pre-selected gene variants 
and the potential risk of running a type II error, the correction for multiple testing in 
the present analysis was substituted by an interpretation-based approach, focusing 
also on confidence interval values. Confidence intervals are more informative than p 




population effect. They also indicate whether a non-significant result is or is not 






4.6 Selection of Fibrinogen related Single 
Nucleotide Polymorphisms 
SNPs used in the presented analysis were selected through a systematic literature 
search for gene-candidate and genome-wide association studies (GWAS) that 
identified genes and/or SNPs associated with circulating concentrations of plasma 
fibrinogen. Specific SNPs identified this way, together with tagging SNPs for any 
genes identified, were considered for inclusion in the final list of SNPs selected for 
subsequent meta-analysis. Secondary search was also carried out through The 
National Human Genome Research Institute database for potential additional 
references.  
There is a possibility off  non-random association of alleles located on different loci 
within the same chromosome; those associations can be calculated via measurement 
of linkage disequilibrium (LD)
304
. If LD is high, one way to explore genetic 
information across a given region or gene is to use a tagging SNP
8
. To identify 
fibrinogen-related tagging SNPs, The International Human Genome Project 
(HapMap) was searched, using the gene list derived from the literature search. 
The final list of fibrinogen related SNPs and tagging SNPs that guided further stages 






4.6.1 Systematic Literature Search 
The objective of the systematic literature search was to identify published articles in 
which gene variants had been found to be associated with circulating levels of 
fibrinogen.  
The inclusion criterion for articles was the description of any human study which 
attempted to establish an association between plasma fibrinogen concentration and 
genetic variance (including gene candidate studies, GWAS and review articles).  This 
allowed for the ultimate comprehensive selection of all published fibrinogen-related 
SNPs. Once articles have been identified, information on gene/SNPs which were 
reported as being statistically significantly associated with plasma fibrinogen levels 
(according to the criteria of that individual study) was extracted. Due to widely 
under-reported effect size in the majority of studies, the minimum effect size 
criterion for SNP-fibrinogen associations was omitted. 
 
Search of Medline, Embase and PubMed 
The primary search for relevant studies was carried out through the electronic 
databases Medline, EMBASE and PuBMed; search was run in parallel with adjusted 
terminology with ‘mesh’ terms (MEDLINE) equalled ‘emtree’ terms (EMBASE). 
‘Thesaurus’ terms were adjusted accordingly to a particular database. Reference lists 




three types of studies that were used for to review according and according to 
inclusion criteria were: 
 Gene-candidate studies  
 Genome-Wide Association studies  (GWAS) 
 Review articles 
Medline search strategy (1946 to May Week 4 2011)* 
 exp Fibrinogen/ (78693) 
 fibrin$.ti,ab. (185090) 
 or 2 (207666) 
 exp genetic variation/ (1024123) 
 (gene$ adj3 varia$).ti,ab. (182571) 
 genetic markers.mp. or genetic marker/ (89638) 
 genes.mp. or gene/ (1775031) 
 exp Polymorphism, Genetic/ (495502) 
 (nucleotide adj3 polymorphism).ti,ab. (34449) 
 (gene$ adj3 (epid$ or caus$ or determine$ or impact$)).ti,ab. (196855) 
 SNP.ti,ab. (77591) 
 (genetic adj3 marker).ti,ab. (9805) 
 or/4-12 (2845630) 
 3 and 13 (9130) 






Research articles were included in they complied with the following criteria 
 investigation of plasma fibrinogen concentration related genes/genetic 
variants 
 human studies 
 abstract available for an initial inspection 
 were published in English language 
 multiple publication of one study (in such cases, identified gene variance 
were assessed for a repletion with already documented evidence) 
 
4.6.2 Search of the National Human Genome Research 
Institute database 
To identify research articles which may have not been identified through the 
literature search of Medline, EMBASE and PubMed, The National Human Genome 
Research Institute (NHGRI) database was accessed. The search of NHGRI was 
guided by the list of all pre-identified genes that had been found through the 
literature search and implicated in altered plasma fibrinogen concentrations. 
However, after removing duplicates extracted from the above search, this yielded no 





4.6.3 Search of the International Human Genome Project 
(HapMap)  
The primary aim of the HapMap organization is the sequencing of the human 
genome; the focus is on a broad range of studies concerned with the role of the 
human genome in health and disease
199
. For the present study, a HapMap search was 
undertaken for tagging SNPs in all genes pre-identified in the literature search 
(supplemented by information on genes implicated in altered plasma fibrinogen 
levels from experts working in the field) according to the criteria presented in the 
table 12: 
Table 12: Parameters for tagging SNPs selection 
Population CEU  
Buffer zone +/- 10 kb where necessary (to get the full gene plus 
additional sequence on each side) this was 
adjusted accordingly 
Pairwise method Tagger Pairwise  
RSquared cut off 0.9 Altered in number of SNPs unhealthy either 
way 










4.6.4 Results of search for fibrinogen relevant SNPs 
The presented search identified 27 fibrinogen relevant genes, 131 fibrinogen-relevant 
SNPs and 530 fibrinogen relevant tagging SNPs.  
Of the three fibrinogen genes themselves, the most studied was found to be the beta 
chain (FGB) polymorphisms, presumably due to evidence from in vitro research
213
. 
Variants in genes for alpha and gamma chains are also known to affect fibrinogen 
synthesis and production, albeit investigation into these was found to be less 
frequent. Several different polymorphisms were identified in each chain.                                                                           
In addition to SNPs located within the fibrinogen genes themselves, the search also 
identified a number of polymorphisms located out-with the fibrinogen genes; these 
genetic variants were also included. There was a very small number of SNPs that 
were listed in other than ‘rs’ number format; to identify those, the ‘dbSNP’ database 
was utilized. This resolved all discrepancies in terminology, thus all SNPs were 
presented in the traditional format. Results of the search for SNPs are presented in 
Figure 7. The final list of fibrinogen related SNPs and tagging SNPs that were 
identified from the studies found in the literature search and from HapMap is 













4.6.5 Final stage of SNP selection 
A list of SNPs as outlined above was sent to all collaborative centers with a request 
form to identify and forward all SNPs that were genotyped for each cohort.  
After all files were converted to a mutually compatible format, further selection was 
carried out; each SNP was checked for occurrence in the remaining cohorts. SNPs 
were excluded if they occurred in 2 or fewer cohorts only. This resulted in further 
reduction, excluding 234 SNPs, bringing the total number of fibrinogen related SNPs 




Chapter 5:  Results: Association of 
inflammatory markers with cognition in the 
follow up phase of the ET2DS 
The chapter is concerned with the ET2DS. It begins with a description of the general 
baseline characteristics of the ET2DS cohort. Comparison between baseline 
characteristics of subjects who did and did not attend the follow up clinic is 
presented. This is followed by reporting bivariate correlation results, illustrating 
relationships between unadjusted (raw) data. Multivariate linear regression analyses 
form the last part of this section. It presents a set of models, first assessing 
association between four inflammatory markers and cognitive performance at the 
follow up wave only, i.e. cognitive impairment predicted by baseline inflammatory 
markers. Further adjustment for respective baseline scores provides an estimated 4-
year cognitive change; adjustment for MHVS, test of a peak pre-morbid cognitive 
functioning, provides an estimated life-time cognitive change. Lastly, conventional 
cardiovascular risk factors and events were controlled for in order to assess the role 
of these in the inflammation-cognition relationship in people with T2DM.  
All analyses were undertaken by myself, except for the imputation of missing 
cognitive data which was undertaken by the ET2DS team; imputed data were used in 
order remain consistent across multiple analyses on different topics conducted by the 




A summary of baseline measures of assessed risk factors and potentially confounding 
variables and baseline cognitive scores summary, available for both attenders and 
non-attenders of the follow up wave, are provided in table 13 and table 14, 
respectively. This allows for a direct comparison between these sub-groups and for 
an assessment of potential survival bias. A comparison of baseline and follow up 
cognitive scores specific to the attenders sub-sample is presented in Table 15. 
In comparison to the entire ET2DS population, there were some, though 
predominantly modest, observed differences in clinical and demographic values of 
subjects cognitively tested at the follow up wave (attenders). In percentile 
representation, gender representation remained approximately same between both 
groups; however, on average attenders were 1 year younger and generally healthier. 
They presented with consistently lower levels of plasma circulating biomarkers; the 
acute phase proteins, plasma fibrinogen and CRP and the cytokine IL-6 significantly 
lower (except for TNF- levels). In terms of cardiovascular risk factors, systolic 
blood pressure and the mean reading of cholesterol level were significantly higher in 
the non-attenders group albeit still within the normal physiological range.  
The same pattern was detected in diagnosed cardio-vascular disease history; 
attenders generally reported a lesser prevalence of cardiovascular events, with the 
exception of TIA. Attenders were more likely to be either never or ex-smokers 
(ceased at least 6 months prior the clinic) and had a lower consumption of alcohol. 




In terms of years spent in formal education and in the social deprivation status 
(SIMD), the observed pattern indicated (in percentage) that attenders generally had 
obtained higher educational attainment and there was a trend toward a higher rank in 














Mean ± SD, 
median (quartile 
range) or n (%) 
Total  
Number 
Mean ± SD, 
median (quartile 




Age (years) 831 67.69 ± 4.16 235 68.71 ± 4.27 0.001 
Male sex 831 430 (51.7) 235 117 (49.8) 0.596 
Duration of diabetes 
(years) 
824 6 (3 – 11) 229 7 (3 – 12) 0.196 
Current treatment 
   Insulin +/-tablets               
   Tablets only 


















HbA1c (%) 804 7.39± 1.13 224 7.41± 1.08 0.872 
Plasma glucose  821 7.54 ± 2.09 228 7.66± 2.13 0.425 
Plasma fibrinogen 828 3.61± 0.75 235 3.78 ± 0.83 0.001 
CRP* 817 3.63  226 5.49 0.001 
IL-6* 829 3.73 235 4.61 0.048 
TNF-alpha* 828 1.33 238 1.46 0.535 
Total cholesterol  826 4.34± 0.90 231 4.23 ± 0.91 0.100 
Systolic BP (mmHg) 829 132.51± 15.87 235 136.09 ± 18.09 0.006 
Diastolic BP (mmHg) 829 68.95±8.87 235 69.44 ± 9.50 0.457 
BMI (kg/m
2
) 831 31.29 ± 5.59 234 31.93  6.03 0.130 
Macrovascular disease  
     MI 
     Angina  
     Stroke 
     TIA 
     PAD 







































Light drinker (<7) 
Moderate drinker (7-15) 




























   Current smoker 
   Ex-smoker 



































Mean ± SD, 
median (quartile 
range) or n (%) 
Total  
Number 
Mean ± SD, 
median (quartile 






   University degree 
   Professional  
   qualification 
   Secondary school 



































   Least deprived 
   Less deprived 
   Deprived  
   More deprived 



























HADS anxiety 831 5 (3 – 8) 234 6 (4 – 9) <0.001 
HADS depression 831 3 (1 – 5) 234 4 (2 – 6)  0.002 
 
 
Values are mean (standard deviation), median (interquartile range)* or percentage** 
HbA1c - glycated haemoglobin; CRP – C-reactive Protein; IL-6 – Interleukin-6; TNF-alpha – Tumour Necrosis Alpha; BMI 
– Body Mass Index; SIMD – Scottish Index for Multiple Deprivation; HADS (A) – Hospital Anxiety Depression Scale 
(Anxiety); HADS (D) – Hospital Anxiety Depression Scale (Depression) 
 
 
Cognitively, attenders presented with significantly higher baseline cognitive scores 
in all subtests as well as in terms of the general intelligence score ‘g’; they were also 
less likely to progress towards a diagnosis of dementia; Table 14 summarises 
individual data. This again suggests a possibility of a methodological issue common 
to longitudinal design, that the physically and cognitively healthier subjects were 










Table 14: Comparison of cognitive baseline scores (Attenders & Non-Attenders) 
 




Total (N) Mean (SD) Total (N) Mean (SD) 
MMSE 830 28.47 (1.6) 233 27.7 (2.5) 0.77   (< .000) 0 – 30 
MMSE<24 830 13 (1.6) 233 17 (7.3) 4        (< .001) 0 – 30 
MHVS 820 31.45 (5.1) 229 29.06 (5.4) 2.39   (< .000) 0 – xxx 
LM 822 25.86 (7.9) 28 23.02 (8.6) 2.84   (< .000) 0 – 50 
Faces 827 66.34 (7.7) 232 63.9 (8.4) 2.44  (< .000) 0 – 94 
BVFT 828 37.77 (12.5) 232 33.88 (13.4) 3.89  (< .000) ad infinitum 
MR 822 13.36 (5.2) 230 10.86 (5) 2.5     (< .000) 0 - 26 
DST 828 50.42 (14.3) 229 44.65 (15.5) 5.77   (< .000) 0 - 93 
LNS 822 9.93 (2.7) 226 8.7 (2.9) 1.23   (< .000) 0 - 21 
TMT-B* 823 101 (79-132) 229 140.76 (75.1) - 45.76 (<.000) in seconds 
‘g’ 804 .12 ( .93) 217 -.44 (1.1) - .32   (< .001) N/A 
Dementia 
Diagnosis 
831 4 (0.5%) 235 15 (6.4%) N/A N/A 
 
Values are mean (standard deviation), median (interquartile range)* or percentage** 
MMSE – Mini Mental State Examination; MMSE < 24 – score indicating early dementia onset; MHVS – Mill Hill Vocabulary 
Scale; LM – Logical Memory (combined immediate and delayed recall); Faces – Faces recognition (combined immediate and 
delayed recall); BVFT – Borkowski Verbal Fluency Test; MR – Raven’s Matrices; DST – Digit Symbol Test; LNS – Letter – 
Number – Sequencing; TMT-B – Trial Making Test – B; HADS (A) – Hospital Anxiety Depression Scale (Anxiety); HADS 
(D) – Hospital Anxiety Depression Scale (Depression); Diagnosis of Dementia as confirmed by GP notes or Information 
Services Division (ISD) 
 
Table 15 provides bivariate correlations between the baseline and follow up 




those two-time scores (r = 0.542 to r = 0.871; p < 0.001). The strongest relationship 
was observed in MHVS scores (r = 0.87; p < 0.001); this highly stable result was 
expected as it supports the notion of ‘crystallised’ ability, assessed by a vocabulary 
test, remaining relatively insensitive to the effect of ageing
17
.  Mean scores of LM 
and Faces improved significantly, suggesting a possibility of a practice effect
232
.  The 
remaining mean scores declined significantly, suggesting an overall cognitive 
decline. 
Table 15: Baseline and Follow-Up cognitive performance of 'Attenders' 
 Baseline Scores Follow-up Scores 
 Number Mean (SD) Number Mean (SD) 
MHVS 820 31.46 (5.07) 818 30.71 (4.94) 
‘g’ 827 0.17 (0.93) 823 0.01 (1.00) 
BVFT  827 37.81 (12.52) 826 36.83 (12.75) 
DST 828 50.43 (14.34) 823 50.01 (14.12) 
TMT-B*  827 101.49 (1.44) 823 111.05 (1.51) 
MR  828 13.36 (5.23) 825 11.5 (5.22) 
LNS 827 9.92 (2.66) 824 8.86 (2.89) 
LM  827 25.83 (7.97) 825 27.27 (8.25) 
Faces 827 66.37 (7.65) 825 69.25 (8.38) 
MMSE 827 28.48 (1.63) 824 28.33 (1.77) 
 
*
Means of TMT-B are geometric means, number indicates seconds needed to complete the task 
** Significant at the p < 0.001 level 
 
Lastly, inter-correlations between baseline cognitive test scores were assessed. All 
cognitive scores and g correlated significantly with all cognitive scores. Some of the 
strongest correlations were detected in tests assessing speed of information 




represents better cognitive performance, the negative values in TMT-B results 
represents a worse performance (the higher number, the longer it takes to complete 
the test). Relatively weaker correlations were found for measures of verbal (LM) and 
non-verbal (Faces) memory. All values are presented in Table 16 below. 
In terms of the follow up cognitive scores, the pattern seems to mirror the baseline 
correlations; whereas the weakest correlations were observed in tests assessing 
verbal and non-verbal memory (LM and Faces, respectively), the strongest values 
were detected in tests assessing speed of information processing (TMT-B and DST). 
All values are presented in Table 17, below.  
 
Table 16: Bivariate correlations between baseline cognitive test scores 
 LM Faces MR DST TMT-B LNS BVFT g* 
MHVS 0.38 0.28 0.45 0.37 -0.37 0.40 0.44 0.28 
LM --- 0.24 0.28 0.27 -0.28 0.31 0.25 0.54 
Faces  --- 0.24 0.29 -0.26 0.20 0.22 0.47 
MR   --- 0.38 -0.46 0.40 0.36 0.67 
DST    --- -.063 0.40 0.40 0.75 
TMT-B     --- -0.50 -0.39 0.80 
LNS      --- 0.46 0.72 
BVFT       --- 0.67 
 
 
Table 17: Bivariate correlations between four years follow-up cognitive test scores 
 LM Faces MR DST TMT-B LNS BVFT g* 




 LM Faces MR DST TMT-B LNS BVFT g* 
LM --- 0.26 0.32 0.37 -0.38 0.37 0.41 0.61 
Faces  --- 0.29 0.29 -0.31 0.22 0.27 0.51 
MR   --- 0.44 -0.48 0.46 0.29 0.69 
DST    --- -.065 0.47 0.41 0.79 
TMT-B     --- -0.53 -0.37 0.81 
LNS      --- 0.41 0.75 
BVFT       --- 0.62 
 
RELEVANT TO TABLE 16 & 17: *Values for associations of g with the seven cognitive tests (except MHVS) are factor 
loadings on basis of imputed cognitive test data. Values for all individual cognitive tests are correlation coefficients from two-
tailed Pearson correlations, p<0.001.  MHVS, Mill-Hill Vocabulary Scale; LM, Logical Memory; MR, Matrix Reasoning; DSC, 
Digit Symbol Coding; TMT-B, Trail-Making- Test B; LNS, Letter Number Sequencing; BVFT, Borkowski Verbal Fluency 
Test 
 
5.1.1 Model assumption 
For the purpose of the multiple linear regression analyses, data were explored and 
inspected for normality, linearity and homoscedasticity. 
5.1.1.1 Data distribution 
The distribution of all continuous variables were compared to the Normal 
distribution, both numerically and visually via histograms and Q-Q plots; obvious 
outliers were checked against a paper record and consequently either corrected or 
removed. All variables that presented as skewed (IL-6, CRP, TNF-alpha, TMT-B, 
smoking (N of packs/year), all right-skewed) were transformed to their natural 
logarithm. For those variables, medians and inter-quartile ranges for the raw values 
are presented. Histograms and Q-Q plots for these variables before and after log 




The remaining variables, deemed as normally distributed, were treated as continuous 
variables and summarized with means and standard deviations values along with p-
values for difference between the two sub-samples of the baseline cohort (attenders 
and non-attenders). All categorical variables are reported as frequency distribution in 


































































































Figure 8: Histograms of the raw and natural log-transformed 
 
5.1.1.2 Associations of dependent variables and potential confounders 
A perfect (or near-perfect) linear relationship between two or more 
predictors/covariates may present the problem of collinearity, therefore a series of 
bivariate (Pearson) correlations were calculated to assess the relationship between all 
cognitive scores and potential confounding variables. One the major advantages of 



































































































this study was the large sample size that allowed for sufficient power to detect even 
small correlation coefficients. There was not a particularly large coefficient between 
predictors and/or covariates, ranging r= -.010 (cholesterol – smoking) to r= .521 
(fibrinogen –C-reactive protein).  In terms of correlation between 
predictors/covariates and cognitive scores, Pearson correlations on raw data were 
conducted for baseline cognitive scores  and for follow up cognitive scores. All 
baseline correlation coefficients were reasonably small (ranged r= -.002 (Fib – LM) 
to r= .182, p<0.01 (IL6 – TMT). Equally, follow up cognitive test scores correlated 
with baseline predictive and confounding variables, with the lowest value r= -.010 
(T2DM – LM) to the highest, r =0.148, p<0.01 (alcohol – MR). Overall, all 
correlation values ranged from low to moderate, suggesting that collinearity was 
unlikely to present in later analyses.  
 
5.1.1.3 Homoscedasticity 
Homoscedasticity is an assumption tested in multiple regressions. It predicts that at 
each level of the predictor value, the variance of the residual remains constant. 
Conventionally, this is examined visually via scatterplots and histograms where the 
residuals associated with the dependent variable shows what variance is left after 
accounting for independent variables. A scatterplot, showing the regressed 
standardised residual on to the standardised predictor value, needs to be visually 
examined. If the plot resembles a bird nest or a funnel plot, it can be assumed the 




the dependent variable are increasing. In this study, based on a visual inspection of 
histograms and scatterplots, it was concluded that this assumption was not violated. 
 
5.1.1.4 Removal of subjects with extreme inflammatory marker values, adjustment 
for mood status 
Acute inflammation might bias the results between plasma biomarker levels and 
cognitive scores. To discount this, the dataset was also examined for the presence of 
extreme values in inflammatory markers. Biomarker levels detected above 1.5 
interquartile range thresholds were deemed as indicative of an acute inflammation; 
all values above this level were regarded as being indicative of acute inflammation 
and abnormally large values may have obscured any potential relationships. 
However, this was detected only sporadically (4.7%). Analyses were repeated after 
exclusion of subjects with extreme measure and this made no significant change to 
the overall results that remained similar.  
In terms of adjustment for mood evaluation scores, evidence indicates an association 
between  prolonged depressive mood and accelerated cognitive decline in elderly 
people
305
 and depressive mood and elevated inflammatory markers
306
.  In the present 
study, adjustment for HADS scores, a validated measure of anxiety and depression 
status, resulted only in marginal alterations to a significance level in global cognitive 
function ‘g’; no noticeable change was detected in analyses assessing individual 
tests. Table 18 shows standardised parameters, standard error values and significance 




with  HADS scores as covariates in following sequence: anxiety score, depression 
score and scores anxiety and depression scores in the final model.  
 





Interleukin – 6 TNF - 
Inflammatory 
Factor 
4-year change1 -.109 (.047)* -.126 (.051)* -.145 (.050)** -.085 (.049) -.194 (.051)*** 
Life-time 
change1 
-.073 (.038) -.068 (.042) -.101 (.041)* -.045 (.039) -.126 (.042)** 
4-year change2 -.105 (.046)* -.117 (.051)* -.138 (.049)** -.083 (.048) -.186 (.051)*** 
Life-time 
change2 
-.067 (.033) -.053 (.042) -.090 (.040)* -.043 (.039) -.111 (.041)** 
4-year change2 -.105 (.047)* -.118 (.052)* -.0139 (.050)** -.083 (.049) -.189 (.052)*** 
Life-time 
change2 
-.066 (.038) -.052  (.042) -.089 (.041)* -.041 (.039) -.112 (.042)** 
 
1 Fully adjusted model (as above) + HADS (Anxiety score) 
2 Fully adjusted model (as above) + HADS (Depression score) 
3 Fully adjusted model (as above) + HADS (Anxiety & Depression scores) 
 
5.1.2 Multiple regressions – baseline marker levels and 




Multiple linear regression analysis allows exploring an effect that 2 or more 
predictors (either continuous or categorical) have on a dependent variable, presented 
as a continuous outcome
278
. Given the type of data collected for the presented study, 
it was deemed as the most suitable analytical approach to determine strength of 
predictive value of inflammatory markers on a 4-year cognitive change and life-time 
cognitive change. At first, series of age and sex adjusted models were fitted to assess 
relationships between baseline inflammatory markers and follow up cognition; these 
associations were analyzed further through a series of linear regressions when either 
4-year cognitive change (adjusted for respective baseline scores) or life-time 
estimated change (adjusted for MHVS score) was modeled. Analyses were repeated 
with cardiovascular risk factors and events as covariates. These were the baseline 
measures of: total cholesterol; myocardial infarction; angina; stroke; transient 
ischaemic attack; smoking; alcohol; HbA1c; duration of type 2 diabetes. Finally, all 
biomarkers and inflammatory factor predictive values were assessed in models 
adjusted for anxiety and depression (HADS) scores.  
Individual biomarkers regression results 
Plasma fibrinogen regression results: 
Plasma fibrinogen level was significantly associated with a follow up decline in ‘g’ 
( = -0.114; p<0.001), 4-year cognitive change ( = -0.108; p<0.01) and a life-time 
change (= -0.084; p<0.01) and independently of risk factors at 4-years (= -0.093; 
p<0.05) and life-time cognitive change ( = - 0.066; p<0.05). Follow up cognitive 




standardised coefficient ranged between -0.073 to -0.113; p<0.05 to p<0.001); except 
for LM ( = -0.042; p=0.215) and Faces (= -0.52; p=0.141).  
After an adjustment for the respective baseline scores, the significant association 
remained at same level in Raven’s Matrices ( = -0.036; p<0.05), BVFT ( = -0.049; 
p<0.05) and LNS ( = -0.097; p<0.01) scores. Significance of association decreased 
in DST scores ( = -0.076; p<0.01) and in TMT-B score ( = 0.03; p<0.05) 
Life-time cognitive decline, as compared to the 4-year change analyses, showed a 
similar pattern. Fibrinogen predicted the same level of cognitive decline in DST ( = 
-0.093; p<0.01) and in TMT-B ( = 0.074; p <0.05) and slightly weakened in LNS ( 
= -0.072; p<0.05).  Significance of association vanished in BVFT ( = -0.049; 
p=0.124) and in Raven’s Matrices ( = -0.051; p=0.175). 
Adjustment for covariates – as indicated in the preceding paragraph, weakened the 
magnitude and statistical significance of most associations; irrespective of other 
factors, fibrinogen was a significant predictor of a decline in DST both in terms of 4-
year change ( = -0.075; p<0.05) and life-time change ( = -0.071; p<0.05), decline 
in LNS at 4 year decline ( = -0.069; p<0.05) and life-time decline ( = -0.060; 
p<0.05) and TMT-B at life-time decline  ( = 0.097; p<0.05). Overall, the most 
effect of the plasma fibrinogen levels was detected in general cognitive ability, 
followed by performance on DST, LNS and TMT-B. No significant association was 
observed either LM or Faces scores.  




Plasma CRP levels significantly predicted decline in general cognitive ability across 
the whole spectrum: follow up ‘g’ ( = -0.123; p<0.001), 4-year change ( = -0.131; 
p<0.001) and independently of covariates ( = -0.105; p<0.05). In terms of life-time 
ability, CRP predicted decline ( = -0.084; p<0.01); however, this significance 
vanished, albeit at borderline value, when adjusted for covariates ( = -0.069; 
p=0.006). In terms of the individual, follow up individual scores, CRP strongly 
affected performance in follow up DST ( = -0.127; p<0.001), slightly less so in 
TMT-B ( = 0.102; p<0.01) and LNS ( = -0.090; p<0.01) and marginally in Ravens 
Matrices ( = -0.084; p<0.05) and BVFT ( = -0.074; p<0.05).   
Same level of significance was observed in 4-year cognitive change scores of DST ( 
= -0.093; p<0.001) and LNS and TMT-B ( = 0.076;  = -0.074; p<0.05, 
respectively). However, in models adjusted for respective baseline measure, 
significance has vanished in Raven’s Matrices ( = -0.043; p=0.138) and BVFT ( = 
-0.029; p=0.249). Life-time estimated cognitive decline was observed in DST score 
( = -0.092; p<0.01) and TMT-B score ( = 0.078; p<0.05) but no other significant 
association was found.  
Independently of cardiovascular conditions, CRP levels was associated with 4-year 
decline in DST, LNS and TMT-B ( = -0.066;  = -0.059;  = -0.059, p< 0.05, 
respectively).  
When the model was set to assess associations between baseline CRP levels and life-




relationship was observed in DST ( = -0.061) and TMT-B performance ( = 0.070; 
p<0.05); no other significant prediction was detected.  
As with the plasma fibrinogen levels, the CRP levels did not predict any significant 
decline in LM and Faces scores. 
Interleukin – 6 regression results 
Interleukin-6 proved to be the strongest predictor across domains, independently of 
covariates. It strongly predicted a follow up decline in ‘g’ ( = -0.195; p<0.001), 4-
year change ( = -0.163; p<0.001), life-time cognitive change ( = -0.153; p<0.001). 
Comprehensive adjustment weakened these associations a little at 4-year cognitive 
decline ( = -0.112; p<0.01) as well as a life-time decline ( = -0.121; p<0.01). 
Compared to plasma fibrinogen and CRP levels, IL-6 significantly predicted a follow 
up cognitive impairment across all domains with standardised coefficient ranging 
from -0.083 to 0.137; p values <0.001 to <0.05. This association was maintained in 
terms of 4-year change (range  = -0.031 to -0.137; p values <0.001 to <0.05), except 
for the TMT-B ( = 0.039; p=0.166). Life-time cognitive change analyses revealed 
statistically significant association for all tests with standardized coefficients ranging 
from -0.086 to -0.140; p values <0.001 to <0.01, except for LM score ( = -0.147; 
p=0.453). 
Full adjustment of the 4-year cognitive scores revealed a sufficient prediction of 
decline in DST score ( = -0.089; p<0.01), MR ( = -0.075; p<0.01) and LNS score 




adjusted model assessing a life-time cognitive change, the significance of association 
was slightly remained of a similar magnitude; it was detectable in DST score ( = -
0.109; p<0.01), LNS score ( = -0.102; p<0.01), Raven’s Matrices ( = -0.102; 
p<0.01) and TMT-B ( = -0.089; p<0.01). Slightly weaker relationship was detected 
between IL-6 levels and Faces score ( = -0.069; p<0.06). 
TNF -  regression results  
In comparison to the above results, level of TNF - proved to be the weakest 
predictor.  In terms of general cognitive ability, strong significant decline was 
detected at the follow up model ( = -0.116; p<0.001). However, the remaining 
analyses revealed only marginal significance at 4-year cognitive change ( = -0.069; 
p<0.05), life-time cognitive change ( = -0.066; p<0.05) and, independently of risk 
factors and events at 4-year follow up measure ( = -0.046; p<0.05). 
However, no relationship was found between this biomarker and fully adjusted the 
life-time cognitive decline ( = -0.036; p=0.95).  
In terms of the follow up scores, significance ranged from Faces ( =-0.111; p<0.01), 
MR ( =-0.103; p<0.01), TMT-B ( =0.089; p<0.01) and weaker for DST ( =-
0.081; p<0.05), BVFT ( =-0.074; p<0.05) and LNS ( =-0.073; p<0.05). No 
significant association were found in LM scores. In comparison to other markers, 
TNF - most strongly predicted decline in non-verbal memory assessed by Faces; 
this relationship is maintained across the spectrum; 4-year cognitive decline ( = -




decline ( =-0.084; p<0.05), independently of CVD factors and events ( =-0.079; 
p<0.05). 
Apart from these associations, TNF -  was a predictor of a 4-year decline in DST ( 
=-0.068; p<0.01), independently of adjusted factors ( =-0.064; p<0.01) and a 
marginal significant predictor of life-time decline in MR ( =-0.605; p<0.05) and of 
a 4-year decline in LNS score ( =-0.042; p<0.05). 
 Otherwise no significant relationships were observed in regards to TNF -  levels. 
Overall, compare to other investigated biomarkers TNF-, showed the weakest effect 
on cognitive performance, with the exception of non-verbal memory.  
General inflammatory factor regression results: 
General inflammatory factor, a component derived from levels of four biomarkers, 
showed a similar predictive pattern as each marker individually; especially, it was 
close to identical with the significance pattern detected in IL6 levels. 
The strongest associations were detected in follow up ‘g’ ( =-0.197; p<0.001), 4-
year longitudinally ( =-0.193; p<0.001) and in terms of life time change ( =-0.137; 
p<0.001). Full adjustment did not affect these associations in 4-year decline model ( 
=-0.136; p<0.001) or life-time change model ( =-0.119; p<0.001). In general, 
follow up models showed significant impairment across all cognitive tests; the 
strongest in DST score ( =-0.179; p<0.001), TMT-B score ( = 0.151; p<0.001), 
LNS and MR scores demonstrating same level of impairment ( =-0.151; p<0.001). 




Faces score ( =-0.108; p<0.01), followed up by scores in LM test ( =-0.077; 
p<0.05).  
In terms of a life time change in cognitive performance, all scores declined 
significantly, except for the LM test. As in previous models, here too the highest 
decline, detected at p<0.001, was observed in measures of attention, information 
processing and mental flexibility (DST: = 140; TMT-B:  = 0.117; and LNS:  = 
0.109). Decline in non-verbal reasoning was also detected (MR:  =-0.100; p<0.01), 
followed by a marginally significant life-time decline in executive functioning 
(BVFT:  =-0.066; p<0.05) and non-verbal memory (Faces:  =-0.48; p<0.05). 
Comprehensive adjustment for cardiovascular risks and events affected those 
associations quite profoundly.  In the 4-year cognitive change model, it remained 
significant strongly for DST score ( =-0.097; p<0.001) and slightly less so in LNS 
score ( =-0.097; p<0.01).  Comparatively, adjustment attenuated associations 
slightly less in a life-time cognitive change models, where apart from the DST score 
( =-0.106; p<0.001) and LNS score ( = 0.084; p<0.01), significant decline was 
also detected in TMT-B score ( = 0.022; p<0.01) and marginally in Faces score ( = 
0.077; p<0.05) and MR score ( = 0.069; p<0.05). 
Overall, these models generated the highest standardised Beta values, especially in 





5.1.2.1 General pattern of significant effect of baseline biomarkers levels on follow 
up cognitive scores 
The results of the presented analyses indicate Interleukin – 6 levels as having the 
strongest predictive role in a 4-year as well as a life-time cognitive decline. Almost 
identical pattern of significance derived from models assessing the predictive power 
of the general inflammatory factor on general cognitive factor as well as individual 
sub-test scores. Unlike the associations predicted by the remaining circulating 
biomarkers, both IL-6 and inflammatory factor affected cognitive performance of 
verbal and non-verbal memory (assessed by Logical Memory and Faces). Majority of 
those associations were detected independently of common cardiovascular risk 
factors and events, suggesting a possible alternative biological pathway in which 
these biomarkers affect cognitive performance at advanced age.   
In terms of individual cognitive scores, overview of the patterns of significance 
suggest that tests assessing non-verbal reasoning, information processing, attention 
and mental flexibility suffered far more severely of both 4 year and life-time 
cognitive decline than tests that aimed to assess domains when verbal skills are 
required (generally linked to crystalized intelligence). This is in line with established 
evidence
17
; however, possibility of limitation common to longitudinal design with 
ageing cohort, such as practice effect and survival bias, are plausible. This will be 
discussed in Chapter 7. 




























































































































































































































































































































































1respective BL score; baseline measures of: Total cholesterol; MI; angina; stroke; TIA; smoking; alcohol; HbA1c; duration of 
T2DM 
2 Mill Hill Vocabulary Score, baseline measures of: Total cholesterol; MI; angina; stroke; TIA; smoking; alcohol; HbA1c; 
duration of T2DM 




















































































































































Chapter 6:  Results: Genetic Association 
Meta-Analysis  
This chapter presents the results of the meta-analyses conducted on data collated 
from a seven population-based studies, the aim of which to determine the 
associations of pre-selected single nucleotide polymorphisms (SNPs) with cognitive 
functioning. Data collection and initial data cleaning was carried out by each 
collaborative center independently and then shared, allowing for individual cohort 
analysis and meta-analysis using raw data.  This required some preliminary 
calculations, corrections and analyses. The results of initial descriptive analysis 
performed on all demographic data and laboratory data and the subsequent 
calculation of the general cognitive factor ‘g’ for each cohort separately, are 
presented. This was followed by a set of unadjusted and subsequently age and sex 
adjusted regression analyses assessing significance of relationship between plasma 
fibrinogen values and pre-selected SNPs, cognitive performance and the same SNPs 
and plasma fibrinogen values and cognitive performance. The results of the meta-
analyses on the relationships of the pre-selected SNPs with plasma fibrinogen levels 






6.1 Description of seven collaborative cohorts 
Table 20 provides a summary of the demographic and clinical data provided by each 
collaborative cohort. The entire dataset for each collaborative cohort was not always 
available. Therefore, comparison of the characteristics of subjects included in the 
analysis with those of excluded subjects (i.e. subjects without available genotype and 
cognitive data) was not possible. On the other hand, demographic data on included 
subjects was available for most studies and for most variables of interest.  
In terms of the age range of the study populations, there were some noticeable 
differences across cohorts. The difference between the mean age of the youngest 
(WHII) and oldest study (LBC 1936) study population was 18.3 years.  Five of the 
seven cohorts comprised of population with mean ages ranging; chronologically 
youngest study was WHII (mean age 60.8; SD 5.94), followed by the AAA trial 
(mean 61.6; SD 6.54), then the ELSA cohort (mean 66.0; SD 9.64), followed by the 
ET2DS (mean age 67.9; SD 4.11) and the LBC 1936 (59.6; SD=0.83). The mean 
ages of the remaining two cohorts, both Scottish, fell within the 70 to 80 year age 
range with the EAS cohort being the younger of the two cohorts (mean age 73.9; SD 
5.3) and the LBC21 being the oldest population of the 7 collaborating cohorts (mean 
79.1; SD 0.57).  The majority of the cohorts had a relatively equal gender 
distribution; exceptions were the WHII study where approximately three quarters of 





Circulating plasma fibrinogen levels were within a very similar range for all cohorts. 
The majority of plasma fibrinogen vales were within the normal physiological range 
of 2.0 – 4.5 g/l
107
 and examination for potential outliers  (>1.5 interquartile range) 
detected only a very small number of outliers in the ELSA, WHII and LBC 1921 
cohorts with the highest value of plasma fibrinogen was 8.9 g/l.  
Examination of cardiovascular risk factors revealed that generally the cohorts with 
the ‘healthiest’ profile was the WHII population (in relation to blood pressure, serum 
cholesterol values and plasma HbA1c values and the presence of T2DM). There was 
a relatively consistent pattern observed for smoking status where the majority of 
subjects were either non-smokers (AAA Trial and WHII) or ex-smokers (EAS, 
ET2DS and LBC 21) and minority of subjects were current smokers. In the LBC 
1936, there were numbers of subjects who either never smoked or gave up at least 12 
months before the data collection. Comparable data were not available for the ELSA 
cohort.  A similar pattern across studies was also observed for data on an average 
number of consumed units of alcohol; most subjects (across all cohorts) reported 
taking 1 to 2 units per in average week in last year. Data for the LBC1936 and WHII 
studies indicated an average alcohol intake of 10.59 and 11.9 units per week, 
respectively. 
There were relatively similar distributions of socio-economic statuses between 
studies. Despite there was differences in the presentation of this information in each 
cohort, percentage values indicated that middle to higher social class was most 
commonly reported. Perhaps correspondingly, the majority of subjects in each 




qualification/training. Interestingly, the LBC 1921 cohort differed in this respect; 
here the majority (87.9%) of subjects completed university education.  
Assessment of mood status was conducted by self-reported questionnaire (Hospital 
and Anxiety Depression Scale, HADS, described in details in Section in all the 
Scotland based cohorts.  Studies showed a similar pattern with mean anxiety scores 
slightly exceeding the mean depression score. However, no sign of clinically 
disturbed mood was detected in neither of these cohorts. ELSA and WII mood 
assessment was carried out with the General Health Questionnaire (GHQ) for which 
data was not available. 
 
   200 
Table 20: Demographic data of seven collaborative cohorts 
 AAA EAS ELSA ET2DS LBC 21 LBC 36 W II 
Total sample 3350 1592 12099 1066 550 1091 10308 
Baseline Year 1998-2001 1987-88 2002-03 2006-07 2000 2004 1985-88 
Total sample received 
(n) 
2312 852 5606 1066 517 1005 3413 
Wave/year used in this 
stud 
1998-2001 1987-88 2008-09 2006-07 2000 2004 2002-04 
Study design Prospective Prospective Prospective Prospective Prospective Prospective Prospective 
Sampling frame General Practices General Practices 
Respondents to 
HSE 
Diabetes Register MHT survivors MHT survivors Workplace 
Sub-Sample for 
presented analysis 
2061 534 5458 1045 517 1005 3413 
Age 61.6 (6.54) 73.9 (5.3) 66.01 (9.64) 67.9 (4.21) 79.1 (0.57) 69.6 (0.83) 60.78 (5.94) 
Gender (male n %) 564 (27.5) 270 (50.7) 2558 (45.7) 535 (51.2) 215 (41.6) 509 (50.6) 2580 (75.6) 
Plasma Fibrinogen 
(g/L) 
3.48 (0.77) 3.24 (.70) 3.23 (0.73) 3.65 (0.7) 3.59 (0.9) 3.28 (0.6) 3.01 (0.6) 
Systolic BP (mm Hg) 147.1 (21.3) 150.5 (21.8) 119.25 (47.2) 133.3 (16.4) 167.&& (26.7) 149.8 (19.2) 128.27 (16.9) 
Diastolic BP (mm Hg) 83.7 (10.7) 79.14 (10.7 66.36 (26.6) 69.1 (9.01) 82.46 (12.9) 81.4 (10.3) 74.4 (10.5) 
Total Serum cholesterol 
(mmol/L) 
6.16 (1.1) 5.12 (1.4)
$ 

















BMI  26.1 (4.3) 26.5 (7.6) 31.4 (5.7) 26.18 (4.1) 27.81 (4.43) 26.7 (4.4) 
CVD (MI and/or 
stroke; n%) 
36 (1.7) 71 (13.3) 471 (8.6) 330 (31.5) 39 (7.5) 247 (24.6) 
$
89 (2.6) – stroke 
only 
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 AAA EAS ELSA ET2DS LBC 21 LBC 36 W II 
Smoking status 





















































Never – 475 (8.8) 
Daily – 804 (14.9) 
5-6d/w – 293 (5.4) 
3-4d/w (582 (10.8) 
1-2/W – 1184 
(22.0) 
1-2/M – 589 (10.9) 
1-2/2xM – 320 
(5.9) 
1-2/year – 398 
(7.4) 
N/A – 546 (10.1) 







 7 (0.7) 
1 (0-100)* 
≥ 1: 265 (51.3) 
≤ 1: 252 (48.7) 
 
10.59 (14.17) 



















I – 79 (14.8) 
II – 199 (37.3) 
IIN – 117 (22.0) 
IIIM – 91 (17.1) 
IV – 37 (6.9) 
V – 8 (1.5) 
VI – 3 (0.4) 
 
$Prof – 301 (4.9) 
Managerial – 1852 
(30.0) 
Skilled – 3554 
(57.7) 
Unskilled – 346 
(5.6) 
Armed forces: 12 
(02) 
Never worked – 85 
(1.4) 




















I – 375 (11.0) 
II – 1399 (41.0) 
IIIN – 327(9.6) 
IIIM – 17 (0.5) 
IV – 3 (0.1) 
V – 3 (0.1) 
Missing - 1289 
(37.8) 
 
Education (n%)*    
University (n, %) 
Post-school Training 
(n,%) 








 112 (21.0) 
 304 (57.0) 


















<16 – 778 (22.8)
$ 
17-18 645(18.9) 
>18 - 1102 (32.3) 
Missing: 887 
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 AAA EAS ELSA ET2DS LBC 21 LBC 36 W II 
Primary (n, %)  2 (0.2) 
 
(26.0) 















Both: 27 (0.4) 
3.85 (2.9) 
5.72 (2.9) 






* If other measure, please indicate  
$  Only baseline data available for this measure 
BP (S) – blood pressure; Ex-smoker - > 6 months ago before clinical assessment;HSE:  HADS (A) & HADS (D) – Hospital Anxiety Depression Scale – anxiety and depression sore, respectively; MHT: Mental 





6.2 General Intelligence Factor ‘g’ 
Although cognitive neuropsychological assessment batteries varied across studies, 
each battery contained mutually compatible tests that enabled calculation of a general 
intelligence factor ‘g’.  
Significant correlation between individual tests assessing three main cognitive 
domains is required for successful calculation of principal components that account 
strongly for the variance between each test score
278
. Summary of all results derived 
from a set of principal component analyses is presented in table 21 below. Individual 
studies’ details, such as contribution and loadings were discussed in relevant sections 












Table 21: Principal Component Analysis: Cognitive scores, collaborative cohorts 




Auditory Verbal Test 0.640 41.0  1 55.8 2.79 
Verbal Fluency Test 0.631 39.8  2 14.9 0.74 
Raven’s Matrices 0.805 64.8  3 13.3 0.67 
Digit Symbol Test 0.821 67.4  4 8.7 0.43 




Logical Memory 0.768 59.0  1 49.6 1.96 
Verbal Fluency Test 0.635 40.3  2 21.2 0.85 
Raven’s Matrices 0.703 49.5  3 16.9 0.67 




Prospective Memory 0.528 33.8  1 45.7 1.83 
Words Recall 0.768 58.9  2 20.4 0.82 
Animals 0.716 39.0  3 19.3 0.77 




Logical Memory 0.530 28.1  1 44.0 3.08 
Faces 0.456 20.8  2 13.0 0.91 
Verbal Fluency 0.678 45.9  3 11.2 0.78 
Ravens’ Matrices 0.663 44.0  4 9.8 0.69 
Digit Symbol Coding 0.753 56.6  5 9.3 0.65 
Letter Number Seq. 0.710 50.4  6 7.8 0.54 
- Trial Making Test-B (ln) 0.793 62.8  7 4.9 0.34 
LBC 1921  
 
 
Logical Memory 0.732 53.6  1 52.1 1.56 
Verbal Fluency Test 0.619 38.3  2 27.9 0.84 
Raven’s Matrices 0.802 64.3  3 19.9 0.59 
LBC 1936  
 
 
Logical Memory 0.645 39.3  1 48.4 2.42 
Verbal Fluency Test 0.707 42.4  2 15.5 0.78 
Raven’s Matrices 0.702 47.6  3 13.3 0.66 
Digit Symbol Test 0.640 49.1  4 12.3 0.62 
Letter 0.775 639  5 10.5 0.52 
Whitehall II  
 
 
AH – 4 0.816 66.7  1 59.7 2.39 
Word List 0.603 36.4  2 18.8 0.75 
Verbal Fluency 0.809 65.5  3 11.8 0.47 




6.3 Results from genetic-association meta-
analysis  
Table 22 summarizes all significant results detected in the meta-analyses of genotype 
and plasma fibrinogen values and genotype and general cognitive function, indexed 
as ‘g’. Prior to the main meta-analyses, linear regressions were carried out, results of 
these were saved and subsequently used in the meta-analyses. 
The first part of the table summarises results for the seven polymorphisms that were 
statistically significantly associated with elevated plasma fibrinogen level; the second 
part shows results of five SNPs that reached the nominal level of significance 
(p<0.05) for association with ‘g’. 
For each significantly associated SNP, information indicating location on the gene, 
total number of people in the analysis as well as the studies which had the SNP 
information available is presented in the table. 
In total, 61 pre-selected SNPs in a total number of 14033subjects were selected for 
the presented meta-analysis. Nominally significant associations were detected 
between seven fibrinogen related SNPs and plasma fibrinogen levels; these were: 
rs4129267 (p= 0.00033); rs7518199 (p=0. 00419); rs8137951 (p=0. 00795); 
rs315952 (p= 0.04037); rs4537545 (p=0 .04117); rs9853387 (p=0.02108) and 
rs1279840 (p= 0.01123). These significant associations persisted the correction for 




adjustment.  None of the significantly associated polymorphisms were in one of the 
fibrinogen genes FGA, FGB or FGG. 
Meta-analysis investigating the relationship between the pre-selected 61 
polymorphisms and the general cognitive factor ‘g’ revealed five SNPs were 
nominally associated with impairment in general cognitive factor ‘g’ at the 
significance threshold of p<0.05. These were rs1800497 (p=0.00475); rs2070016 
(p=0.03917); rs4681 (p=0.04259); rs4251961 (p=0.00578) and rs1130864 
(p=0.04049).  Adjustment for age and sex did not attenuate these associations greatly 
except those for rs4681 (p=0.10467) and for rs1130864 (p=0.09281), which both 
became non-significant at the p=0.05 level.  
In the case of the rs1130864 SNP (CRP gene), significant results were observed in 
both meta-analysis (assessing the relationship between plasma fibrinogen and the 
SNP and ‘g’ and the SNP); there was a weak, marginal level of significance in the 
age and sex corrected model investigating the plasma fibrinogen – SNP relationship 
and a marginally significant association between plasma fibrinogen SNP and the 
general cognitive factor ‘g’. The magnitude of all associations was small.  
Forest plots illustrating the relative strength and contributing to the overall 
significant results are presented in for the unadjusted and age and sex corrected 
models of SNPs and plasma fibrinogen levels and the same for the SNP and ‘g’ 






In this study sample, 7 out of the 61 pre-selected polymorphisms were significantly 
associated with plasma fibrinogen and 5 out of the 61 selected polymorphisms were 
associated with the general cognitive factor ‘g’(p< 0.05). The remaining two SNPs 
which were associated with ‘g’ were located within inflammation-related genes. 
These findings are discussed further in the text.  
Only two associations were linked to fibrinogen genes directly: FGA (rs2070016) 
and FGB (rs4681); both significantly associated with impairment in general 
cognitive ability and only one polymorphism was significantly linked to both, 
elevated plasma fibrinogen levels and impaired general cognitive ability ‘g’; this was 
the rs113084(CRP gene). Majority of the remaining significantly associated 
polymorphisms are located within inflammation-related genes. The results of the 
meta-analysis were therefore consistent with the assumption of my thesis that 
increased levels of circulating inflammatory markers play an important role in 
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Table 22: Results: meta-analysis 
SNP Chr 
Chr. Pos. on 
hg 18(bp) Gene Total No 
Total 
No/study 








 Non-adj. Adjusted Non-adj. Adj. Non-adj. Adj. Non-adj. Adj. 











































































































































































Chapter 7: Discussion 
In this chapter the findings of the work undertaken for this thesis are discussed. The 
main findings in relation to each of the four biomarkers are considered, including 
discussion of findings from the longitudinal analysis of the ET2DS, and in the case 
of fibrinogen, including results from the genetic analysis. Wherever possible, results 
are discussed and compared with existing evidence.  Methodological issues are 
highlighted where appropriate as well as in sections specifically addressing the pros 
and cons of using longitudinal epidemiological studies and genetic studies 
respectively in the investigation of cognitive decline.  This chapter also has a major 
focus on possible neuro-pathological mechanisms resulting in accelerated cognitive 
decline. The chapter concludes by highlighting the importance of the evidence and 
implications for further research.  
 
  211 
7.1 Summary of main findings – the ET2DS  
An association of plasma cytokines and acute-phase proteins with 4-year and life-
time cognitive decline in older adults with type 2 diabetes has largely been supported 
by the analysis presented from the ET2DS. In particular, higher levels of all four 
measured markers of inflammation, as well as the general inflammatory factor, 
predicted greater decline in general cognitive ability, independent of major 
cardiovascular risk factors and events (with the exception of TNF-alpha in the 
adjusted life-time decline model). The overall pattern of results indicated the most 
consistent association across all cognitive domains for the general inflammatory 
levels and plasma IL-6 levels. The acute-phase proteins, plasma fibrinogen and CRP,  
were particularly associated with accelerated decline in measures of speed of 
information processing, attention and mental flexibility, working memory and 
information organization. The detected patterns of association with cognitive decline 
were consistent in terms of both late-life decline and life-time decline; in a majority 
of domains that were affected in the 4-year assessment, life-time decline was also 
observed. The exception to this was performance on the Logical Memory test, 
suggesting marginal or no decline in verbal memory performance. Overall, the 
direction and magnitude of associations were consistent with the available literature 
Baseline measures of the circulating inflammatory cytokines IL-6 and TNF-alpha 
largely predicted significant decline in the whole range of cognitive domains tested. 
A great number of these associations were independent of conventional 
cardiovascular factors and events, suggesting a possible direct relationship of the 
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cytokines with brain function; perhaps through neuroinflammation. This was 
especially observed in models assessing the role of IL-6.  
Similar results for IL-6 as were found in the ET2DS were also obtained in the MAAS 
study. Here, the highest tertile of IL-6 levels predicted the greater decline in a 
general cognitive score, irrespective of adjusted variables
236,237
 and in orientation and 
working memory
237
.  In the study by Schram
239
, combining the Rotterdam and 
Leiden cohorts, IL-6 was significantly associated with general decline and decline in 
memory but only in the smaller, Leiden cohort; in the large sample used in the 
Rotterdam study, IL-6 predicted annual decline in general but only in participants 
who were also carriers of APOE 4. Similar results were also detected in the 
PROSPER study, in which increased IL-6 concentration significantly predicted 
associateddecline in executive and memory functioning. Additionally, IL-6 genotype  
carriers performed significantly worse in an executive, functioning task
245
.   
Interestingly, in the ET2DS, TNF-alpha was the weakest predictor of cognitive 
decline overall, in terms of the smallest effect as well as the least number of 
associations that reached the p< 0.05 level of statistical significance. At all levels of 
modeling, higher TNF-alpha was associated with poorer scores in non-verbal 
memory, measured by the Faces test; however, in the remaining cognitive domains 
only sporadic associations were detected. In particular, TNF-alpha showed no 
significant association with decline in scores for neuropsychological tests that 
assessed executive function (despite an association with lower ‘one-off’ follow up 
scores). These results are opposed to findings from the Framingham study where 
TNF-alpha levels were significantly associated with decline in executive functioning 
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but no with scores at a single time point. While the Framingham cohort was largely 
comparable to the ET2DS population in terms of size, age, and sex, baseline TNF-
alpha levels were slightly higher in the ET2DS (1.33 compared with 1.2 pg/ml). 
Also, compared with the diabetic population, only 12 percent of the Framingham 
cohort was diagnosed with T2DM and there was a slightly lower prevalence of CVD. 
On remaining descriptive variables of interest, however, these cohorts were 
comparable and the selection of covariates was largely identical
242
. One possible 
explanation for the conflicting results is the shorter length of the follow up in the 
ET2DS (4 years in the ET2DS and an average 6.3 years in the Framingham study), 
allowing less time for decline to have occurred.  Also, possibility of methodological 
and other differences between cohorts must be considered. The Framingham study 
was commenced in 1948, that is almost six decades before the ET2DS baseline data 
collection. Perhaps due to a differing time points and associated differences in life 
style habits, most notably in smoking status (approximately 40% and 17% in 
Framingham and the ET2DS, respectively)
257,307
.  A possibility of a cohort effect 
might be an additional explanation of the differences between each study results.  
In the ET2DS, the acute- phase proteins, plasma fibrinogen and CRP, largely showed 
similar pattern in their associations with 4-year, as well as life-time decline in the 
various cognitive tests.  Results from the Framingham study indicated an association 
of plasma fibrinogen with annual decline in executive functioning, attention and 
mental flexibility and a borderline significant relationship between CRP levels and 
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In the AAA Trial, plasma fibrinogen and CRP levels significantly predicted decline 
in general cognitive ability as well as the remaining cognitive domains, except for 
memory functioning
251
. Results from the EAS also indicated a significant, CVD-
independent, relationship between plasma fibrinogen and decline in general cognitive 
ability and verbal memory
241
. Owing to cross-over of research teams involved in the 
AAA, EAS and ET2DS, the latter two in particular have similar methodology, 
especially in the selection of neuropsychological tests and analytical approach but the 
remaining studies were also methodologically similar to the ET2DS. All were 
reasonable large cohort studies with at least 39 months of follow up and the selected 
covariates used in fully adjusted models were similar to those in the ET2DS. The 
only distinct difference was in the prevalence of T2DM that makes participants in the 
ET2DS cognitive functioning more vulnerable and susceptible to the effect of 
systemic inflammatory markers.  
As for the cytokines, associations of the acute--phase proteins with cognitive decline 
were largely independent of all adjusted vascular covariates, again raising the 
possibility of a direct relationship between the proteins and brain function. 
Altogether, the epidemiological evidence suggests the possibility of a peripheral-to-
brain system communication and subsequent neuro-inflammation as a plausible 
biological mechanism that eventually results in poorer cognitive performance. In this 
model, circulating levels of IL-6 and, to a lesser degree, plasma fibrinogen levels, 
would appear to have the strongest effects on the brain as they were the strongest 
predictors of cognitive decline. 
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7.1.1 Possible role of depression and vascular disease in 
the inflammation/cognition association  
Although my findings would be consistent with a direct effect of inflammatory 
mediators on the brain, there are several other possible explanations for the 
associations detected. Two of these (depression and vascular disease as mediators of 
any effect) are considered here. Methodological issues which might have affected my 
results are considered later in the chapter. 
 
Depression  
Systemic inflammation and neuro-inflammation in particular, has been directly 
linked with the prevalence of depression, especially in elderly populations
81,85,308,309
. 
This is possibly due to integration of cytokines and acute phase proteins and the 
hypothalamic-pituitary-adrenal axis (HPA) and the locus coeruleus-norepinephrine 
(LC-NE)
85
. Increased levels of these biological markers of inflammation are linked 
with HPA hyperactivity that in turn is associated with central obesity, insulin 
resistance, high blood pressure and dyslipidaemia
85
, factors directly relevant to 
T2DM. Therefore, especially in diabetic populations, it can be reasoned that 
depression might mediate the effect of inflammatory markers on cognitive 
performance. However, such findings were not detected in the presented analyses on 
the ET2DS. This might be explained by a number of factors. Depression is a 
complex condition, developing over a long period of time with a whole range of risk 
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factors and determinants
46
.  In the ET2DS, depression status was assessed at a single 
time point using a ‘screening’ questionnaire, whereas the majority of the cited 
evidence is drawn from data on mental health status (i.e., doctor-diagnosed history of 
clinical depression, melancholic depression, etc.). Furthermore, subjects returning to 
a follow up wave of cognitive assessment are known to be generally healthier, 
including better psychological well-being, than their non-attending counterparts
61
. 
Nevertheless, given the plausible biological mechanism between elevated 
inflammatory markers and the risk of depression, especially in diabetic populations, 
in future waves of assessment this may become more evident in the ET2DS.  
As expected with any complex condition, to determine the direction of the 
relationship between depression and cognition has proved troublesome.  Evidence of 
whether depression incidence in adults diagnosed with mild cognitive impairment 
increases conversion into frank dementia is inconclusive
310
. Alternatively, it can be 
argued that people with clinically detectable cognitive decline are more prone to 
develop depressive symptoms; brain regions that are most affected by age-related 
neuro-degeneration mechanisms and are first affected in the early stages of 
Alzheimer’s disease, are also directly involved in maintaining mental health status 
and thus making these adults more disease-vulnerable. Alternatively, systemic 
inflammation has been proposed in this pathological mechanism, but whether its role 
may be confounding or mediating is unclear. Psychological stress can cause an acute-
phase response via activation of the HPA axis and the LC-NE system
90
. Equally, 
chronic low-grade inflammation associated with long-term medical conditions 
(diabetes, cardiovascular co-morbidity), can be a reason for poor mental health, 
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which in turn, might exacerbate production of dedicated cytokines and acute-phase 
markers. This is even more plausible in the light of evidence that the relationship 
between prevalence of depression and elevated inflammation seems to span across a 




Large and robust studies such as Whitehall II reported the role of IL6 and plasma 
fibrinogen, but not CRP, in11.8 years follow up assessment of depressive symptoms, 
including cognitive symptoms of depression, independent of common biological and 
social risk factors
312
. Despite the large size of this cohort, the purposeful sampling 
methods (only civil servant, much younger (mean age 50) may bias the results and 
must be considered when interpreting these in the light of relevant other evidence. 
Generally, depressive symptoms are more prevalent in representative population of 
women
313
 but this was not reported by the Whitehall II study. Also, authors reported 
that there was no significant evidence of reverse relationships, i.e. depression 
measured at follow up did not significantly relate to baseline measures of 
inflammatory markers. This suggests a one-directional relationship with 
inflammation acting as a risk factor for depression. Nevertheless, further studies need 
to ascertain the direction and magnitude of this relationship. In particularly, focus on 
diabetic population may be clinically beneficial, provided a higher level of diabetes- 
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Vascular Disease 
Understanding the role of cardiovascular status in mechanisms underlying cognitive 
decline might lead to a better understanding of the shared patho-physiology of age-
related cognitive decline and also the two most common forms of dementia, 
Alzheimer’s disease and vascular dementia. People with diabetes have a 
comparatively higher prevalence of cardio-vascular disease compared with the non-
diabetic population
314
.  Furthermore, people with diabetes are more likely to suffer 
from chronic, low-grade inflammation
81





 has been well documented.  
With regards to stroke, it is complicated to assess the exact extent to which this event 
contributes to cognitive change, as cognitive assessment pre- and post-stroke are 
very seldom available.  In the ET2DS, pre-morbid cognitive ability was estimated 
with a vocabulary test, which is a great methodological advantage. The analysis 
included in this thesis did not include assessment of the relationship between 
cardiovascular disease and cognitive change. However, such analysis in the ET2DS 
has recently been completed. This showed a statistically significant association of 
baseline history of stroke with change in general cognitive ability ‘g’, determined by 
adjustment of late-life ‘g’ for the MHVT (p=0.002) and with change in executive 
functioning (p=0.012), attention and mental flexibility (p<0.001) and information 
processing and working memory (p<0.001). Also, scores on these tests contributed 
most to the overall cognitive ability factor ‘g’, in contrast to age and sex matched, 
non-diabetic population
317
. Successful performance on these particular cognitive 
domains depends on brain regions that generally show greater age-related neuro-
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pathological changes and vulnerability to vascular events
33
, suggesting a possible 
role of T2DM in acceleration of these age-related cognitive changes. Very similar 
results were found when the relationship between baseline history of myocardial 
infarction and estimated life-time change in cognitive performance was assessed; in 
addition to decline in general cognitive ability (p=0.017), information processing 
(p=0.013) and non-verbal reasoning (p=0.005) also were also significantly associated 
with the outcome of interest
318
. To our knowledge, this was the first study that 
reported results of relationship between stroke (as an isolated risk) and life-time 
change in cognitive performance. In light of the fact that cardiovascular co-morbidity 
is one of the highest risk factor for accelerated cognitive decline and the lack or 
inconsistency of prospective data, especially in diabetic population, the need for 
further prospective studies are warrant. 
A role for TNF-alpha in the development of fronto-temporal dementia has been 
suggested
319
, although rather than a direct effect on the brain in the form of neuro-
inflammation, this may be due to the role of TNF-alpha in activation of an acute-
phase response. Activation of acute-phase proteins (fibrinogen and CRP) results in 
altered blood viscosity with a consequent influence on brain functioning via reduced 
cerebral blood flow. Fronto-temporal dementia is usually associated with vascular 
events, most likely stroke or TIA
31
, and a role TNF-alpha in carotid atherosclerosis 
has been reported
320
, which makes this ‘vascular-mediated’ pathway more plausible. 
Nevertheless, further research is required to ascertain the mechanism by which TNF-
alpha might contribute to age-related cognitive change, especially in diabetic 
populations exhibiting with higher concentrations of inflammatory markers. 
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It is relatively widely accepted that people with diabetes are more likely to present 
with declined cognitive performance as a result of a wide range of co-existing 
conditions, potentially including elevated inflammatory markers as well as the 
presence of cardiovascular co-morbidity. Whereas in the ET2DS plasma fibrinogen 
was significantly associated with the majority of cognitive tests in terms of 4-year 
and life-time change (except for verbal and non-verbal memory), this was not 
reported in the Caerphilly study, despite their robust neuropsychological assessment 
and follow-up of 5 years. Also, the Caerphilly study comprised of male subjects 
only, who are more likely than women to suffer from cardio-vascular conditions
321
  
thereby increasing the risk of impaired or altered cognitive performance. Whether the 
presence of T2DM in the ET2DS could account for the conflicting results is 
debatable but possible.  
To identify the mechanism(s) by which inflammation, cardiovascular disease and 
T2DM contribute to age-related cognitive dysfunction is methodologically difficult, 
mainly due to the inter-relationship between the various vascular factors. The latter 
might, at least in part, explain current inconsistency in evidence and lack of diabetes-
specific findings. Precise and detailed understanding of the mechanism(s) may help 
to guide further clinical work in terms of focus on specific types of dementia. For 
example, conflicting evidence exists in terms on the role of T2DM in the aetiology of 
Alzheimer’s disease and vascular dementia. In a 5-year follow up study, MacKnight 
et al.
322
, detected a link between T2DM and vascular cognitive impairment, however, 
this relationship did not significantly increase the prevalence of either Alzheimer’s 
disease or vascular dementia. Overall, evidence suggests that the role of T2DM in the 
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ageing brain is complex with a range of possible biological mechanisms underlying 
the eventual change in cognitive ability.  
7.1.2 Possible direct effect of inflammatory markers on 
the brain 
Any causal role of inflammatory mediators in cognitive decline may involve a direct 
effect of the biomarker on the brain, especially if the cardiovascular pathology is 
being by-passed, as suggested by the independence of the biomarker-cognition 
association from cardiovascular risk factors and disease as was the case in the 
ET2DS. A role for increased levels of IL-6, particularly in impaired hippocampal 
activity, has been documented in epidemiological studies
323
 and experimental, 
mainly animal models, such as reduced synaptic plasticity in rats
324
 and a long-term 
potentiation
325
. The proposed rationale for the role of IL-6 in neuro-inflammation is 
that IL-6 is capable of penetrating the blood-brain-barrier directly, and subsequently 
altering the brain-immune response system 
326
. Braida et al
100
 provide further 
evidence, assessing the trajectory of cognitive ability of transgenic mice, where 
animals with over-expressed IL-6 presented a 63% reduction in cognitive ability, 
whereas those not expressing IL-6 improved their cognition (maze learning and 
reduced amnesic effect). Moreover, non-steroid and anti-inflammatory medication 
were shown to restore neurogenesis in the hippocampus of rats
84
.  
Currently, no comparable results are available for humans; the animal studies, 
however, provide promising evidence of a key role for IL-6 in overall cognition and 
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memory function specifically. Indeed , hippocampal grey matter volume atrophy has 
been inversely correlated with peripheral levels of IL-6 in otherwise healthy 
community-dwelling subjects, aged 30-54 years
327
; i.e., in a population sample two 
decades younger and T2DM-free compared with the ET2DS cohort.  
Given this suggestive evidence and the potential clinical benefits in terms of 
development of risk-group’s tailored prevention and an early intervention, there 
seems to be justifiable scope for further research conducted with humans, for 
example, providing periodic measures of cognitive scores in relation to plasma levels 
of IL-6.  Of interest, cerebral over-expression of IL-6 in transgenic mice affected 
long-term potentiation (LTP)
325
, an effect occurring in the hippocampus and the 
cerebral cortex and representing activities that underpin memory and learning 
utilization
31
. Strictly speaking, without a fully functional hippocampus people would 
suffer from impaired sense of identity, disorientation in place and time, dysfunction 
in everyday tasks and would find it difficult or impossible to identify where they are, 
where they intended to go and how to get there. All these difficulties seem to 
correspond with the clinical presentation of people diagnosed with Alzheimer’s 
disease
31
; it is therefore reasoned that the hippocampus is one of the first brain 
regions to suffer damage in this condition
328
.  
The above observations are particularly relevant when it comes to diabetic 
populations. One of the possible mechanisms to account for decreased cognitive 
function in diabetic populations is linked to insulin resistance as a contributor to 
hyper-insulinaemia and with the consequence of accelerated cognitive decline
329
. 
Insulin might play a role in accelerated cognitive decline through a direct effect on 
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the brain
99
. Peripheral insulin is transported to the central nervous system through the 
blood-brain barrier. Insulin receptors are distributed around the brain, most notably 
in CA1 and the dentate gyrus, subfields of the hippocampal formation
330
. The 
principal function of the hippocampus is the transference of information from short-
term into long-term memory and spatial navigation, episodic, autobiographical and 
anterograde memory
331
, Clinically, impairment of these cognitive functions 
correspond with performance of the people with Alzheimer disease
332
. This is further 
supported by the evidence that abnormal insulin activities can play a role in associate 
learning and memory formation
333
.  Conversely, the administration of insulin was 
shown to significantly improve cognitive performance, particularly in the memory 
functioning of patients diagnosed with Alzheimer’s disease
334
. A possible 
explanation is the role of insulin in regulation of phosphorylation of tau protein
330
 as 
well as affecting extracellular amyloid beta levels
335,336
. The results of the ET2DS 
would be consistent with exacerbation/acceleration of this age and diabetes related 
impairment and decline that is apparent through the effect of elevated circulating IL-
6 levels exacerbating detectable decline in cognitive ability. This makes IL-6 a 
particularly important risk factor for age-related cognitive decline.  
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7.2 Summary of the main findings - Genetic 
associations 
This section will discuss the results of the meta-analyses performed to assess the 
association between pre-selected fibrinogen-related SNPs and cognitive impairment. 
First, the relationship between plasma fibrinogen-related SNPs and levels of plasma 
fibrinogen are discussed; followed by discussion of the associations between the 
same fibrinogen-related SNPs and general cognitive ability ‘g’.  
The rationale for this study was based on previous epidemiological observations 
suggesting a possible role for raised plasma fibrinogen levels in the aetiology of age-
related cognitive impairment. The work aimed to expand on recent evidence 
indicating a significant relationship of the plasma fibrinogen related SNP rs2227414 
(a SNP in the FGB gene) with circulating fibrinogen levels and cognitive ability in 
three Scottish cohorts
337
. This aim was to investigate this intriguing finding further 
by: 
1. Increasing statistical power through an investigation conducted on data from a 
larger sample derived from collating data on over 14,000 subjects data and  
2. Testing a wider selection of SNPs previously associated with plasma fibrinogen 
levels, including SNPs out-with the three main fibrinogen genes FGA, FGB and 
FGG. 
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Meta-analysis of data collated from seven large, population based cohorts, was used 
to assess the significance of associations between plasma fibrinogen related gene 
variants and general cognitive ability, indexed by ‘g’.  
A previously intended approach, Mendelian randomisation, was eventually rejected 
due to potential the quality of the instrument as well as potentially confounding 
effect. The core principle of Mendelian randomisation is that genes are randomly 
assigned from parental alleles during a stage called meiosis
183
. This is implied across 
the whole population, making the genetic effect rather robust. Therefore it is 
reasoned that genes (gene variances) can be successfully used as an instrumental 
variables that help to by-pass the effect of potentially mediating or confounding 
factors and thus disentangle the potentially causal relationship between predictor and 
outcome of interest
188,338
. The three key assumptions that need to be satisfied for the 
gene variance to classify as an instrumental variables are
339
:  
1. The instrumental variables (gene variant) must be unrelated to any of the 
potentially confounding factors; 
2. The instrumental variables (gene variant) must be associated with the 
predictor of interest and  
3. The instrumental variables (gene variant) must be independent to the 
outcome of interest  
Following these fundamental principles of the Mendelian Randomisation approach 
would require reliable relationship between fibrinogen-related SNPs and plasma 
fibrinogen levels whilst no relationship between fibrinogen-related SNPs and either 
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any of potentially confounding factors or the outcome, i.e. performance on 
neuropsychological assessment, in this analysis the general cognitive factor ‘g’). 
Whereas the assumption one and three cannot be statistically tested and merely rely 
on biological and other explanation, the second premise can be tested. As presented 
in the section 6.3, of the included 61 fibrinogen-related SNPs, only seven showed a 
significant relationship with elevated plasma fibrinogen levels. More so, these 
associations were not subjected to a correction for multiple testing that would further 
reduce the number of significant associations.  The choice of selected fibrinogen-
related SNPs has been discussed above (section 4.6). Nevertheless, this result 
suggests the lack of strength of the selected instrumental variable, i.e. fibrinogen-
related SNPs, presenting a serious concern for the analysis run in Mendelian 
Randomisation fashion. Furthermore, the exclusion of all SNPs possibly related to 
factors and events associated with either plasma fibrinogen circulation and/or 
cognitive dysfunction would have greatly reduced selection and final number of gene 
variants eligible for the meta-analysis.  
Therefore the Mendelian randomisation approach was rejected; instead a set of linear 
regression models and meta-analysis of collated unstandardized parameters, were 
undertaken.  This approach is consistent with the recent Scottish study which 
identified fibrinogen-related gene variants that showed a significant association with 
cognitive performance
337
. First, the selected SNPs were modeled against plasma 
fibrinogen were modeled and second, the same SNPs were modeled against the 
global cognitive ability ‘g’ was modeled. Both models were carried out at two stages: 
unstandardized raw values and age and sex adjusted values.  
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7.2.1 Associations of plasma fibrinogen levels with pre-
selected SNPs  
Having selected SNPs from the literature on the basis of published associations with 
circulating plasma fibrinogen, my initial set of analyses explored the relationship 
between these SNPs and plasma fibrinogen measured in the participating cohorts. 
Results from this meta-analysis indicated that just seven of the SNPs were 
significantly associated with elevated levels of plasma fibrinogen at the 0.05 level of 
statistical significance. Adjustment for age and sex made only a very small difference 
to the level of significance. Neither did it greatly affect the magnitude of effect size 
detected for each SNP implying that the relationship between gene variants and 
plasma fibrinogen level were relatively independent of age and sex.  
The seven SNPs indicated by this modeling of fibrinogen-related SNPs from a range 
of genes against plasma fibrinogen levels indicated these seven gene variants were: 
rs4129267 (IL6R), rs7518199 (IL6R), rs8137951 (SHANK3), rs315952 (IL1RN), 
rs4537545 (IL6R), rs9853387 (PCCB) and rs1279840 (PCCB).  Interestingly, none 
of these gene variants lies within the fibrinogen genes FGA, FGB or FGG. However, 
the majority of these genes lie on the inflammatory pathway; specifically, IL6R and 
IL1RN, interleukin-6 receptor and interleukin 1 receptor antagonist, respectively. 
Both IL-1 and IL-6 cytokines are known to be powerful markers of the liver acute-
phase response; this includes increase in plasma fibrinogen in the circulation
81
.  
Indeed, the strongest level of significance and the largest effect size was observed in 
the relationship between plasma fibrinogen and rs4129267 (IL6R). With regards to 
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the remaining associated SNPs/genes, the relationship with plasma fibrinogen is 
biologically less obvious. The SHANK3 gene is primarily responsible for making a 
protein that plays a role in functioning of synapses and also a formation and 
maturation of dendritic spines, essential for the transmission of nerve impulses. 
Previously, SHNAK3 mutations have been found in people suffering from an autistic 
spectrum disorder
340
 and also in individuals with intellectual disability and/or 
delayed intellectual development
341
 . The PCCB gene is responsible for forming a 
functioning enzyme propionyl-CoA that plays a key role in the normal processing of 
proteins, particularly in a breakdown of several amino acids. Approximately 55 
various mutations in the PCCB gene are prevalent in individuals who suffer from 
propionic academia, condition where the body is only partially/not able to process 
specific types of proteins and lipids
342
.  
The lack of significant associations between the remaining 54 SNPs and plasma 
fibrinogen can be explained by several reasons. Firstly, although SNPs were 
identified from published literature included in an electronic database, according to 
clearly defined inclusion/exclusion criteria, a considerable degree of heterogeneity 
exists between the studies populations identified in this way and those included in 
this project; there is therefore a high possibility that the original findings simply did 
not translate into the presented replication populations. Furthermore, depending on 
allele frequency, selected SNPs might contribute less to plasma fibrinogen 
concentration than was initially implied. A larger sample size would clarify this 
possibility. In order to account for an issue linked to LD, the HapMap database was 
searched for tagging SNPs in genes known to influence plasma fibrinogen levels. 
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Nevertheless, a possibility exists that SNPs significant in this analysis are more 
proximate and thus linked to the true variant than the tagging SNPs identified by the 
search. Lastly, although all studies clearly report all criteria applied to conditions of 
blood withdraw and details of laboratory measures, the possibility of inconsistency in 
plasma fibrinogen measures between studies affecting the final results cannot be 
ruled out fully. There is also the possibility that the original findings were false 
positive findings and/or that my own negative findings were false negative findings.  
 
7.2.2 Associations of plasma fibrinogen SNPs and global 
cognitive ability 
The main aim of the presented meta-analysis was to determine the association 
between fibrinogen-related SNPs and global cognitive ability. Again, analysis was 
conducted in two steps: unadjusted and age and sex adjusted models.  
Of the 61 modelled SNPs, five were significantly associated with ‘g’ at the level of 
p< 0.05: rs1800497 (ANKK1), rs2070016 (FGA), rs4681 (FGB), rs4251961 (IL1RN), 
and rs1130864 (CRP).  None of these SNPs were found to be significant predictors 
of plasma fibrinogen levels, apart from the last mentioned SNP rs1130864 (CRP). A 
very weakly significant association was detected between these SNPs and ‘g’. 
However, this was only observed independently of age and sex covariant, with the 
effect size above average within the scale of magnitude detected in this study; for the 
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SNP-plasma fibrinogen relationship, it was 0.5 (95% CI -0.01 – 0.11), for the SNP – 
‘g’ association -08 (95% CI -0.16 – 0.00). The negative value of effect size values in 
SNP and ‘g’ associations indicate the minor allele frequency.  
An overlap of significant associations was observed only in two out of the seven 
participating cohorts (the EAS and ET2DS) a total sample of 1579 subjects. These 
results therefore did not benefit from collating the large dataset that was carried out 
in order to increase the possibility of reaching enough statistical power to detect a 
true association. In fact, except for the rs4251961 (IL1RN) polymorphism that was 
also genotyped in the ELSA and Whitehall II (beside the ET2DS), the remaining 
SNPs that were significantly associated with impairment in ‘g’, were only genotyped 
and detected in Scottish cohorts.  
All selected SNPs were modelled directly in unadjusted and age and sex adjusted 
analysis; all but two of the 5 SNPs which were significantly associated with ‘g’ 
(p<0.05), were significantly associated with impairment in ‘g’ independently of age 
and sex. The exception was the rs4681 (FGB) variant; the magnitude of effect sizes 
differed slightly between unadjusted and adjusted models at 0.6 (95% CI 0.00 - 0.11) 
and 0.4 (95% CI -0.01 – 0.09), respectively.  The second exception was the 
rs1130864 (CRP); here also there was only a slight difference between magnitude of 
the effect size between models at -0.08 (95% CI -0.16 – 0.00) and -0.7 (95% CI -0.15 
– 0.01), respectively. 
The most interesting finding is the overlap of significant associations between 
plasma fibrinogen levels, fibrinogen related rs1130864 (CRP) and impaired global 
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cognitive ability. A previous Mendelian randomisation study of the CRP gene did 
implicate this biomarker  in a whole range of conditions, including inflammation, 
insulin resistance and diabetes
343
, coronary heart disease
344
 and, quite recently, in 
impairment of late-life cognitive ability
345
. The latter study involved considerable 
overlap with the current study in terms of the included cohorts; four Scottish cohorts 
that formed the total study sample (i.e., the AAA, EAS, ET2DS and LBC 1936) were 
also investigated in the present analysis ANCOVA results indicated significant 
prediction of impairment in the verbal fluency score (in AAA), and attention and 
mental flexibility, information processing speed and non-verbal memory (in ET2DS). 
Other associations did not reach the nominal significance level of p<0.05
345
. In the 
present study, the rs1130864 SNP was genotyped in 5 of the7 collaborating cohorts 
and showed a significant level of prediction of impaired general cognitive ability 
only in the EAS and the ET2DS. Somewhat surprisingly, association between 




The Rotterdam study investigated the relationship between three CRP gene variants, 
including rs113084 and incidence of dementia. In comparison with the Scottish 
cohort study
337
 and my own study, the Rotterdam study was based on prospective 
follow-up (mean 9.2 years) for frank dementia and a large sample of just under 6000 
subjects, mean age 68.9 years (SD 8,7). Whereas 607 cases of dementia were 
diagnosed during the follow up period, there was no significant association detected 
between the rs1130864 SNP and risk of dementia.  In my study, the association was 
only detected in data collated from the EAS and the ET2DS cohorts; these cohorts 
 
  232 
comprised of comparatively older adults that suffered from a high prevalence of 
cardiovascular comorbidity (the EAS) and also type 2 diabetes (the ET2DS). 
Inconsistency in findings of an association between the CRP gene variants and 
cognitive impairment may be due to variation in the study population, differences in 
measures of phenotype (especially cognitive) data or it might indicate results 
obtained in my study were due to chance, highlighting the need for replication of this 
finding in further, larger studies with measures of both cognitive 
impairment/dementia and cognitive decline.  
The fibrinogen gene SNP rs2070016 (FGA) that determines clot structure
213
, has 
been implicated to contribute to prevalence of hypertension (MONICA/KORA 
study
346
) and to cerebral small vessel disease. The Rotterdam Study
347
, perhaps due 
to a very small study sample, failed to detect significance association of rs2070016 
with severe carotid artery disease in predominantly male subjects
348
, which alongside 
the rs4681 failed to predict coronary heart disease
130
 but managed to support the role 
of this gene variants in plasma fibrinogen synthesis
130
.  Overall, the involvement of 
increased plasma levels of fibrinogen in these pathological mechanisms is leading to 
a decreased cognitive performance, as documented by a number of epidemiological 
observations
16,239,241,317
.   
As with the previously reported analysis, here too the majority of markers that were 
significantly associated with ‘g’ lie on the inflammatory pathway of the bodily 
mechanism. Above that, two out of the five SNPs lie within the fibrinogen gene. 
Additionally, there is a strong biological interplay, primarily linked to hepatic 
response and activated immune system that influences production and synthesis of 
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plasma fibrinogen circulation. These were the rs4251961 (IL1RN) and rs1130864 
(CRP) SNPs.  The strongest relationship, in terms of the magnitude of the detected 
effect size, was between ‘g’ and the rs1800497 (ANKK1) SNP.  ANKK1 gene is 




, alcohol and 
tabacco smoking dependency
349,351
; additionally, A1 allele is linked to prevalence of 
addition, antisocial-type of behaviour and attention-deficit hyperactivity disorder
352
.  
Additionally, the role of the IL1RN, the IL-1 receptor gene that was significantly 
linked to plasma fibrinogen concentration in this study (rs315952) and to impairment 
in global cognitive ability (rs4251961) is of interest. Biologically, IL-1 has the 
primary role of a mediator of non-infections inflammation and B-cell maturation as 
well as further cytokines release
82
. Together with TNF-alpha, it induce expression 
and secretion of IL-6 and all these cytokines are implicated in the development of 
atherosclerotic plaque and in acute coronary conditions
353
. Furthermore, IL-6 is 
known to regulate expression of IL-1by release of IL-1 receptor antagonist and TNF-
alpha
85
. The fundamental role of IL-6 in activation of acute-phase proteins, such as 
plasma fibrinogen and CRP, associated with increased blood viscosity, has been 
documented
106




IL-1 also has a central role in neuro-inflammation; this multi-potent protein is known 
to accompany age-related neuro-degenerative changes
354
. For example, in AD 
patients’ brain, overexpression of IL1RN was detected, directly relevant to AD 
typical brain neuropathological changes
355
. Therefore there is an implied possibility 
of the role of this gene’s variants within IL1RN gene that directly affects brain 
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efficiency through a process of neuro-inflammation, masking the true effect of 
plasma fibrinogen. Equally though, there is a possibility of a reverse relationship 
where elevated plasma fibrinogen levels might cover up the true causal factor, in this 
case the IL1 interleukin 1 receptor antagonist. Determining the exact nature of the 
bio pathological relationship of modifiable risk factors is beyond the scope of this 
investigation. Nevertheless, it is reasonable to assume that, despite the weak 
association signals and small effect sizes of these associations, the CRP and IL1RN 
genes can be implicated in with a reasonable degree of certainty.  
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7.3 Evaluation  
7.3.1 Longitudinal analysis - ET2DS 
Longitudinal epidemiological studies on cognitive decline present a number of 
problems, weaknesses and challenges in interpretation, including those shared with 
any other chronic health condition as well as those specific to cognitive ageing.  
Methodological obstacles characteristic of longitudinal observational studies on 
cognitive decline will be discussed in relation to the design of the ET2DS. This 
critique draws on an article published by Allen
173
 which highlights the main 
obstacles in longitudinal studies investigating the relationship between cognitive 
performance and diabetes.  
Epidemiological studies that encapsulate the complexity of the ageing process must 
deal with the complex and dynamic multifactorial and multidimensional relationship 
between a wide range of potentially important variables which may be causal, 
confounding, mediating or co-incidental in terms of their association with cognitive 
decline. The majority of biomarkers that are thought to contribute to 
neuropathological mechanisms that affect the speed and trajectory of cognitive 
ageing in diabetic populations are also likely to be associated with cognitive decline 
in epidemiological observations of general populations and it is difficult to 
distinguish diabetes-specific risk factors for accelerated cognitive decline. Since 
differences in age-related cognitive profiles exist between individuals in a given 
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population, longitudinal cognitive data that report a change in cognitive scores within 
individuals over time are increasingly reported.  
It is well recognized that the selection of participants for epidemiological studies of 
cognitive ageing can introduce a set of substantial biases that need to be considered 
when interpreting the results
252
. This applies equally to studies of diabetic
173
 as well 
as general populations. Perhaps inevitably, the portion of the population that can be 
considered as suitable for cognitive ageing investigations as well as the profile of 
those who are willing to engage in such studies, is skewed towards subjects with 
higher childhood cognitive scores
59
.  Generally, people with higher childhood 
intelligence scores are more likely to have higher educational attainment, leading to 
white-collar jobs and a higher social and socio-economic status
59,61
. There is also a 
significantly greater chance of engaging in a healthier lifestyle (i.e., diet, exercise, 
etc.) with a consequently lower prevalence of medical risk factors likely to be 
associated with accelerated cognitive decline
356
.  
Use of birth cohort data allows assessment of the possible effect of pre-morbid 
intelligence on age-related (patho)biological risk factors, including levels of 
peripheral and central levels of circulating inflammatory markers (which themselves 
show age-related increase concentration
357,358
).  Luciano et al reported evidence of 
‘reverse causation’ where a childhood (age 11) intelligence score significantly 
predicted circulating levels of CRP at the age 70
234
. Of interest, CRP levels are 
known to be higher among people with conventional cardiovascular risk factors and 
co-morbidities, such as diabetes and metabolic syndrome, increased blood pressure, 
obesity and dyslipidaemia
82,359
. To explain their findings, Luciano et al postulated 
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that the lower levels of childhood IQ measures are associated with less advanced 
health awareness, lower socio-economic status and less-healthy life-style
360
 and 
consequently determine physical health at older age. Individuals with higher 
childhood IQ score are also more likely to remain engaged in cognitively demanding 
exercise activities (i.e., problem solving puzzles, reading, etc.) and psychological 
wellbeing may also be greater with enhanced mental health strategies and social 
networks for necessary support
61
.  The transfer and sharing of both the genes and 
environments involved in developing cognitive traits from parent to off-springs may 
also play a role.   
Increased mortality rates have also been linked to poorer childhood intelligence
59,361
; 
since most neurodegenerative changes, associated with clinical manifestation of 
cognitive difficulties, commence and develop at an advance age, there is a strong 
possibility of survival bias. This methodological limitation is heightened in 
prospective studies where not only study participants are likely to have generally 
healthier cognitive, physical and mental health status at baseline, but also, healthier 
subjects are more likely to attend for follow up assessment. As a consequence, study 
results are often drawn from samples which may not be representative of true rates 
and patterns of cognitive decline in the general or targeted population
252
.  
To complicate matters further, the more able participants are also more likely to 
exhibit a practice effect in the result of their cognitive testing
232
. In longitudinal 
studies of ageing, the same battery of neuropsychological assessment is often 
repeatedly administered to assess trajectories and patterns of change in cognitive 
performance. This provides the possibility of encoding information into long-term 
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memory with potential subsequent retrieval. There are some types of memory, for 
example episodic memory (memory for event and personal information) or working 
memory (storage and processing at the same time) which show faster, age-related 
progressive decline
362
 than other, such as prospective memory (memory for future 
events) and semantic memory (factual memory)
40
. Moreover, there are some people 
who can actually manifest a clinical improvement on some (particularly memory) 
tests, as they get older, performing significantly better than their younger 
counterparts
363
. There is some evidence to suggest that this is due to a more efficient 
and effective use of external cues
364
; the selective drop out of frail and less-able 
participants results in re-testing of the relatively healthier survivors who are therefore 
more likely to benefit from practice
365
.  This is may be further complicated by a 
potential ‘ceiling’ effect for the most able and the a ‘floor’ effect for the least able
232
. 
Ability to apply compensatory strategies and/or draw on pre-existing cognitive 
patterns and cues would be consistent with the notions of the cognitive reserve
38,366
 
and  ‘successful ageing’
367
. The latter argues that contrary to traditional views (that 
cognitive decline is an integral, inevitable part of the ageing process), 
cognitive/mental decline occurs due to one or more identifiable, often preventable 
and modifiable risk factor
367
.  Nevertheless, individual difference is this ‘gain’ tends 
to diminish gradually with greater age, possibly being balanced by neuropathological 
brain ageing processes
282
.   
In addition to the limitation listed above, prospective studies assessing cognitive 
health in people with diabetes diagnosis, including the ET2DS, may have specific, 
diabetes-related issues. The incidence of severe hypoglycaemia and chronic 
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hyperglycaemia have been proposed to influence cognitive ability in type 1 and type 
2 diabetes, respectively
172,180
 and these factors need to be considered in multivariate 
analysis (as well as other potential confounders which are not specific to diabetes). In 
terms of the problem of evidence of reverse causality and the medical and 
psychological conditions that co-exist with diabetes presents a particularly important 
issue in the selection of representative diabetes-specific study populations. In 
addition, non-cognitive changes in personal ability, for example sensory loss or 
affected vision due to diabetic retinopathy (that itself is associated with speedy 
cognitive decline
368
), might affect the persons’ practical skills and ability to complete 
the cognitive tasks. 
An important aim of epidemiological studies on cognition is to identify aetiological 
mechanisms underlying age-associated cognitive decline. The latter involves 
identifying potential risk factors’ and their inter-relationship and, ideally, 
establishing the causal nature of particular determinants. However, as with any 
condition, the most that can be determined from an observational epidemiological 
study such as the ET2DS is association (or correlation) between putative risk factors. 
Importantly, for studies on cognitive decline, the relationship between cognition and 
physical health may well be bi-directional and a wide range of with variables, 
whether measured or unmeasured, may either confound or mediate any association 
between risk factors and cognitive ability. These factors must be given careful 
consideration in the analysis and interpretation of study findings. 
Lastly, in the presented study, regression analyses were conducted using the 
individual marker and finally using an inflammatory factor that was derived through 
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four inflammatory markers-based PCA. Decision for this approach was discussed in 
the section 3.8.1.2.  In an alternative approach, inflammatory markers would be used 
as covariates in each of the model. This approach would allow assessing the 
association between predicting inflammatory markers whilst controlling for each of 
the three other biomarkers.  It can be argued that including three more covariates 
might weaken the power of the regression analysis. On the other side, this approach 
might have been more valuable as it would provide standardised coefficients that 
would allow assessing the strength of relationships in flexible way. Therefore further 
analysis shall also explore this approach. 
7.3.2 Genetic Association Study 
Previous results of epidemiological observation and genetic association studies 
indicated the role of plasma fibrinogen in a whole range of conditions that were 
subsequently significantly associated with age-related cognitive impairment and 
decline, including a significant relationship between plasma fibrinogen levels and 
accelerated decline in cognitive performance. Therefore a genetic association study 
was carried out with the attempt to ascertain more robustly the role of plasma 
fibrinogen in aetiology of cognitive decline. The next section will discuss the 
strength and limitation of this methodological approach, and then conclude with 
summary and implication for further research work.  
The work undertaken in this thesis represents the first large-scale examination of the 
relationship between specifically selected gene variants implicated in altered plasma 
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fibrinogen levels and age-related cognitive change. It was done through the collation 
of datasets from multiple well-defined, population based cohorts; applied meta-
analysis of this type can reduce false positive and false negative findings
369
. Most 
studies assessing genetic associations do so through already published results. The 
most common approach is to extract each study’s’ effect size and/or p values and 
through statistical analyses arrive at conclusions on the role of the particular gene 
variant in phenotypes of interest
369
. Inevitably, this brings up issues linked to the 
quality of published studies, and one of the major issue linked to genetic-association 
meta-analysis, that publication  is in favour of large effect size, statistically 
significant results
194
. One of the main issues in meta-analysis of secondary data is the 
major difference in choice of covariates that might affect the genotype-phenotype 
relationship
370
; subsequent large inconsistencies in reported results might skew the 
results of meta-analysis. 
In my study, individual subject data were available; this allowed for calculation of 
the required values that were subsequently collated in the meta-analysis. Having such 
raw genetic and cognitive data available, including control over determination of the 
general cognitive factor ‘g’, meant that it was possible to conduct both uncorrected 
models as well as models corrected for age and sex in a considerably robust manner. 
Furthermore, each study was checked independently for population stratification, 
reducing one of the major obstacles in genetic association studies. All results were 
derived from data from prospective population-based cohort studies; these included 
large study populations with well-defined selection criteria and susceptibility to 
study bias was limited.  
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The majority of gene-association studies suffer from small sample sizes that do not 
allow for sufficient power to detect of subtle differences and weaker associations. 
Here the combination of reasonably homogeneous cohorts resulted in a large overall 
total number of included subjects, which were treated as it from a single cohort, 
thereby increasing power to detect associations. Despite this, the power may have 
still been limited to detect particularly small effect sizes, therefore there is a 
possibility of false negative results.  
 
Evaluation of measures of cognitive function across collaborating cohort  
One of the major weaknesses of the presented meta-analysis is the cross-sectional 
nature of the extracted data on cognition, i.e. data were only available for cognitive 
ability at a single time point. Although this should not have had an effect on the 
relationship between SNP and cognitive ability, it would have been interesting and 
potentially more informative to investigate the association of genetic variants with 
late-life cognitive decline as the phenotype most amenable to subsequent 
modification. However, between the seven selected cohorts, there were far too many 
inconsistencies in the time scale of serial cognitive assessments to enable a valid and 
comparable measure of cognitive decline to be created and after careful consideration 
of the role this adjustment was ruled out. There is a possibility that lack of 
association was not due to true absence of an effect of a particular SNP on cognition, 
but rather due to methodological issues such as measurement discrepancies, 
differences and/or errors in measurement of cognitive phenotype, which may have 
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weakened potentially observed effect sizes. Methodological constrains that affected 
the reliability and validity of the ‘g’ values is discussed below.  
For the purpose of the meta-analysis, the general intelligence factor ‘g’ was 
calculated per individual cohort. The seven individual ‘g’ values were derived from 
tests that were available for the three main cognitive domains – memory, executive 
functioning and information processing.  All neuropsychological tests that were 
administered in each cohort were standardised with a high degrees of sensitivity to 
detect potential subtle changes in cognitive performance. However, the 
neuropsychological test batteries that were used to assess individual cognitive 
domains differed between studies. There was a substantial overlap in the 
administered batteries in the Scottish cohorts, own to collaboration between research 
teams. Cognitive scores from the two large English cohorts, ELSA and Whitehall II, 
differed considerably from the Scottish cohorts. This is specifically relevant to 
assessment of memory functioning. In the Scottish cohorts, verbal memory tests 
(Adult Verbal Learning Test and Logical Memory) assessed retrospective memory
4
. 
Verbal memory functioning heavily relies on the function of the medial temporal 
lobe
7
 and this region, critical for consolidation of short-term to long-term memory, is 
known to be the first affected by neurodegenerative changes lined to MCI and early 
onset of Alzheimer disease
48,58
. On the other side, in the English cohorts prospective 
memory was assessed by ‘word list’ tasks. Prospective memory functioning is 
generally associated with the frontal lobe region
371
. Whereas this area of the brain is 
particularly vulnerable to the effect of age-related neuroanatomical changes
26
, 
clinical symptoms are compatible with localized damage, such as fronto-temporal 
 
  244 
dementia or vascular dementia
7
.  Unlike the Alzheimer’s disease, variation and 
reduction of a cerebral blood flow has been implicated in the pathogenesis associated 
with clinical symptoms of dementia of vascular type. Neuroimaging studies support 
this view; despite divergence of functionality linked to particular brain region, there 
is no evidence of a one, same, biological network that would modulate general 
intelligence functioning
372
. This discrepancy means that general intelligence factors, 
calculated for individual study, were derived from scores indicating different types of 
memory performance. Results of the meta-analyses indicated that all but one 
significant association that was detected between gene variances and the general 
intelligence factor, were observed only in the Scottish cohorts (the exception was in 
the SNP IL1RN). Therefore it seems that one of the possible reasons why the meta-
analysis did not benefit from the large collated data set, was the inconsistency in 
measurement of specific cognitive function. 
Furthermore, collated data from seven independently organized cohorts meant that it 
was not possible to apply clearly defined standardizes operational procedures that 
would be consistently adhered to through the entire process of cognitive data 
collection. Therefore the test scores might have been influenced by issues, such as 
measurement error, participants’ motivation to testing and precision of test 
administration. Moreover, further variability exists in terms of the length of time 
differences between each wave of data collection in each cohort, which affects 
homogeneity of each cohort’s ‘g’ value. Also, despite the meta-analysis presented in 
this study was conducted on ‘g’ that was derived from cross-sectional data, these 
tests scores were drawn from prospective-based data sets. Therefore there is a 
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possibility of a selective attrition and practice effect
173,252
. This lack of control over 
each study designs might have affected otherwise robust measures of cognitive 
ability ‘g’
277
. Consequently, this might have affected the robustness of results of the 
meta-analysis and lead to the lack of association between genotype data and 
cognitive performance indexed by ‘g’.  
 
Causal Inference and Mechanisms  
The results of this study are consistent with involvement of plasma fibrinogen level 
in accelerated age-related cognitive decline. The genotypes that were significantly 
associated with impaired overall cognitive ability have been shown previously to 
influence circulating plasma fibrinogen levels; albeit such association was not 
detected in the present analysis.  
The rs4681 (FGB) has been shown to be directly involved in fibrinogen synthesis 
and the rs2070016 (FGA) to determine clot structure
213,373
. This suggests that 
fibrinogen may alter age-related cognitive ability via its haemostatic and rheological 
properties. This is in line with mounting evidence indicating the role of elevated 
plasma fibrinogen level in Alzheimer’s disease and with ischaemic stroke and 
vascular dementia. In this study, both of these genes were implicated in age-related 
cognitive impairment in the general cognitive factor ‘g’.  
Alternative pathways have also been implicated by the results of this study. The 
identified genes are also known to contain gene variants that are either indirectly 
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linked to biological mechanisms that activates the acute-phase response (IL1RN 
gene), or are acting in parallel with other inflammatory markers that are also 
activated through the hepatic response (CRP gene). Plasma fibrinogen levels also are 
elevated indirectly via biological mechanisms that are linked to alcohol dependency, 
substantial cigarette smoking or mental health issues and neuro-psychiatric disorders, 
mechanisms associated with the ANKK1 gene.  
The hypothesis of a direct brain effect in the form of neuro-inflammation also needs 
to be considered, especially in the light of close biological interplay between 
cytokines IL-1 and IL-6. These are known to penetrate the blood-brain barrier and 
via the activation of glial cell, to trigger the whole cascade of immune-response 
processes. This hypothesis is in line with Reiner et al. (CARDIA study
374
).  They 
reported a reasonably strong statistically significant relationship of the rs4251961 
(IL1RN gene) and CRP, IL-6 and plasma fibrinogen levels. Overexpression of IL-1 
in the brains of patients with Alzheimer’s’ disease and its involvement in neuro-
degeneration is also evident. In addition, the rs315952 (IL1RN gene) may affect 
levels of plasma fibrinogen through an indirect biological mechanism whilst 
contributing significantly to cognitive dysfunction directly through a process of 
neuro-inflammation, exacerbating the overall mechanism resulting in age-related 
cognitive impairment in a large, population, community-dwelling citizens.  
Although the presented evidence can be seen as a consistent with causal involvement 
of plasma fibrinogen in cognitive impairment, there are also issues affecting the 
validity and strength of the overall results from the meta-analysis. Genetic 
association studies often require large datasets of few a thousand participants in order 
 
  247 
to reach sufficient statistical power due to small effect sizes of individual genetic 
variants
194
.  In order to address this issue, the presented meta-analysis was conducted 
on a large, collated dataset. Nonetheless, there is a possibility that the overall small 
magnitude of expected effect sizes might reflect the need for a larger study 
population.  
The instrumental variable, i.e. the pre-selected individual fibrinogen-related SNPs 
may have not been sufficiently strong. The possibility of a high allele frequency 
might have resulted in a disruption between the (potentially) causal SNP and the one 
pre-selected for this analysis (from the literature search or the HapMap database), 
and therefore the one that was requested from the collaborative centers and 
subsequently subjected to linear regressions and meta-analysis. Indeed, it has been 




Determination of the phenotype of interest, that is the general cognitive ability factor 
‘g’, was conducted from raw cognitive scores received from each cohort 
independently. However, since data collection was carried out in each collaborative 
center independently, no control was possible in terms of assuring a standardised 
operational procedure common to all seven cohorts; although the same cognitive 
domains were tested in each study, the precise tools differed, especially between the 
Scottish and English cohorts.  
Interestingly, in the SNs- cognition meta-analysis all but one of the statistically 
significant gene variants came from the Scottish based studies that share the almost 
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the same psychology cognitive neuropsychological battery (in the SNPs-plasma 
fibrinogen meta-analysis all seven studies were evenly represented. This has raised 
the possibility that the benefit of collating data from different cohorts into one large 
dataset might have been lost due to the heterogeneity in cognitive assessment and 
scores available to calculate the general cognitive factor.  
The possibility of a confounding effect linked to population stratification
21,375
 is 
reasonably unlikely considering that a request was made only for data from a 
European-origin only subjects and each study investigators conducted a thorough 
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7.4 Conclusion and future direction  
The primary aim of this study was to investigate associations between circulating 
inflammatory biomarkers and cognitive impairment and cognitive decline in 
advanced age. The aim was addressed in two steps. The first part of this thesis 
focused on prospective data derived from a diabetic ageing population, the ET2DS. 
In this relatively unique, large-scale epidemiological study that focuses entirely on 
older, diabetic population, plasma levels of cytokines IL-6 and TNF-alpha and acute 
phase proteins plasma fibrinogen and CRP were modelled in a set of linear 
regressions to determine change in cognitive ability over 4-years and estimated life-
time cognitive decline. In the second stage of the thesis, pre-selected fibrinogen-
related SNPs and fibrinogen-related tagging SNPs were modelled against plasma 
fibrinogen and against the general cognitive ability factor ‘g’ that was derived 
through principal component analysis in each study individually. Linear regressions 
and meta-analysis assessing the strength of genetic associations was carried out on a 
large data set, consisting of seven, population based cohorts; five Scottish and two 
English cohorts.  
Modelling baseline plasma biomarkers levels against follow up cognitive scores, 
adjusted either for a respective baseline score (determining four-year change in 
cognitive performance) or for scores of a vocabulary test estimating peak cognitive 
ability (determining estimated life-time cognitive change) revealed an overall decline 
in the general cognitive factor ‘g’ associated with the baseline levels of all 
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investigated biomarkers, at all stages of the models (the lowest magnitude was 
observed on the TNF-alpha models).  
The strongest and most statistically significant associations were detected in analyses 
modeling the general inflammatory maker and IL-6 levels. These associations were 
most noticeable for tests measuring information processing speed, attention and 
mental flexibility and working memory. Only slightly weaker relationships were 
detected in analyses that modeled levels of acute phase proteins (plasma fibrinogen 
and CRP) with a very similar pattern across cognitive domains. The majority of 
associations persisted after adjustment for conventional cardiovascular factors and 
events.  
Results of the ET2DS longitudinal analysis have made a contribution to the body of 
evidence on the systemic inflammation and late-life cognitive ability relationship. 
Specifically, the presented results add by providing a prospective data analysis, 
suggesting that increased levels of circulating inflammatory markers might directly 
affect the brain, possibly through penetrating the blood brain barrier and by their role 
in neuroinflammation, thereby accelerating age-related cognitive decline. This 
suggests that patients’ risk of accelerated age-related cognitive decline can 
potentially be reduced though a clinical intervention, focusing on management of 
systemic inflammation. Further epidemiological studies can compare risk factors 
associations with cognitive decline between people with and without type 2 diabetes 
to determine if the ET2DS results are specific only to diabetic older people or 
general ageing population. This would further clarify whether elevated inflammatory 
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markers are, and if so, how strongly, risk factors affecting the trajectory of cognitive 
ageing 
With regards to the genetic association analysis, it was hypothesised that 
polymorphisms that have been shown previously to be determinants of circulating 
plasma fibrinogen may significantly affect general cognitive ability in a large data set 
of non-demented, community-dwelling citizens in Scotland and England. I also 
investigated statistical significance of the relationship between pre-selected SNPs 
and plasma fibrinogen levels.  
Whereas there were 7 SNPs that were associated with levels of plasma fibrinogen at 
the statistical level of p<0.05, only 5 SNPs were significantly associated with 
impairment in the general cognitive factor ‘g’. Polymorphisms rs1130864 (CRP 
gene) seem to affect plasma fibrinogen level, however, this was a marginally 
significant associations, only just reaching the p<0.05 level; also, the effect size 
magnitude was small.  Number of methodological issues might have accounted for 
this finding, most notable relatively weak predicting variable (plasma fibrinogen-
related SNPs were extracted from published literature, therefore there was a 
substantial lack of control) and relatively weak outcome variable (own to differences 
between the selection and data collection of cognitive tests that formed the general 
intelligence factor ‘g’).  It is therefore not clear whether these results were false 
positives, whether they indicate a role of plasma fibrinogen in accelerated decline in 
general cognitive ability via its hemostatic and rheological properties or whether 
other inflammatory markers, known to have a strong patho-biological relationship 
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with plasma fibrinogen have an important role, affecting the quality of cognitive 
performance directly through the brain neuro-inflammatory mechanisms.  
The overall aim of this thesis, (both the prospective analysis of change in cognitive 
performance in the ET2DS as well as the genetic association analysis) was to explore 
a possible causal relationship between plasma fibrinogen and impaired general 
cognitive ability. The results suggest that inflammatory pathways are indeed 
implicated in accelerated cognitive impairment and decline in ageing populations.  
The relatively small effect sizes found in the multivariate model might be also 
accounted for by a methodological issues and nature of research into cognitive 
ageing.   
Strength of this thesis is that it provided evidence of a longitudinal change in 
cognitive performance in a clearly defined ageing cohort with comprehensive 
cognitive and biomedical/laboratory data. Modelling baseline measures of 
biologically related inflammatory markers against different measures of cognitive 
performance (4-year and life-time) showed results consistent with a relationship 
between peripheral and central inflammation leading to accelerated cognitive 
decline. Review of the literature suggested that this was the first large scale study in 
older people with type 2 diabetes to assess such a wide range of inflammatory 
markers and to address change over time prospectively.  
Further novel findings were generated through a genetic association study conducted 
in a large dataset collated from well defined, population based prospective studies. 
Despite the limitations, such as limited strengths of the instrumental variable and 
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difficulties defining measured phenotype more precisely, meta-analysis of 
approximately 14 300 subject demonstrated that fibrinogen-related SNPs located in a 
wide range of genes seem to represent significant determinants of age-related 
impairment in general cognitive ability, supporting the findings of the prospective 
ET2DS in terms of an effect of inflammation has on the speed of age-related changes 
in cognitive performance. 
It is still premature to declare a causal nature of the inflammation-cognition 
relationship. However, the findings have important implications for further studies. 
In terms of the epidemiological evidence on the role of systemic inflammation in 
age-related cognitive decline in T2DM, a further follow up wave in the ET2DS, 
providing serial cognitive assessment scores, would be ideal for modelling the 
pattern and speed of decline in general cognitive ability. It would also allow 
observation of the pattern of decline in specific cognitive domains. Such study design 
could also allow for measurement of biomarker trajectories (i.e. serial laboratory 
measures of systemic inflammatory markers). Results could further inform 
subsequent investigations in the form of a randomised control trial testing an 
evidence-based clinical intervention in a diabetic population.  
Furthermore, randomised control trial (RCT), one of the highest-rated designs in 
epidemiological research, might focus on an investigation of modification of levels 
of circulating inflammatory markers though a pharmaceutical treatment. However, 
methodological constrains of RCT, such as requirement of participants’ motivation to 
adhere to allocated type of treatment for a prolonged period of time may lead to 
samples that are not typical of the general population as well as target (risk group) 
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population. Also, in comparison to observational cohort studies RCT commonly 
suffer from a higher attrition rate as well as the reduced duration of follow-up. 
Alternative approach to assess potential causal role of the risk factors is the use of 
gene variance as a proxy variable in regression analysis. This, indeed, was the aim of 
the second part of the presented thesis.  
The genetic association study, a number of directions can be taken further. This study 
focused on plasma fibrinogen related polymorphisms in the three fibrinogen genes 
themselves as well as genes and variants that showed a significant association in with 
plasma fibrinogen, despite the fact that their primary role might be through 
alternative mechanisms. Results of the meta-analysis support and suggest that the 
role of neuro-inflammation in the aetiology of age-related cognitive impairment is 
certainly plausible. Further study, modelling a wider range of inflammation-related 
genetic variants, in particularly those related to IL-1, IL-6 and TNF-alpha would 
certainly add to the existing evidence. Use of stronger ‘instrument’ (in terms of 
association with the relevant circulating biomarker) would also advance knowledge 
further. In my study, I found only 7 out of 61 pre-selected SNPs to be significantly 
associated with plasma fibrinogen levels; most likely due to variability of study 
populations upon which my information was drawn.  Recent research suggests that a 
‘multi-SNPs’ instrument may be a stronger instrument for modelling potentially 
causal associations between biomarkers and outcomes. 
The presented thesis has demonstrated the importance of research and clinical 
attention to age-related cognitive functioning, with emphasis on identification of 
protective as well risk factors, allowing identification of most vulnerable 
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populations. Findings of the presented longitudinal analysis (the ET2DS) have been 
disseminated at Diabetes UK conferences and published in the peer-reviewed 
journal
171,318
. At the time of completing this thesis, further manuscript focusing 
directly in the outcome of this thesis, is under review.  
This thesis has added to the body of current evidence some highly important results, 
albeit these represent a fraction of the aetiology of the complex phenomena of 
cognitive ageing. Future studies could extend this investigation, focusing on a wider 
array of risk factors and their direct role on the neuro-inflammatory processes within 
the human brain. Such analyses would ultimately lead to identification of biological 
and pathological mechanisms responsible for the pattern and speed of cognitive 
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Appendices 
Appendix A: Results of studies reviewed in Chapter 2 
Table 23: Literature Review: Results 
Author/ 
year 




et al., 2002  
A&S; household income, education level, marital 
status, ethnicity and health (smoking, alcohol, 
physical activity, BMI, HbA1c, total cholesterol, 
BL (sys, dias), T2DM, cancer, MI, stroke, hip 
and/or bone fracture) 
Decline (2.5ys): general cognition: diff btw low to mid 
tertile p=0.002; and diff between mid to high p=0.006 
Decline (7ys): general cognition: diff btw low to mid 
tertile p=0.45; and diff between mid to high p=0.01 
 
 
Reported baseline characteristics of 
differences between yes/no follow-up 






A&S; household income, education level, marital 
status, ethnicity and health (smoking, alcohol, 
physical activity, BMI, HbA1c, total cholesterol, 
BL (systolic, diastolic), T2DM, cancer, MI, 
stroke, hip and/or bone fracture) 
Abstraction: Impairment:  IL6 (>3.8): OR:1.52; 95% CI 
1.01-2.27 
Global cognition: Impairment 3rd IL6 (>3.8): OR: 1.62; 
95% CI: 1.07-2.45) 
SPMSQ: decline 3rd IL6 (>3.8); OR:1.88; 95% CI: 1.20-
2.94 
ADJUSTED: 
SPMSQ: IL (>3.8): OR 1.67; 95% CI: 1.04-2.67) 
NO significant associations with CRP at any level 
 
Cross-sectional/IL 6 analyses: generally 
linear negative relationship (equal to 
ET2DS).  
Dik et al., 
2005 
A&S; education, APOE, depressive symptoms, 
rheumatic diseases,  use of non-steroid anti-
inflammatory drugs, aspirin, smoking and 
alcohol, physical activity, CVD (atherosclerosis, 
stroke, TIA, T2DM) 
 1st CRP 2CRP 3CRP 
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Author/ 
year 


















 1st IL6 2IL6 3rd IL6 
































MT., et al., 
2007  
sex, and education level, BMI, 
diabetes mellitus, and prevalent CVD, APOE e4, 
CVD, and atherosclerosis 
Rotterdam Study Leiden 85+ Study 
 
CRP (n=2433): R2; p-value CRP (n=440): R2; p-value 



















IL-6 (n=304): R2; p-value IL-6 (n=440): R2; p-value 













Memory 0.01; 0.60 Memory 0.02; 0.03 
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Author/ 
year 




    
Luciano, 
M., et al., 
2009  
BMI, BP (D), Tot chole, T2DM presence, 
HbA1C, smoking status 
 
All associations accounted for by childhood 
IQ, CVD risk factors or both.  
Most interesting result: IQ at 11 years 
predicted elevation of CRP and fib  
 
Marioni, 
RE, et al., 
2009  
ABI, BP (D), Tot cholesterol, smoking status. 
 
 
Baseline CRP and fibrinogen levels were 
associated negatively with age and sex-
adjusted follow-up scores on the majority of 
the cognitive tests, and the general cognitive 
ability factor (correlations= -0.054 to 0.105, 
p<.05). In analyses adjusting for baseline 
cognitive scores, asymptomatic 
atherosclerotic disease, and cardiovascular 
risk factors, both markers predicted decline in 
several cognitive domains (excluding 
memory). Baseline plasma viscosity, but not 
hematocrit, was associated negatively with 
follow-up test scores for general 
cognitive ability, information processing 
speed, and mental flexibility (correlations= -
0.050 to -0.098, p<.05) and with decline 
 across the same domains (p<.05). 
Rafnsson, 
S., et al., 
2010  
A&S; depression, smoking, alcohol, 
diabetes/glucose intolerance,  
major cardiovascular disease from baseline up to 
6 months prior to cognitive testing in 2002/03 
either respective BL cognitive score or NART 
 4-years decline Life-time decline 
In a fully adjusted models, plasma fibrinogen 
associated with a greater 4 year decline in 
verbal memory and 
in no-verbal reasoning, but only with verbal 
memory in life-time cognitive decline 
 Beta SE Beta SE 
LM -1.94 .92* -3.28 1.52** 
MR -.97 .55* -.20 .71 
VF -.45 .60 -.54 .95 
DS
T 
-.18 .53 -.29 .82 
‘g’ -.02 .04 .04 .07 
Jefferson, 
A.L., et al, 
2011  
 
CRP - LM-D .02 -.02-.06 .297 
 CRP- TMT-B .00 -.01-.01 .629 
CRP- visual reproduction -.01 .00-.03 .648 
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Author/ 
year 
Covariates (adjusted analyses) Results (p-values, OR, CI) 
Interpretation/limitations/ 
implications 
    
CRP – Boston Naming 
test 
-.02 -.04-(-.00) .044 
    
IL6 - LM-D .02 -.03-.08 .388 
IL6- TMT-B .01 -.01-.02 .342 
IL6- visual reproduction -.02 -.07-.02 .316 
TNF-a - LM-D -.02 -.11-.07 .606 
TNF-a- TMT-B .04 .01-.07 .004 
TNF-a - visual 
reproduction 
.00 -.07-.08 .941 
TNF-similarities test -.08 -.16-(-.00) .046 
Mooijaart, 
SP., et al., 
2011  
A+S 




SP., et al., 
2013  




Cross-sectional (5653 subjects): 
Higher concentration associated with 
impaired EF, independent of CVD. 
No association with memory. 
Longitudinal: 
IL6 predicted decline in EF and 
memory, both independent of CVD 
*Adjusted for co-varieties 
 
  283 
Appendix B: ET2DS: Cognitive Testing Pack 
PART 3 – Cognitive function testing 
 





BM .  (If < 4.0, re-arrange appointment) 
 
 
Cognitive Test Battery: 
 
Time tests started ______:______ (24hr clock) 
 
Tick box if complete If test incomplete/difficulty 
encountered, specify 









   
 
Logical memory 1 
(WMS-III) 




   




   
 
Digit symbol test 
(WAIS-III) 









   
 
Logical memory 2 
(WMS-III) 
   
 Faces 2 (WMS-III)    
 Visual reaction test    
* Circle final score for data entry 
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Appendix C: Data request forms from the 
collaborating cohorts 
 
Collaborator's request to access data and/or biological samples from the 
English Longitudinal Study of Ageing 
1. Name of all applicants, affiliations and contact details 
a) Ms Markéta Keller, PhD Researcher, University of Edinburgh, Public Health 
Sciences, Teviot Place, Edinburgh EH8 9AG, m.keller@sms.ed.ac.uk, Tel: 0131 
650 6964 
b) Dr Jackie Price, Clinical Senior Lecturer in Epidemiology, University of 
Edinburgh, Public Health Sciences, Teviot Place, Edinburgh EH8 9AG, 
Jackie.Price@ed.ac.uk, Tel: 0131 650 3240 
2. Title of project (less than 30 words): Evaluation of fibrinogen as causal risk 
factor for cognitive impairment in older age 
start date:  01. 05. 2010                                                         end date:    31. 08. 2012 
3. Brief description of project (no more than 1-2 sides A4 with up to 10 key 
references) 
(This must include a) a list of SNPs to be genotyped, b) pre-existing data on 
genotype frequency and c) reference any of the applicant’s previous experience in 
this area) 
Background 
An increasing body of evidence suggests that circulating plasma fibrinogen may 
have a role in cognitive decline in ageing populations.  A number of large-scale 
epidemiological studies have demonstrated statistically significant associations 
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between raised plasma fibrinogen levels and poorer cognitive ability 
1
 and some 
have demonstrated association between raised fibrinogen and cognitive decline 
2, 3, 4
. 
There are also patho-physiological mechanisms which might explain a direct 
relationship between circulating fibrinogen levels and reduced cognitive ability, 
including reduced cerebral blood flow associated with raised plasma viscosity as a 
result of elevated fibrinogen levels in the blood.  However, associations between 
plasma fibrinogen and cognition reported in epidemiological studies may be the 
result of confounding, for example by vascular diseases (although vascular disease 
may also be a mediating factor). It is therefore important to investigate the potential 
causal nature of such epidemiological associations.  One method of doing this is to 
use fibrinogen genotype, known to affect fibrinogen levels, as proxy for plasma 
fibrinogen levels (the instrumental variable approach) and to test the association 
between fibrinogen genotype and cognitive ability directly.  In our own research, on 
a diabetic cohort, we have demonstrated an association between fibrinogen gene 
variants (FGA and FGB) and cognitive ability, but findings were not replicated in 
other populations.  However, the total sample size of the included studies was 
relatively small and genetic variants were not selected systematically to best reflect 
variation in fibrinogen levels. 
Aim 
The aim of the project is to determine the association between pre-selected SNPs 
(those which are known or suspected to affect plasma fibrinogen levels) and 
cognitive phenotypes in meta-analysis of large cohort studies, including those based 
in Edinburgh (AAA Trial, ET2DS, EAS and LBC 1936), ELSA and Whitehall II. 
The Project 
Systematic review and discussion with experts in the field to identify SNPs 
associated with altered fibrinogen levels (and possibly fibrinogen structure), 
including review of the results of recent GWAS studies. Please see the attached 
Excel sheet for the final results of a literature search for fibrinogen related SNPs 
(115) and for fibrinogen related tagSNPs (identified through the International 
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HapMap Project website (495). This list of SNPs will help to determine which 
SNPs are available in each of the included studies and which SNPs are common to 
more than one study.  
Collation of data from the 6 included studies and discussion around the potential for 
additional genotyping where individual studies do not already have fibrinogen-
related SNP data.  J Price has some limited funds which could potentially support 
this additional genotyping if necessary, or funds may become available through 
UCLEB/metabochip. 
Analysis of association between pre-selected SNPs and plasma fibrinogen levels in 
each study. 
Analysis of association between pre-selected SNPs and cognitive phenotypes, where 
possible, as meta-analysis (depending on study homogeneity and ability to derive a 
common cognitive outcome across studies). 
References: 
1. Marioni, R., E., et al., Genes, Brain and Behaviour, Vol. 9 Issue 3, Pages 348 -
 352 
2. Rafnsson, S., B., Deary, I., J., Smith, S., B., et al., JAGS 2007;55:700-7 
3. Schram, M., T., Euser, S., M., de Craen, A., J., M., et al., JAGS 2007;55:708-16 
4. Van Oijen, M., Witteman, J., C., Hofman, A., et al., Stroke. 2005;36:2637 
4. Rationale for undertaking this project with the ELSA rather than other 
datasets 
Availability of detailed cognitive function testing on a large, elderly cohort and data 
on biomarkers of interest. 
5. If DNA is being requested, please state amount and rationale for request for 
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DNA 
At this stage in the collaboration, no additional genotyping is being requested as we 
will first determine which fibrinogen-related SNPs are already available in each 
study before proceeding further 
6. Sample size calculation N/A 
7. Funding: Has/will the project be(en) peer reviewed and funded? 
The project is part of an ESRC PhD studentship awarded to Marketa Keller 
8. Analyses: What key variables will be required for analysis? 
SNP data – please refer to the attached Excel file 
Plasma fibrinogen (measured at as many phases of the study as possible) 
Cognitive phenotypes – measures for tests of each cognitive domain and where 
available, the general intelligence factor ‘g’ 
Estimate of pre-morbid cognitive functioning (measured by MHVS or NART).  
Assessment of anxiety and depression  
Demographic data – age, age at the data collection time, sex, socio-economic 
background, smoking history, history of alcohol consumption, history of type 2 
diabetes 
9. Electronic data: Will the project require deriving or producing new 
variables from existing data? 
No 
10. DNA samples: Are there any special requirements for the DNA extraction 
or potential problems with using pre-amplified rather than genomic DNA? 
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N/A 
11. Feasibility and quality control: Do(es) the applicant(s) have sufficient 
experience and expertise to carry out the analysis?  
Although forming part of the PhD project, the analysis will be closely supervised by 
Dr Jackie Price (epidemiologist) and Dr Niall Anderson (senior lecturer in genetic 
statistics, University of Edinburgh).  Additional advice on analysis will be available 
from Professor Paul McKeigue (expert in Mendelian Randomisation analyses).  
Professor Ian Deary (psychologist) and other members of the MRC centre for 
Cognitive Ageing and Cognitive Epidemiology in Edinburgh.  We also foresee that 
analyses will be discussed with ELSA collaborators as part of efforts towards joint 
publication of results. 
12. Collaborative input: Will the applicants be working work collaboratively 
with the original investigators and/or a member from the ELSA team  
Yes, with Dr Meena Kumari 
13. Statistical expertise: Will the analysis require statistical input from ELSA? 
See above 
14. Agreement: 
I confirm that I have read the above and am happy to comply with the terms and 
conditions. 
Signature                         Date: 17. 05. 2011 
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LBC1921/36 Data request form 
 
Provisional title of study:Evaluation of fibrinogen as causal risk factor for cognitive 
impairment in older age – study of 6 ageing cohorts  
Principal researcher (include institution address, email & phone) 
Markéta Keller 
College of Medicine and Veterinary Medicine 
The University of Edinburgh 
Teviot Place 
Edinburgh; EH8 9AG 
Email: m.keller@sms.ed.ac.uk 
Tel: 0784 343 2017 
Provisional author list 
Dr Jackie Price 
Dr Mark Strachan 
Dr Niall Anderson 
Prof Ian Deary 
Ms Insa Feinkohl 
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Dr Stela Masle  
And representatives from collaborating centres  
Brief rationale for study 
Background 
An increasing body of evidence suggests that circulating plasma fibrinogen may have a 
role in cognitive decline in ageing populations.  A number of large-scale epidemiological 
studies have demonstrated statistically significant associations between raised plasma 
fibrinogen levels and poorer cognitive ability 1 and some have demonstrated association 
between raised fibrinogen and cognitive decline 2, 3, 4. There are also patho-physiological 
mechanisms which might explain a direct relationship between circulating fibrinogen 
levels and reduced cognitive ability, including reduced cerebral blood flow associated 
with raised plasma viscosity as a result of elevated fibrinogen levels in the blood.  
However, associations between plasma fibrinogen and cognition reported in 
epidemiological studies may be the result of confounding, for example by vascular 
diseases (although vascular disease may also be a mediating factor). It is therefore 
important to investigate the potential causal nature of such epidemiological associations.  
One method of doing this is to use fibrinogen genotype, known to affect fibrinogen 
levels, as proxy for plasma fibrinogen levels (the instrumental variable approach) and to 
test the association between fibrinogen genotype and cognitive ability directly.  In our 
own research, on a diabetic cohort, we have demonstrated an association between 
fibrinogen gene variants (FGA and FGB) and cognitive ability, but findings were not 
replicated in other populations.  However, the total sample size of the included studies 
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was relatively small and genetic variants were not selected systematically to best reflect 
variation in fibrinogen levels. 
Aim 
The aim of the project is to determine the association between pre-selected SNPs, known 
or suspected to affect plasma fibrinogen levels, and cognitive phenotypes in meta-
analysis of large cohort studies, including those based in Edinburgh (AAA Trial, 
ET2DS, EAS and LBC1936), ELSA and Whitehall II. 
1. Marioni, R., E., et al., Genes, Brain and Behaviour, Vol. 9 Issue 3, Pages 348 - 352 
2. Rafnsson, S., B., Deary, I., J., Smith, S., B., et al., JAGS 2007;55:700-7 
3. Schram, M., T., Euser, S., M., de Craen, A., J., M., et al., JAGS 2007;55:708-16 
4. Van Oijen, M., Witteman, J., C., Hofman, A., et al., Stroke. 2005;36:2637 
Main variables to be analysed 




history of alcohol consumption  
history of type 2 diabetes 
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Data for statistical analysis: 
age, gender 
age at the data collection  
fibrinogen related SNPs (please refer to attached Excel Sheets) 
fibrinogen (plasma level, when collected) 
history of cardiovascular events (MI, angina, stroke)  
current (and previous where available) cognitive functioning  values gained for 
individual testing, general intelligence factor ‘g’ where available 
estimate of pre-morbid cognitive functioning (measured by MHVS or NART).  
assessment of anxiety and depression 
Which journal(s) are you considering? 
Genes Brain Behaviour  
Age and Ageing 
Psychosomatic Medicine 
Signed: Markéta Keller                 Date: 31. 10. 2011  
 (Applicant)  
Signed: _____________________________________ Date:________________ 
(Ian Deary, study director) 
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Whitehall II Data Application Form  
Preferred member of the WII team to be the WII Contact Researcher (if any):  
Dr Meena Kumari 
1. PRINCIPAL INVESTIGATOR  
Title, forename, surname:  Ms Markéta Keller  
Employing Organisation: The University of Edinburgh  
Position in organisation: PhD student  
Address of organisation: Teviot Place; College of Medicine and Veterinary Medicine; 
Edinburgh; EH8 9AG  
Telephone: 0131 6506964 
Email: m.keller@sms.ed.ac.uk  
Dr Jackie Price  
Employing Organisation: The University of Edinburgh  
Position in organisation: Clinical Senior Lecturer in Epidemiology  
Address of organisation: Teviot Place; College of Medicine and Veterinary Medicine; 
Edinburgh; EH8 9AG 
Telephone: 0131 650 3240 
Email: Jackie.price@ed.ac.uk 
Please attach the Principal Investigator’s Curriculum Vitae. 
2. RESEARCH TEAM / CO-APPLICANTS  
Details of each Research Team member involved in the proposed project. 
Research Team members / Co-applicants   Employing Organisation Position in 
organisation Contact details                        (Email address/Telephone no) 
Dr Jackie Price;  The University of Edinburgh 
Clinical Senior Lecturer in Epidemiology and Public Health Tel: 0131 650 3240 
Jackie.Price@ed.ac.uk 
Ms Markéta Keller The University of Edinburgh PhD student Tel: 0131 
6506964 
m.keller@sms.ed.ac.uk 
3. PUBLICATIONS OF THE RESEARCH TEAM MEMBERS 
List of the main publications of each Research Team member involved in the project. 
Dr Price: 
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Lind PA, Luciano M, Horan MA, Marioni RE, Wright MJ, Bates TC, Rabbitt P, Harris 
SE, Davidson Y, Deary IJ, Gibbons L, Pickles A, Ollier W, Pendleton N, Price JF, 
Payton A, Martin NG. No association between choliniergic muscarinic receptor 2 
(CHRM2) genetic variation and cognitive abilities in three independent samples. 
Behavior Genetics 2009;39:513-23. 
Marioni RE, Stewart MC, Murray GD, Deary IJ, Fowkes FGR, Lowe GDO, Rumley A, 
Price JF. Peripheral levels of fibrinogen, C-reactive protein, and plasma viscosity predict 
future cognitive decline in non-demented individuals. Psychosom Med 2009; 71:901-6. 
Riccardo E. Marioni, Ian J. Deary, Gordon D. Murray, Gordon D. O. Lowe,  Snorri B. 
Rafnsson,  Mark W. J. Strachan, Michelle Luciano, Lorna M. Houlihan, Alan J. Gow, 
Sarah E. Harris, Marlene C. Stewart, Ann Rumley, F. Gerry R. Fowkes, Jackie F. Price. 
Genetic Variants Associated With Altered Plasma Levels of C-Reactive Protein are not 
Associated With Late-Life Cognitive Ability in Four Scottish Samples. Behav Genet. 
2010;40:3-11. 
Marioni R, Strachan MWJ, Reynolds R, Deary IJ, Lowe GDO, Rumley A, Fowkes FGR, 
Frier BM, Lee A, Murray GD, Price JF. Association between raised inflammatory 
markers and cognitive decline in elderly people with type 2 diabetes: the Edinburgh 
Type 2 Diabetes Study. Diabetes 2010 Mar;59(3):710-3. 
Marioni RE, Lowe GDO, Rumley A, Murray GD, Deary IJ, Strachan MWJ, Price JF, on 
behalf of the ET2DS investigators.  Blood rheology and cognition in the Edinburgh Type 
2 Diabetes Study. Age Aging 2010;39:354-9. 
Riccardo E Marioni, Ian J Deary, Gordon D Murray, F Gerry R Fowkes, Jackie F Price.  
Associations between polymorphisms in five inflammation-related genes and cognitive 
ability in an elderly population. Genes Brain Behav. 2010;9:348-52. 
Bolton JL, Marioni RE, Deary IJ, Harris SE, Stewart MC, Murray GD, Fowkes FGR, 
Price JF. Association between Polymorphisms of the Dopamine Receptor D2 and 
Catechol-o-Methyl Transferase Genes and Cognitive Function. Behavior Genetics 
2010:40:630-8. 
Houlihan LM, Wyatt ND, Harris SE, Hayward C, Gow AJ, Marioni RE, Strachan MW, 
Price JF, Starr JM, Wright AF, Deary IJ.  Variation in the uric acid transporter gene 
(SLC2A9) and memory performance. Hum Mol Genet. 2010;19:2321-30. 
Riccardo Marioni, Ian Deary, Gordon Murray, Gordon Lowe, Mark Strachan, Michelle 
Luciano, Lorna Houlihan, Alan Gow, Sarah Harris, Ann Rumley, Marlene Stewart, F. 
Fowkes, Jackie Price. Genetic Associations Between Fibrinogen and Cognitive 
Performance in Three Scottish Cohort.  Behavior Genetics (In Press - available on line). 
Aspasia Angelakopoulou, Tina Shah, Reecha Sofat, Sonia Shah, Diane Berry, Jackie 
Cooper, Jutta Palmen, Ioanna Tzoulaki, Andrew Wong, Barbara J Jefferis, Nikolas 
Maniatis, Fotios Drenos, Bruna Gigante, Rebecca Hardy, Ross Laxton, Karin Leander, 
Anna Motterle, Iain Simpson, Liam Smeeth, Andy Thomson, Claudio Verzilli, Diana 
Kuh, Helen Ireland, John Deanfield, Mark Caulfield, Chris Wallace, Nilesh Samani, 
Patricia B Munroe, Mark Lathrop, F Gerry Fowkes, Michael Marmot, Peter H Whincup, 
John Whittaker, Ulf de Faire, Mika Kivimaki, Meena Kumari, Elina Hypponen, Chris 
Power, Steve E Humphries, Philippa Talmud, Jackie Price, Richard Morris, Shu Ye, 
Juan Pablo Casas, Aroon D Hingorani. Integration of GWAS signals for lipids, diabetes 
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and coronary heart disease: A strategy to map causal pathways. Cardiovascular 
Biomarker Genetics Collaboration. European Heart Journal (under re-submission Feb 
2011). 
Ms Keller: 
Neal, R., Keller, M., Belcher, J., and Wilkinson, C., 2099, ‘How are men with prostate 
cancer followed up in the UK? Analysis of data from primary care case-notes and the 
general practice research database’, Copenhagen SAPC abstract.  
Member of the Prostate Cancer research team for the following: 
Watson E, O'Brien R, Campbell C, Weller D, Neal RD, Wilkinson C, Rose P. The push 
towards primary care? Views of health professionals on the role of primary care in the 
follow-up of men with prostate cancer. Family Practice (in press) 
O’Brien R, Rose P, Campbell C, Weller D, Neal RD, Wilkinson C, McIntosh H, Watson 
E. "I wish I'dtold them": a qualitative study examining the unmet psychosocial needs of 
prostate cancer patients during follow-up after treatment. Patient Education and 
Counselling 2010 doi:10.1016/j.pec.2010.07.006 
O’Brien R, Rose PW, Campbell C, Weller D, Neal RD, Wilkinson C, Watson E. Prostate 
cancer patients’ experiences of follow-up after treatment: a qualitative study. BJU 
International 2010 DOI:10.1111/j.1464-410X.2010.09292.x 
McIntosh HM, Neal RD, Rose P, Watson E, Wilkinson C, Weller D, Campbell C. 
Follow-up care for men with prostate cancer and the role of primary care: a systematic 
review of international guidelines. Br J Cancer 2009;100:1852-1860 
4. PREVIOUS APPLICATIONS  
Have you or any of the Research Team members/Co-applicants applied for Whitehall II 
data in the past? No, we have not. 
5. FUNDING  
Do you already have funding to carry out this project? No – part of a PhD studentship   
If you are planning to seek funding to carry out this project and the grant application is 
to be partially or totally based in the use of Whitehall II data, please give details about 
the funding application. 
Synopsis of application (max 100 words) 
6. RESEARCH PROJECT  
6.1 PROJECT TITLE 
Causal Risks for Age Related Cognitive Impairment  
6.2 SUMMARY 
The aim of the project is to determine the association between pre-selected SNPs (those 
which are known or suspected to affect plasma fibrinogen levels) and cognitive 
phenotypes in meta-analysis of large cohort studies, including those based in Edinburgh 
(AAA Trial, ET2DS and EAS), ELSA and Whitehall II.  
6.3 CONTEXT 
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N/A 
6.4 PROJECT DESCRIPTION 
Background 
An increasing body of evidence suggests that circulating plasma fibrinogen may have a 
role in cognitive decline in ageing populations.  A number of large-scale epidemiological 
studies have demonstrated statistically significant associations between raised plasma 
fibrinogen levels and poorer cognitive ability 1 and some have demonstrated association 
between raised fibrinogen and cognitive decline 2, 3, 4. There are also patho-
physiological mechanisms which might explain a direct relationship between circulating 
fibrinogen levels and reduced cognitive ability, including reduced cerebral blood flow 
associated with raised plasma viscosity as a result of elevated fibrinogen levels in the 
blood.  However, associations between plasma fibrinogen and cognition reported in 
epidemiological studies may be the result of confounding, for example by vascular 
diseases (although vascular disease may also be a mediating factor). It is therefore 
important to investigate the potential causal nature of such epidemiological associations.  
One method of doing this is to use fibrinogen genotype, known to affect fibrinogen 
levels, as proxy for plasma fibrinogen levels (the instrumental variable approach) and to 
test the association between fibrinogen genotype and cognitive ability directly.   
In our research, on a diabetic cohort (ET2DS), we have demonstrated an association 
between fibrinogen gene variants (FGA and FGB) and cognitive ability, but findings 
were not replicated in other populations.  However, the total sample size of the included 
studies was relatively small therefore our aim is to carry out this analysis on large 
number of participants.  
Scientific hypothesis 
In line with the principle of Mendelian Randomisation, our aim is to determine the 
potential causal relationship between the circulating plasma fibrinogen level and 
cognitive functioning in ageing population. 
Objectives 
We propose to examine the relationship between pre-selected fibrinogen related SNPs 
and: 
- plasma fibrinogen level; 
- current cognitive functioning; 
- pre-morbid cognition; 
- cognitive decline (determined by discrepancy between pre-morbid and current 
cognitive function 
Methodology and planned statistical analyses 
1. Literature review identified SNPs associated with altered fibrinogen levels (and 
possibly fibrinogen structure), including review of the results of recent GWAS studies. 
Please see the attached Excel sheet for the final number of SNPs (115) and tagSNPs 
(495). 
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2. Data collection (ET2DS); follow up after 4 years, anticipated the end of May, 
2011. This dataset will contribute to the meta-analysis. 
3. Meta-analysis of 6 large cohort 
Planned statistical analysis  
The details of the statistical analysis plan are still to be decided. The primary analysis 
will concentrate on the association between SNPs and either (i) tests of cognitive 
function common to all cohorts or (ii) a summary cognitive score derived from each 
cohort. 
Additionally, the following analyses will be carried out: 
- Descriptive analysis to determine population characterises  
- Principal component analysis to generate the ‘g’ (general intelligence factor) 
Competing interests 
None known. 
References (max 10) 
1. Marioni, R., E., et al., Genes, Brain and Behaviour, Vol. 9 Issue 3, Pages 348 - 352 
2. Rafnsson, S., B., Deary, I., J., Smith, S., B., et al., JAGS 2007;55:700-7 
3. Schram, M., T., Euser, S., M., de Craen, A., J., M., et al., JAGS 2007;55:708-16 
4. Van Oijen, M., Witteman, J., C., Hofman, A., et al., Stroke. 2005;36:2637 
 
6.5 PLANNED SCIENTIFIC OUTPUTS 
Intended outputs/publications arising from the use of these data, including abstracts, 
posters and research papers. 
1. PhD thesis 
2. number of publications in peer reviewed journals 
7. DATA REQUESTED 
Data required for analysis: 
Demographic data: 
- socio-economic background 
- smoking history 
- history of alcohol consumption  
- history of type 2 diabetes 
Data for statistical analysis: 
- age 
- age at the data collection time 
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- sex 
- fibrinogen related SNPs (please refer to attached Excel Sheet) 
- fibrinogen (plasma level) 
- current cognitive functioning; values gained for individual testing, general 
intelligence factor ‘g’ where available 
- estimate of pre-morbid cognitive functioning (measured by MHVS or NART).  
- assessment of anxiety and depression  
1) Download the WII data dictionary from the Whitehall II website 
(www.ucl.ac.uk/whitehallII). It is an Excel file containing the exact variables names of 
the data items held in the WII database. 
2) Highlight all of the variables needed. The list of highlighted items must be 
consistent with the project proposal. 
3) Attach the highlighted WII data dictionary file to this application form. 
Whitehall II Data User’s Agreement 
To be signed once the data sharing application has been approved. 
Title, forename, surname: Markéta Keller, MSc     
Work Address: University of Edinburgh, College of Medicine & Veterinary Medicine, 
Teviot Place, EH8 (AG  
Telephone: 0131 6503124     
Email: m.keller@sms.ed.ac.uk  
Project title: Systemic Inflammation and Late-Life Cognitive Ability  
 
I agree that my project will use the requested Whitehall II data and is to be conducted 
according to the guidelines specified in the document entitled “Whitehall II Policy on 
Data Sharing”. I confirm that I have read this document and agree to abide by the terms 
and conditions outlined there within.    
I accept that my access to the Whitehall II resource is limited only to what is relevant for 
completion of the above named project.  
Signature of WII data user:  
Name in block capitals: MARKÉTA KELLER   
Date: 11. 01. 2011  
Signature of research members  Names in block capitals        Date 
Signature of the WII Contact Researcher:                                                                    
Name in block capitals:                                                                    .      
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Date:                                                                    .      
Signature of Prof. Sir Michael Marmot/ Prof Mika Kivimaki:                                                                     
Name in block capitals:                                                                    .      
Date:                                                                    .      
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Appendix D: fibrinogen-related SNP; literature search 
Table 24: Literature search – fibrinogen-related SNPs; GWAS 
Study Sample Outcome  Design  ES/CI/ etc. Gene/Loci/ 
Position 
SNP Stats Results/Comments 






GWAS  337343 SNPs 
associated with 






















































19 SNPs were associated-all 
associations in paper. 
Fibrinogen and CRP level 
correlate (r=0.4), these genes 
were assessed. IL6R 
(8192284) and CD300LF 
SNP associated with CRP 
level.  LEPR!!! 
Dehghan, A., et 
al., 2009 [all] 
GWA analysis 





CV risk factors, 


































4 loci marked by SNPs 
showing GW sign P<5.0x10-
8);3 novel loci and 1 SNP in 
FGB 
NB: rs1800787know to 
directly affect gene 
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Study Sample Outcome  Design  ES/CI/ etc. Gene/Loci/ 
Position 
SNP Stats Results/Comments 






















transcription in basal and 
IL-6 stimulated condition 








in the fibri 
genes and 
circulating 
levels of both 
‘functional’ 
fibri and total 
fibri in a large, 
multi-center, bi-




A total of 59 
polymorphic sites 
had a minor allele 
frequency of ≥ 5% 
in either the EA or 





































All values in 
article, p. 
A common haplotype tagged 
by the A minor allele of the 
well-studied FGB−455 G/A 
promoter polymorphism 
(FGB 1437) was confirmed 
to be strongly associated 
with increased plasma 
fibrinogen levels. Two non-
coding variants specific to 
African-American 
chromosomes, FGA 3845 A 
and FGG 5729 G, were each 
associated with lower 
plasma fibrinogen levels. In 
European-Americans, a 
common haplotype tagged 
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Table 25: Literature search – fibrinogen-related SNPs; gene-associations/meta-analyses studies 




SNP Stats Results 







Meta-analysis if 6 
GWAS (ARIC, 
CHS, FHS, RS, 
MONICA/KORA, 
Ausburg Study 
and BBCS 1958) 
 FGB 
FGB (exon 7) 
IRF1 







All 4 loci confirmed by 
WGHS (Danik et al, 
2009).  
Details of these GWAS below, 
also summery presented in 
Deghan, 2009 





















P = 0.11 
 
P=0.001 
Absence of an association 
between the beta-
fibrinogen gene -148C/T 
polymorphism and 
susceptibility to CAD and 
the possibility that -
455G/A polymorphism (in 
particular, allele A) 
increases susceptibility to 
this disease in the 
Chinese population. 
Gohil 
















genes to assess 
their genetic 














Other than fibri gene 













Accounting for 3.1% 
variances of plasma fibri 
level 
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SNP Stats Results 
fibrinogen 
Iacoviello, 








Total number not 
included 
No info FGB -455  18 significant association 
3 non 
1 +/-  association 
 
Morgan, 









risk factors for 
Acute coronary 
syndrome 
Replication of 85 
variance in 70 
genes 
 FGB -455 P=0.03 Only the -4ff promoter was 
Any of the 85 varia 
nominally sign, otherwise 
nces  were significant 








with plasma fibri 
and CHD 
Meta-analysis of 





 Fibri robustly related to 
genetic variants BUT 
unrelated to CHD 
Voetsch 
B.  Loscalzo 
J., 2004 [M] 
Review (132 
references) 
Review of the 
most common 
genetic variations 






 FGB -455 G/A 
-854 G/A 
 Incosistently associated 
with plasma fibri level and 
with phenotype 
Iacoviello, 










Review of 23 
studies (1991-
2001) 












18 significant association 
3 non 
1 +/-  association 
 
De Maat, 
MP., et al., 
2001 [p] 
Review  Effects of diet, 
drugs and genes 
on plasma fibri 




Both associated with 
plasma fibri level but not 
with risk of CV event. 
148C/T good as close to 
IL-6 receptor  
Keavney, 4685 MI A meta-analysis FGB rs1800790 P=0.015C/C  Genotype also mild sign 
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SNP Stats Results 









Studies of Infarct 
Survival) and 19 
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Appendix E:  
Table 26: Final list of pre-selected fibrinogen-SNPs 
SNP name AAA EAS ELSA ET2DS LBC21 LBC36 WII p value re-coding Alleles 
 
2061 533 5600 1045 517 1005 3413       
rs4129267   x x x x x x 0.0603 GG=2; AG=1; AA=0 AG 
rs7518199   x x x     x 0.076 AA=2; CA=1; CC=0 AC 
rs8137951       x x x x 0.0158 GG=2; AG=1; AA=0 AG 
rs315952     x   x x   0.903 AA=2; AG=1; GG=1 AG 
rs4537545     x   x x   0.284 GG=2; AG=1; AA=0 AG 
rs9853387   x   x     x 0.1307 AA=2; GA=1; GG=0 AG 
rs1279840   x   x     x 0.5474 GG=2; AG=1; AA=0 AG 
rs1800497 x     x       0.7733 CC=2; CT=1; TT=0 CT 
rs2070016 x     x x x   0.2774 TT=2; CT=1; CC=0 CT 
rs4681 x     x       0.5452 AA=2; GA=1; GG=0 GA 
rs4251961   x x x     x 0.6098 AA=2; GA=1; GG=0 AG 
rs1130864 x x   x x x   0.7189 CC=2; CT=1; TT=0 CT 
rs10889550   x   x x x x 0.0493 AA=2; AG=1; GG=1 AG 
rs9436297   x   x x x x 0.2231 AA=2; GA=1; GG=0 AG 
rs11208660   x   x     x 0.0364 GG=2; AG=1; AA=0 AG 
rs1137101   x   x x x x 0.7488 AA=2; GA=1; GG=0 AG 
rs17415296   x   x     x 0.0443 CC=2; AC=1; AA=0 AC 
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SNP name AAA EAS ELSA ET2DS LBC21 LBC36 WII p value re-coding Alleles 
 
2061 533 5600 1045 517 1005 3413       
rs4845625   x   x     x 0.0187 GG=2; AG=1; AA=0 AG 
rs6689393   x   x     x 0.0361 GG=2; AG=1; AA=0 AG 
rs4072391   x   x     x 0.0411 GG=2; AG=1; AA=0 AG 
rs2287049       x x x x 0.0002 AA=2; GA=1; GG=0 AG 
rs3171845   x   x x x x 0.7729 GG=2; AG=1; AA=0 AG 
rs315921   x   x     x 0.1593 GG=2; AG=1; AA=0 AG 
rs12613336   x   x x x x 0.0177 AA=2; GA=1; GG=0 AG 
rs7607205   x   x x x x 0.5386 CC=2; AC=1; AA=0 AC 
rs6750325   x   x     x 0.7207 CC=2; AC=1; AA=0 AC 
rs6748782   x   x x x x 0.2946 CC=2; AC=1; AA=0 AC 
rs2887915   x   x x x x 0.6406 GG=2; AG=1; AA=0 AG 
rs10490320   x   x x x x 0.6606 AA=2; GA=1; GG=0 AG 
rs7574001   x   x     x 0.0111 AA=2; GA=1; GG=0 AG 
rs9844666   x   x x x x 0.3895 GG=2; AG=1; AA=0 AG 
rs1153877   x   x     x 0.1598 GG=2; AG=1; AA=0 AG 
rs556788   x   x     x 0.1276 AA=2; GA=1; GG=0 AG 
rs16844401   x   x x x x 0.4095 GG=2; AG=1; AA=0 AG 
rs9282763   x   x     x 0.0853 AA=2; GA=1; GG=0 AG 
rs1148   x   x x x x 0.2261 AA=2; CA=1; CC=0 AC 
rs2069827   x   x        0.1983 CC=2; AC=1; AA=0 AC 
rs2069840 x x   x        0.004 GG=2; CG=1; CC=0 CG 
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SNP name AAA EAS ELSA ET2DS LBC21 LBC36 WII p value re-coding Alleles 
 
2061 533 5600 1045 517 1005 3413       
rs10733789   x   x x x x 0.3696 AA=2; GA=1; GG=0 AG 
rs6479891   x   x     x 0.9282 GG=2; AG=1; AA=0 AG 
rs7081614   x   x     x 0.0193 AA=2; GA=1; GG=0 AG 
rs10822152   x   x     x 0.4884 AA=2; GA=1; GG=0 AG 
rs10761741   x   x     x 0.4467 CC=2; AC=1; AA=0 AC 
rs7923609   x   x x x x 0.4105 AA=2; GA=1; GG=0 AG 
rs10995530   x   x     x 0.0221 AA=2; GA=1; GG=0 AG 
rs1169288   x   x     x 0.679 AA=2; CA=1; CC=0 AC 
rs2464196 x x   x x x x 0.7093 GG=2; AG=1; AA=0 AG 
rs4817986   x   x     x 0.0905 CC=2; AC=1; AA=0 AC 
rs715586   x   x x x x 0.3007 GG=2; AG=1; AA=0 AG 
rs2285395   x   x x x x 0.3904 GG=2; AG=1; AA=0 AG 
rs11265618     x   x x   0.1934 GG=2; AG=1; AA=0 AG 
rs1386821     x   x x   0.5904 AA=2; AC=1; CC=0 AC 
rs2069832 x   x         0.6302 GG=2; AG=1; AA=0 AG 
rs2070011 x   x         0.597 GG=2; AG=1; AA=0 AG 
rs4240872     x   x x   0.2002 AA=2; AG=1; GG=1 AG 
rs2287047         x x x 0.0011 GG=2; AG=1; AA=0 AG 
rs2070022 x       x x   0.5964 CC=2; CT=1; TT=0 CT 
rs17070145 x     x       0.7733 CC=2; CT=1; TT=0 CT 
rs2227412 x     x       0.0449 AA=2; GA=1; GG=0 AG 
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SNP name AAA EAS ELSA ET2DS LBC21 LBC36 WII p value re-coding Alleles 
 
2061 533 5600 1045 517 1005 3413       
rs1205   x   x       0.4722 CC=2; TC=1; TT=0 CT 
rs4220 x     x x x   0.8438 GG=2; GA=1; AA=0 AG 
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